学术周报 · IF≥10

心血管科领域文献阅读汇编

2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
78
临床研究
48
基础研究
30
IF≥20
17
IF 10-20
61
子领域
27
期刊种类
28
数据日期
2026-10-17

★本周 Top 10 高影响力文献

#论文期刊IF
1Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades.NatureIF 56.1
2Intracoronary imaging to assess atherosclerosis and to guide percutaneous coronary intervention.European heart journalIF 45.3
3Temporary mechanical circulatory support in cardiogenic shock.European heart journalIF 45.3
4Genotype and arrhythmic risk in dilated cardiomyopathy.European heart journalIF 45.3
5Palmitic acid promotes hypertrophic memory in cardiomyocytes via KDM5A/H3K4me3.European heart journalIF 45.3
6Immunoregulatory gene GIMAP6 suppresses lethal atherosclerotic vasculopathy and ischemic heart failu...CellIF 45.1
7Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Ri...CirculationIF 41.3
8Definition and Prognosis of Mitral Regurgitation in Transthyretin Amyloid Cardiomyopathy: A Multicen...CirculationIF 41.3
9Cardiovascular Complications of Chronic Liver Disease.CirculationIF 41.3
10Impact of Prolonged Spaceflight on Cardiac Structure and Function: An Exploratory Longitudinal Obser...CirculationIF 41.3

Ŧ期刊分布统计

期刊篇数IF
European journal of preventive cardiology14IF 10.0
Cardiovascular research10IF 12.5
Circulation9IF 41.3
European journal of heart failure6IF 10.3
Stroke4IF 11.1
European heart journal4IF 45.3
Ageing research reviews3IF 15.5
Progress in cardiovascular diseases3IF 10.6
Science advances2IF 13.9
Advanced healthcare materials2IF 11.0

1心力衰竭 (17篇)

临床研究 (13篇)

European journal of heart failure IF 10.3 2026-10-17 PMID: 42888496
Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) is central to acute heart failure (AHF) diagnosis in dyspneic emergency departments (ED) patients, but optimal thresholds remain uncertain. This study aimed to evaluate the diagnostic accuracy of various NT-proBNP thresholds for AHF, across the general population and these key subgroups. A systematic review and meta-analysis were conducted, including studies published up to August 28, 2025, that reported the diagnostic performance of NT-proBNP thresholds for AHF in dyspneic ED patients. The analysis included 31 studies comprising 26,948 patients. To exclude AHF, a fixed threshold of ≤300 ng/L yielded an area under the receiver operator characteristic curve (AUC) of 0.73 (0.69-0.77), with high sensitivity of 97.9% (96.9-98.5) and lower specificity of 46.2% (36.4-56.2); the negative predictive value of this threshold was 97.0% (96.5-97.4). Age-dependent thresholds (≥450 ng/L for patients aged <50 years, ≥900 ng/L for those aged 50-75 years, and ≥1,800 ng/L for those aged ≥75 years), evaluated in 14,410 patients, achieved an AUC of 0.84 (0.83-0.85) with a more favorable balance between sensitivity of 85.9% (85.0-86.7) and specificity of 82.0% (81.2-82.9). In patients with CKD (N=2,271), all fixed thresholds yielded AUC <0.80; age-dependent thresholds showed an AUC of 0.77 (0.75-0.78) with specificity of 62.6% (59.4-65.7). In patients with obesity (body mass index ≥30), only age-dependent thresholds were assessed, in 3,562 patients; AUC was 0.82 (0.81-0.84) and sensitivity was 81.2% (79.2-83.1), broadly comparable to the overall population. A threshold ≤300 ng/L provides excellent rule-out performance for AHF, while age-dependent NT-proBNP thresholds offer superior diagnostic performance for ruling in AHF in the ED compared to fixed thresholds, and demonstrate consistent accuracy across subgroups. However, evidence in patients with CKD and obesity remains limited, both in terms of sample size and the range of thresholds evaluated.
中文摘要:N末端B型利钠肽前体(NT-proBNP)浓度对急诊科呼吸困难患者急性心力衰竭(AHF)的诊断至关重要,但最佳阈值仍不确定。本研究旨在评估不同NT-proBNP阈值在总体人群及关键亚组中诊断AHF的准确性。研究纳入截至2025年8月28日发表、报告NT-proBNP阈值在急诊呼吸困难患者中诊断AHF性能的文献,开展系统综述和荟萃分析。分析共纳入31项研究、26,948例患者。用于排除AHF时,固定阈值≤300 ng/L的受试者工作特征曲线下面积(AUC)为0.73(0.69-0.77),敏感度为97.9%(96.9-98.5),特异度较低,为46.2%(36.4-56.2);该阈值的阴性预测值为97.0%(96.5-97.4)。年龄依赖阈值(<50岁患者≥450 ng/L,50-75岁患者≥900 ng/L,≥75岁患者≥1,800 ng/L)在14,410例患者中评估,AUC为0.84(0.83-0.85),敏感度85.9%(85.0-86.7)与特异度82.0%(81.2-82.9)之间平衡更佳。在慢性肾脏病(CKD)患者(N=2,271)中,所有固定阈值的AUC均<0.80;年龄依赖阈值的AUC为0.77(0.75-0.78),特异度为62.6%(59.4-65.7)。在肥胖(体重指数≥30)患者中,仅评估了年龄依赖阈值,共3,562例;AUC为0.82(0.81-0.84),敏感度为81.2%(79.2-83.1),与总体人群大致相当。阈值≤300 ng/L对AHF具有很好的排除性能,而年龄依赖NT-proBNP阈值在急诊科支持AHF诊断方面优于固定阈值,并在各亚组中表现出一致的准确性。不过,CKD和肥胖患者中的证据在样本量和已评估阈值范围两方面仍然有限。
Nature cardiovascular research IF 12.6 2026-10-15 PMID: 42881254
Right ventricular (RV) size and function inform prognosis in many cardiovascular diseases, but assessment by two-dimensional transthoracic echocardiography is challenging. Here we show that a deep learning model, Dimensional Reconstruction of Imaging Data-Right Ventricle (DROID-RV), can estimate RV end-diastolic diameter and identify RV systolic dysfunction from transthoracic echocardiography videos. We trained DROID-RV in 17,141 ambulatory cardiology patients (51,188 studies and 383,881 video clips) and validated model predictions in 9,112 primary care patients and 831 patients with RV ejection fraction assessed by three-dimensional transthoracic echocardiography. Across multiple test samples, DROID-RV accurately estimates RV end-diastolic diameter and identifies RV dysfunction, although model prediction error increases at extremes of RV size and function. We additionally show that RV size and function predictions are associated with incident mortality, atrial fibrillation and heart failure. Our work demonstrates how deep learning can automate RV assessment and risk stratification at scale using two-dimensional echocardiography.
中文摘要:右心室大小与功能可提示多种心血管疾病的预后,但用二维经胸超声心动图评估并不容易。我们展示了一个深度学习模型——右心室成像数据维度重建(DROID-RV),可从经胸超声心动图视频中估算右心室舒张末期内径并识别右心室收缩功能障碍。DROID-RV在17141例门诊心血管患者中训练(51188次检查、383881个视频片段),并在9112例基层医疗患者和831例经三维经胸超声心动图测定右心室射血分数的患者中验证模型预测。在多个测试样本中,DROID-RV能较准确估算右心室舒张末期内径并识别右心室功能障碍,但在右心室大小与功能的极端值处模型预测误差增大。我们还发现,右心室大小与功能的预测值与新发死亡、心房颤动和心力衰竭相关。这项工作说明深度学习可利用二维超声心动图大规模自动化右心室评估与风险分层。
European journal of heart failure IF 10.3 2026-10-15 PMID: 42876202
Sex-based disparities in patient enrollment and treatment effects in heart failure (HF) randomized controlled trials (RCTs) have been reported. We aim to systematically analyze sex-based enrollment and treatment effect differences in HF RCTs over time. RCTs enrolling patients with chronic HF were systematically searched on PubMed-MEDLINE. Eligible trials included pharmacological or device-based interventions with a hard primary endpoint (mortality and hospitalization) and reporting enrollment of women. Sex-specific treatment effects (HR or RR) were extracted. Meta-analyses were performed using random-effects models, and pre-specified subgroup analyses were performed. A total of 56 RCTs (39 drug, 17 device) were included. The pooled proportion of women enrollment was 27.0% (95%CI: 22.0% to 32.4%) in drug trials and 25.3% (95%CI: 21.0% to 29.9%) in device trials. Women were more underrepresented in HF with reduced ejection fraction (HFrEF) than in HF with preserved EF (HFpEF) trials (21.0% vs 49.6%, p < 0.001). Among drug trials reporting sex-specific effects, the pooled sex interaction for RCTs reporting HR was 0.94 (95%CI 0.89-1.01) and RR was 0.81 (95%CI 0.68-0.96), suggesting potentially greater benefit for women. No interaction was observed between HFrEF and HFpEF trials (HR: p = 0.44; RR: p = 0.95). The pooled interaction estimate on event counts was 0.90 (95%CI 0.84-0.96). For devices, the pooled sex interaction for RCTs reporting HR was 1.05 (95%CI 0.90-1.22) and RR was 0.68 (95%CI 0.50-0.93). Women remain underrepresented in HF RCTs. Sex-stratified analyses suggest a potentially greater relative benefit of drug intervention in women, which might inform future RCTs. Further studies are required to investigate the mechanisms of these differences.
中文摘要:心力衰竭随机对照试验中患者入组和治疗效应的性别差异已有报道。本研究旨在系统分析慢性心力衰竭随机对照试验随时间的性别入组和治疗效应差异。在PubMed-MEDLINE系统检索入组慢性心力衰竭患者的随机对照试验。纳入试验为药物或器械干预,具有硬主要终点(死亡和住院),并报告女性入组情况。提取性别特异性治疗效应(HR或RR)。采用随机效应模型进行荟萃分析,并进行预设亚组分析。共纳入56项随机对照试验(39项药物试验,17项器械试验)。女性入组合并比例为药物试验27.0%(95%CI:22.0%至32.4%),器械试验25.3%(95%CI:21.0%至29.9%)。女性在射血分数降低的心力衰竭(HFrEF)试验中的代表性低于射血分数保留的心力衰竭(HFpEF)试验(21.0%对49.6%,p<0.001)。在报告性别特异性效应的药物试验中,报告HR的随机对照试验合并性别交互作用为0.94(95%CI 0.89-1.01),报告RR者为0.81(95%CI 0.68-0.96),提示女性可能获益更大。HFrEF与HFpEF试验之间未观察到交互作用(HR:p=0.44;RR:p=0.95)。基于事件计数的合并交互估计为0.90(95%CI 0.84-0.96)。对于器械试验,报告HR的随机对照试验合并性别交互作用为1.05(95%CI 0.90-1.22),报告RR者为0.68(95%CI 0.50-0.93)。女性在心力衰竭随机对照试验中仍代表性不足。按性别分层分析提示药物干预对女性可能具有更大的相对获益,或可为未来随机对照试验提供参考。这些差异的机制仍需进一步研究。
European journal of preventive cardiology IF 10.0 2026-10-15 PMID: 42875024
The impact of tirzepatide and dulaglutide on major adverse cardiovascular events (MACE) and heart failure (HF) outcomes according to HF status is unknown. Patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease were treated with tirzepatide up to 15 mg or dulaglutide 1.5 mg weekly (average 4 years). The incidence of MACE-3 [cardiovascular (CV) death, myocardial infarction (MI), stroke], MACE-4 (CV death, MI, stroke, coronary revascularization) and composite of all-cause or CV death and hospitalization or urgent visits for HF were analysed in patients with and without a history of HF. A history of HF (20.3%) was associated with more coronary artery disease and prior MI. Incidences of event categories were higher in the HF group. The hazard ratio (HR) for all-cause death or hospitalization or urgent visits for HF on tirzepatide vs. dulaglutide was 0.83 [95% confidence interval (CI) 0.70-0.99] in patients with HF and 0.88 (95%CI 0.78-1.00) without HF. The HR for CV death or hospitalization or urgent visits for HF was 0.85 (95%CI 0.70-1.03) and 0.96 (95%CI 0.83-1.12), for MACE-3 0.90 (95%CI 0.76-1.08) and 0.93 (95%CI 0.83-1.04), and for MACE-4 0.81 (95%CI 0.69-0.95) and 0.91 (95%CI 0.83-1.00) in patients with and without HF, respectively. The patient-reported outcomes of APPADL and EQ-5D-5L visual analogue scores improved and were higher on tirzepatide in both groups. With overall non-inferiority established, this exploratory analysis revealed lower rates of the composite of all-cause death or HF events, or MACE-4 among patients with T2D and HF treated with tirzepatide compared with dulaglutide.
中文摘要:替尔泊肽和度拉糖肽对主要不良心血管事件(MACE)及心力衰竭结局的影响是否因心力衰竭状态而异尚不清楚。2型糖尿病合并动脉粥样硬化性心血管疾病患者接受替尔泊肽最高15 mg或度拉糖肽1.5 mg每周治疗,平均4年。分析有或无心力衰竭病史患者的MACE-3(心血管死亡、心肌梗死、卒中)、MACE-4(心血管死亡、心肌梗死、卒中、冠状动脉血运重建)以及全因死亡或心血管死亡与心力衰竭住院或紧急就诊复合终点的发生率。心力衰竭病史占20.3%,与更多冠状动脉疾病和既往心肌梗死相关。心力衰竭组各类事件发生率更高。替尔泊肽对比度拉糖肽的全因死亡或心力衰竭住院或紧急就诊风险比在心力衰竭患者中为0.83(95%置信区间0.70-0.99),无心力衰竭患者中为0.88(95%置信区间0.78-1.00)。心血管死亡或心力衰竭住院或紧急就诊的风险比分别为0.85(95%置信区间0.70-1.03)和0.96(95%置信区间0.83-1.12),MACE-3分别为0.90(95%置信区间0.76-1.08)和0.93(95%置信区间0.83-1.04),MACE-4分别为0.81(95%置信区间0.69-0.95)和0.91(95%置信区间0.83-1.00)。患者报告的APPADL和EQ-5D-5L视觉模拟评分在两组中均改善,且替尔泊肽组更高。在总体非劣效性已确立的情况下,这项探索性分析显示,2型糖尿病合并心力衰竭患者中,替尔泊肽相比度拉糖肽的全因死亡或心力衰竭事件复合终点或MACE-4发生率更低。
European journal of heart failure IF 10.3 2026-10-14 PMID: 42874074
Lower extremity compression therapy has been proposed as an adjunct to mitigate diuretic resistance during acute decompensation of heart failure (ADHF). We evaluated the effect of lower leg compression with elastic bandages on diuretic efficiency in patients with diuretic-resistant ADHF. Historical cohort study enrolling adult cardiac ICU admissions with ADHF who used elastic bandages (EB) at Mayo Clinic in Minnesota from 2007 to 2017. The diuretic efficiency before and after applying EB was the primary outcome. A total of 176 patients with heart failure who received elastic bandages were included. The in-hospital mortality rate, the median hospital length of stay, and 30-day hospital readmission were 9.7%, 11.4 days (IQR 7.1-19.0), and 11%, respectively. When EB was applied, the average daily loop diuretic dosage was decreased by a mean difference of 1.19 mg per 40 mg furosemide equivalent (95% CI: 0.22 to 2.2; p = 0.016). The average post-EB diuretic efficiency was 1,355 mL (IQR 1,119, 1,590) per 40-mg furosemide, which was significantly higher than before EB application, with a mean difference of 340 mL per 40-mg furosemide equivalent (95% CI: -554, -125; p = 0.002). A higher diuretic efficiency led to lower diuretic doses. Average daily urine output before and after EB application was not different (2,642 pre-EB vs. 2,792 post-EB mL/day; 95% CI: -455 to 154; p = 0.33). EB use enhances diuretic efficacy during ADHF. Further studies are needed to determine the potential clinical benefits and risks of applying EB compression treatment in ADHF.
中文摘要:下肢加压治疗曾被提出作为急性心力衰竭失代偿(ADHF)期间减轻利尿剂抵抗的辅助措施。我们评估小腿弹力绷带加压对利尿剂抵抗性ADHF患者利尿效率的影响。这是一项历史性队列研究,纳入2007年至2017年明尼苏达州Mayo Clinic心脏ICU收治的成人ADHF患者,这些患者使用了弹力绷带(EB)。主要结局为应用EB前后的利尿效率。共纳入176例接受弹力绷带的患者。院内死亡率、住院时间中位数和30天再入院率分别为9.7%、11.4天(IQR 7.1-19.0)和11%。应用EB时,袢利尿剂平均每日剂量减少,均差为每40 mg呋塞米等效剂量1.19 mg(95% CI:0.22至2.2;p=0.016)。应用EB后的平均利尿效率为每40 mg呋塞米1355 mL(IQR 1119,1590),显著高于应用EB前,均差为每40 mg呋塞米等效剂量340 mL(95% CI:-554至-125;p=0.002)。较高的利尿效率导致较低的利尿剂剂量。应用EB前后的平均每日尿量无差异(应用前2642 mL/天 vs 应用后2792 mL/天;95% CI:-455至154;p=0.33)。EB使用可增强ADHF期间的利尿疗效。仍需进一步研究确定在ADHF中应用EB加压治疗的潜在临床获益与风险。
European journal of heart failure IF 10.3 2026-10-13 PMID: 42867408
The Global Registries and Surveys Programme-Heart Failure (GRASP-HF) is a prospective, multicentre, international observational study assessing implementation of the 2021/2023 ESC-HF-Guidelines. GRASP-HF is aligned with the Improving Care through Accreditation and Recognition in Heart Failure (ICARe-HF) programme, which links centre-characteristics with guideline-implementation performance. To compare baseline characteristics, guideline-directed-medical-therapy (GDMT) implementation, and in-hospital outcomes between GRASP-HF patients managed in centres participating or not participating in the ICARe-HF programme. GRASP-HF patients were stratified by ICARe-HF participation, clinical settings, acute (AHF) vs chronic HF (CHF) and ejection fraction (EF) subtypes. Hierarchical multivariable logistic regression models evaluated associations with quadruple therapy implementation and in-hospital mortality. Among 10,936 patients (63.3% CHF, 36.7% AHF), patients from ICARe-HF participating centres (51.3%) were older, more comorbid but with less severe congestion. In both CHF and AHF, ICARe-HF centres demonstrated greater GDMT utilization, particularly angiotensin receptor-neprilysin inhibitors and sodium-glucose-cotransporter-2 inhibitors. In HFrEF, quadruple therapy was more frequently implemented (47% vs 40% in CHF; 27% vs 24% at AHF discharge) and remained associated with ICARe-HF participation after adjustment, Odd Ratio (OR) =1.73, 95% Confidence Interval (CI) :1.17-2.55. Target doses remained suboptimal, particularly after AHF. Although crude in-hospital mortality was lower in ICARe-HF centres (2.3% vs 5.5%), this association was attenuated after multivariable adjustment (OR=0.87, 95% CI:0.48-1.56). Participation in the ICARe-HF programme was associated with more comprehensive implementation of contemporary GDMT, particularly in HFrEF. The association with in-hospital mortality was attenuated after adjustment and should be considered exploratory.
中文摘要:全球注册与调查项目-心力衰竭(GRASP-HF)是一项前瞻性、多中心、国际观察性研究,评估2021/2023 ESC-HF指南的实施情况。GRASP-HF与改善心力衰竭认证与认可照护(ICARe-HF)项目相衔接,该项目将中心特征与指南实施绩效联系起来。研究比较参与与未参与ICARe-HF项目的中心所管理的GRASP-HF患者在基线特征、指南导向药物治疗(GDMT)实施和院内结局方面的差异。GRASP-HF患者按是否参与ICARe-HF、临床场景、急性心衰(AHF)与慢性心衰(CHF)以及射血分数(EF)亚型进行分层。采用分层多变量logistic回归模型评估与四联疗法实施及院内死亡率的关联。在10936例患者中(63.3%为CHF,36.7%为AHF),来自ICARe-HF参与中心的患者(51.3%)年龄更大、合并症更多,但淤血程度较轻。在CHF和AHF中,ICARe-HF中心的GDMT使用率更高,尤其是血管紧张素受体-脑钠肽酶抑制剂和钠-葡萄糖协同转运蛋白-2抑制剂。在HFrEF中,四联疗法更常实施(CHF为47%对40%;AHF出院时为27%对24%),校正后仍与参与ICARe-HF相关,OR=1.73,95%CI 1.17-2.55。目标剂量仍不理想,尤其在AHF后。ICARe-HF中心的粗院内死亡率较低(2.3%对5.5%),但多变量校正后该关联减弱(OR=0.87,95%CI 0.48-1.56)。参与ICARe-HF项目与当代GDMT更全面的实施相关,尤其在HFrEF中。与院内死亡率的关联在校正后减弱,应视为探索性结果。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 42867362
There is limited information on the heart failure (HF) epidemic and its temporal changes. Current research aimed to report the HF epidemic over the past three decades in the Rotterdam Study, covering the prevalence and incidence of HF, comorbidities and risk determinants. Using data from the population-based Rotterdam cohort, three Epoch groups [Epoch 1990s (1989-1993, N=7,983), Epoch 2000s (1997-2001, N=7,738), and Epoch 2010s (2009-2014, N=6,170)] were identified, with a mean age of nearly 70 years. For each Epoch group, point prevalence at baseline and 5-year HF incidence rate, comorbidities at baseline, and HF risk determinants (using Cox proportional hazards models) were calculated. Point prevalence of HF was 3.3% in Epoch 1990s, 6.0% in Epoch 2000s, and 4.8% in Epoch 2010s, with an increase from the 1990s to 2000s followed by a decline in the 2010s, yielding an overall statistically significant upward trend (p<0.001). 5-year incidence of HF per 1,000 person-years was 16.3 (95%CI: 15.0 to 17.8), 10.3 (95%CI: 9.2 to 11.4) and 7.9 (95%CI: 6.9 to 9.0) in respective epochs, with a downward trend. Hypertension was the most common comorbidity in HF patients, followed by dyslipidemia and kidney dysfunction. The association of hypertension and diabetes with risk of incident HF decreased over time. Coronary heart disease (CHD), atrial fibrillation (AF) and stroke all showed increasing hazard ratios across groups. The prevalence of HF increased during the past decades in a population-based setting, while HF incidence declined. Hypertension and diabetes tended to become less critical risk factors for new-onset HF nowadays, while CHD, AF, and stroke showed trends toward stronger associations with HF risk over time.
中文摘要:关于心力衰竭(HF)流行情况及其时间变化的信息有限。当前研究旨在报告鹿特丹研究过去三十年HF流行情况,涵盖HF患病率与发病率、合并症及风险决定因素。利用基于人群的鹿特丹队列数据,识别三个年代组[1990年代组(1989-1993,N=7,983)、2000年代组(1997-2001,N=7,738)和2010年代组(2009-2014,N=6,170)],平均年龄近70岁。对每个年代组,计算基线时点患病率和5年HF发病率、基线合并症及HF风险决定因素(使用Cox比例风险模型)。HF时点患病率在1990年代组为3.3%,2000年代组为6.0%,2010年代组为4.8%,从1990年代到2000年代上升,随后在2010年代下降,总体呈统计学显著上升趋势(p<0.001)。各年代每1000人年的5年HF发病率分别为16.3(95%CI:15.0至17.8)、10.3(95%CI:9.2至11.4)和7.9(95%CI:6.9至9.0),呈下降趋势。高血压是HF患者最常见的合并症,其次是血脂异常和肾功能不全。高血压和糖尿病与新发HF风险的关联随时间减弱。冠心病(CHD)、心房颤动(AF)和卒中在各组中均显示风险比增加。在基于人群的环境中,过去数十年HF患病率上升,而HF发病率下降。如今高血压和糖尿病作为新发HF关键风险因素的趋势减弱,而CHD、AF和卒中与HF风险的关联随时间呈增强趋势。
European journal of heart failure IF 10.3 2026-10-13 PMID: 42865104
Patients from socioeconomically deprived and ethnically diverse backgrounds are under-represented in cardiovascular research. EARLY-HF is a community-based pilot study designed to predict incident HF in primary care. We aimed to assess effectiveness of recruitment strategies for engaging underserved populations and quantify the burden of unrecognised CVD. Prospective cohort study enrolling 550 adults aged ≥50 years with two or more cardiometabolic risk factors and no prior diagnosis of HF. Participants were recruited via: (i) targeted identification using electronic health records in eight primary care centres; (ii) digital advertising and targeted social media campaign; (iii) ten community outreach events; (iv) direct referral from family or friends. The baseline study visit included ECG, blood sampling, and imaging. 185 (34%) participants were from the most deprived Index of Multiple Deprivation (IMD) quintile and 97 (18%) were of non-White ethnicity. Primary care and digital advertising were the most effective recruitment strategies, enrolling 444 (81%) and 68 (12%) participants respectively, while maintaining diverse representation. The social media campaign generated 15,207 advertisement clicks and 1,012 expressions of interest at a cost of £5.93 per sign-up. Community outreach events enrolled 5 (1%) participants and were resource intensive. A substantial burden of previously unrecognised CVD was identified: 125 (23%) participants had clinically actionable cardiac abnormalities, including 46 (9%) with previously unrecognised myocardial infarction, 331 (60%) had uncontrolled blood pressure (≥140/90 mmHg), and 162 (30%) had elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP ≥125 pg/ml). Primary care-embedded and digital recruitment strategies can effectively engage underserved communities at risk of HF, at scale and at low cost. This population has a very high burden of unrecognised CVD.
中文摘要:来自社会经济贫困和族裔多样背景的患者在心血管研究中代表性不足。EARLY-HF是一项基于社区的试点研究,旨在预测初级保健中发生的心力衰竭。我们拟评估招募策略对覆盖服务不足人群的有效性,并量化未被识别的心血管疾病负担。这项前瞻性队列研究纳入550名年龄≥50岁、具有两项或以上心脏代谢危险因素且既往未诊断心力衰竭的成年人。参与者通过以下方式招募:(i)在八家初级保健中心利用电子健康记录进行目标识别;(ii)数字广告和定向社交媒体活动;(iii)十场社区外展活动;(iv)家人或朋友直接转介。基线研究访视包括心电图、采血和影像学检查。185名(34%)参与者来自多重剥夺指数(IMD)最贫困五分位,97名(18%)为非白人族裔。初级保健和数字广告是最有效的招募策略,分别纳入444名(81%)和68名(12%)参与者,同时保持了多样性代表性。社交媒体活动产生15,207次广告点击和1,012次意向表达,每次注册成本为5.93英镑。社区外展活动纳入5名(1%)参与者,且资源消耗较大。研究识别出大量既往未被识别的心血管疾病负担:125名(23%)参与者存在具有临床可干预性的心脏异常,包括46名(9%)既往未被识别的心肌梗死,331名(60%)血压未控制(≥140/90 mmHg),162名(30%)N末端B型利钠肽原升高(NT-proBNP ≥125 pg/ml)。嵌入初级保健和数字化的招募策略能够以规模化、低成本方式有效覆盖有心力衰竭风险的服务不足社区。该人群未被识别的心血管疾病负担很高。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 42340801
Obesity and regional fat distribution are associated with adverse cardiovascular outcomes, yet the prognostic significance of specific adiposity phenotypes in individuals with left ventricular systolic impairment remains incompletely defined. Body mass index (BMI) incompletely captures fat distribution and may underestimate metabolically adverse adiposity. Participants from the community-based UK Biobank Imaging Enhancement Programme who underwent cardiac magnetic resonance (CMR) imaging were evaluated. Individuals with CMR-defined left ventricular systolic impairment [left ventricular ejection fraction <50%] were identified, while participants with prevalent heart failure at baseline were excluded. Adiposity was assessed using BMI, waist circumference (WC), waist-to-hip ratio (WHR), body fat percentage, and total fat mass. Associations between adiposity measures (per 1 SD increase) and all-cause and cardiovascular (CV) mortality were evaluated using Cox proportional hazards models adjusted for age, sex, hypertension, diabetes mellitus, hypercholesterolaemia, and smoking. Left ventricular (LV) impairment aetiology was classified as ischaemic or non-ischaemic using International Classification of Diseases, 10th Revision codes or self-reported prior myocardial infarction. All analyses were performed using R 4.4.0 within the UK Biobank Research Analysis Platform. Among 5615 participants with CMR-defined LV systolic impairment (mean age 56.7 ± 7.4 years; 52% male), 290 all-cause and 76 CV deaths occurred over a median follow-up of 13.5 years. In fully adjusted analyses, BMI was associated with increased all-cause [hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.05-1.34] and CV mortality (HR 1.37, 95% CI 1.11-1.69). Central adiposity measures demonstrated stronger associations with outcomes, particularly WC (all-cause HR 1.25; CV HR 1.49) and WHR (all-cause HR 1.30; CV HR 1.52). Compared with a BMI-based reference model (C-statistic 0.67 for all-cause and 0.71 for CV mortality), inclusion of WC and WHR resulted in modest but statistically significant improvements in discrimination (ΔC up to +0.008 for all-cause and +0.012 for CV mortality), whereas general adiposity measures, including body fat percentage and total fat mass, did not meaningfully improve incremental discrimination. In this large imaging-defined cohort of individuals with LV systolic impairment, central adiposity measures, particularly WC and WHR, were more strongly associated with CV mortality than BMI, body fat percentage, or total fat mass. These findings suggest that fat distribution, rather than overall adiposity alone, provides important prognostic information in individuals with LV systolic impairment. Biobank Project ID 55469.
中文摘要:肥胖及区域脂肪分布与不良心血管结局相关,但特定肥胖表型在左心室收缩功能受损人群中的预后意义仍未完全明确。体重指数(BMI)不能完整反映脂肪分布,可能低估代谢不良性肥胖。研究纳入英国生物银行影像增强计划中接受心脏磁共振(CMR)成像的社区参与者,识别经CMR定义左心室收缩功能受损(左心室射血分数<50%)者,排除基线时已患心力衰竭者。采用BMI、腰围(WC)、腰臀比(WHR)、体脂百分比和总脂肪量评估肥胖。使用Cox比例风险模型评估各肥胖指标(每增加1个标准差)与全因死亡和心血管死亡的关系,模型校正年龄、性别、高血压、糖尿病、高胆固醇血症和吸烟。左心室功能受损病因依据国际疾病分类第十版编码或自报既往心肌梗死分为缺血性与非缺血性。所有分析在英国生物银行研究分析平台内使用R 4.4.0完成。5615名经CMR定义左心室收缩功能受损参与者(平均年龄56.7±7.4岁;52%为男性)中,中位随访13.5年期间发生290例全因死亡和76例心血管死亡。完全校正分析中,BMI与全因死亡风险升高相关[风险比(HR)1.19,95%置信区间(CI)1.05-1.34],也与心血管死亡风险升高相关(HR 1.37,95% CI 1.11-1.69)。中心性肥胖指标与结局的关联更强,尤其是WC(全因死亡HR 1.25;心血管死亡HR 1.49)和WHR(全因死亡HR 1.30;心血管死亡HR 1.52)。与基于BMI的参照模型(全因死亡C统计量0.67,心血管死亡0.71)相比,纳入WC和WHR使判别能力出现幅度不大但具有统计学意义的改善(全因死亡ΔC最高+0.008,心血管死亡+0.012),而体脂百分比和总脂肪量等总体肥胖指标未带来有意义的增量判别改善。在这一大型影像学定义左心室收缩功能受损队列中,中心性肥胖指标,尤其是WC和WHR,与心血管死亡的关联强于BMI、体脂百分比或总脂肪量。这些发现提示,在左心室收缩功能受损人群中,脂肪分布而非单纯总体肥胖程度可提供重要预后信息。英国生物银行项目ID 55469。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 41123417
To evaluate whether tirzepatide use is associated with a reduced risk of new-onset heart failure (HF) in patients with obesity. We conducted a retrospective cohort study using the TriNetX global database, identifying adults with obesity (body mass index >30 kg/m2) between January 2022 and June 2025. Patients prescribed tirzepatide were compared with matched controls not receiving the drug. Propensity score matching was applied to balance baseline characteristics. The primary outcome was incident HF within one year. Secondary outcomes included all-cause mortality, hospitalization, and major adverse cardiovascular events (MACEs). A total of 381 026 matched individuals (190 513 per group) were analyzed. Tirzepatide use was associated with a significantly lower risk of new-onset HF [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.50-0.56; P < 0.001], as well as reduced 1-year all-cause mortality (HR, 0.31), hospitalization (HR, 0.46), and MACEs (HR, 0.55), all P < 0.001. Subgroup analyses across age, sex, comorbidities, and medications showed consistent results. Negative control outcomes confirmed robustness. Tirzepatide may reduce the risk of developing HF and improve cardiovascular outcomes in obese individuals. These findings highlight its potential role in HF prevention and warrant further prospective studies.
中文摘要:评估替尔泊肽使用是否与肥胖患者新发心力衰竭风险降低相关。利用TriNetX全球数据库开展回顾性队列研究,纳入2022年1月至2025年6月体质指数>30 kg/m2的成年人。将处方替尔泊肽者与未接受该药的匹配对照比较,采用倾向评分匹配平衡基线特征。主要结局为一年内新发心衰。次要结局包括全因死亡、住院和主要不良心血管事件(MACE)。共分析381026名匹配个体(每组190513名)。替尔泊肽使用与新发心衰风险显著降低相关(HR 0.53;95%CI 0.50-0.56;P<0.001),并与1年全因死亡(HR 0.31)、住院(HR 0.46)和MACE(HR 0.55)降低相关,均P<0.001。按年龄、性别、合并症和用药分层分析结果一致。阴性对照结局证实稳健性。替尔泊肽可能降低肥胖个体发生心衰的风险并改善心血管结局。这些发现提示其在心衰预防中的潜在作用,值得进一步前瞻性研究。
Progress in cardiovascular diseases IF 10.6 2026-10-12 PMID: 42863622
Peak oxygen consumption (pVO2) has been widely recognized to identify potential pathophysiological mechanisms of exercise intolerance and to stratify risk in patients with heart failure (HF). To develop a non-exercise equation to estimate pVO2 (esVO2) and to determine its association with all-cause mortality. A total of 5176 HF patients (age 48 ± 17 years) who underwent a CPET for clinical reasons, and were followed between May 2011, and December 1, 2023. Clinical and historical variables and forced expiratory volume in 1-s (FEV1) were used in a stepwise multivariate regression analysis to predict pVO2 measured from CPET. Kaplan-Meier curves and Cox proportional hazards analyses were used to determine the association between esVO2 and all-cause mortality. The first esVO2 model was significantly associated with pVO2 (multiple R = 0.73, P < 0.001). Two other models considered gender separately (male: multiple R = 0.72, P < 0.001 and female (multiple R = 0.70, P < 0.001). A fourth model was proposed when spirometry is not available (age, BMI, resting SBP, HR and gender (multiple R = 0.69, P < 0.001)). The fifth proposed model included history of atrial fibrillation and previous stroke (multiple R = 0.70, P < 0.001). Kaplan-Meier survival curves differentiated patients according to esVO2 and pVO2 ≤ and > 14 mL/kg-1 per min-1. Univariate Cox proportional hazard analyses indicated significant prognostic value when esVO2 and pVO2 were ≤ 14 mL/kg-1 per min-1 (P = 0.001). Multivariable nonexercise models combining spirometry and/or clinical variables commonly obtained during a clinical assessment predict pVO2 reasonably accurately in HF.
中文摘要:峰值耗氧量(pVO2)已被广泛用于识别运动不耐受的潜在病理生理机制,并对心力衰竭(HF)患者进行风险分层。研究旨在建立无运动方程估算pVO2(esVO2),并确定其与全因死亡的关系。共纳入5176例因临床原因接受心肺运动试验(CPET)的HF患者(年龄48±17岁),随访时间为2011年5月至2023年12月1日。采用临床与病史变量及第1秒用力呼气容积(FEV1)进入逐步多变量回归分析,以预测CPET测得的pVO2。采用Kaplan-Meier曲线和Cox比例风险分析确定esVO2与全因死亡的关系。首个esVO2模型与pVO2显著相关(多重R=0.73,P<0.001)。另两个模型分别考虑性别(男性:多重R=0.72,P<0.001;女性:多重R=0.70,P<0.001)。当无肺功能检查时提出第四个模型(年龄、BMI、静息收缩压、心率和性别,多重R=0.69,P<0.001)。第五个模型纳入心房颤动病史和既往卒中史(多重R=0.70,P<0.001)。Kaplan-Meier生存曲线按esVO2和pVO2≤与>14 mL/kg/min区分患者。单变量Cox比例风险分析显示,当esVO2和pVO2≤14 mL/kg/min时具有显著预后价值(P=0.001)。结合肺功能检查和/或临床评估中常用临床变量的多变量无运动模型可在HF中较准确预测pVO2。
Circulation IF 41.3 2026-10-11 PMID: 42860037
Left atrial (LA) stiffening augments the LA V wave, pressurizing the pulmonary artery (PA) out of proportion to left ventricular end-diastolic pressure. We characterized the pathophysiologic, diagnostic, and clinical implications of LA stiffening, as defined by prominent V waves, in heart failure with preserved ejection fraction. In this retrospective cohort study, patients with heart failure with preserved ejection fraction and less than moderate mitral regurgitation at rest underwent invasive hemodynamic exercise testing. Patients with heightened operant LA stiffening were defined by the PA wedge pressure (PAWP) V wave exceeding mean PAWP by ≥10 mm Hg. A previously used formula for V wave-corrected PAWP was validated against the PAWP waveform pressure-time-area to explore impact of the V wave on transpulmonary pressure gradients. Clinical, echocardiographic, hemodynamic, and outcome data were compared for patients with and without prominent V waves. Compared with patients without prominent V waves (n=844, 79%), those with prominent V waves (n=225, 21%) were older and more likely to be women, with more severe LA myopathy, evidenced by greater LA volume index (42.2±15.0 versus 32.5±13.0 mL/m2, P<0.001), lower LA reservoir strain (16.4±7.5% versus 23.2±8.3%, P<0.001), more atrial fibrillation (61.3% versus 22.9%, P<0.001), and increased operant LA reservoir stiffness (0.59±0.25 versus 0.23±0.24 mm Hg/mL, P<0.001). Patients with prominent V waves had markedly higher PA systolic pressure than those without (54±16 versus 38±12 mm Hg, P<0.001) despite no difference in end-diastolic PAWP-PA pressure gradient (3±5 versus 3±4 mm Hg, P=0.950). Incorporating the V wave into PAWP improved correlation between directly measured PAWP pressure-time integral compared with mid-A wave PAWP (R2=0.96 versus R2=0.86, P<0.001 for comparison). In patients with prominent V waves, the prevalence of combined pre- and postcapillary pulmonary hypertension decreased from 60.2% to 29.3% after V wave correction for the transpulmonary pressure gradients. Despite similar corrected pulmonary vascular resistances in patients with and without prominent V waves, apparent PA compliance was much lower in patients with prominent V waves (3.03±1.56 versus 4.90±2.27 mL/mm Hg, P<0.001), augmenting right ventricular afterload, and these changes were coupled with more severe right ventricular dysfunction, tricuspid regurgitation, blunted cardiopulmonary exercise reserve, and increased risk of hospitalization for heart failure or death in patients with versus without prominent V waves (adjusted hazard ratio, 2.09 [95% CI, 1.53-2.86]; P<0.001). More than 1 in 5 patients with heart failure with preserved ejection fraction display prominent V waves in excess of end-diastolic PAWP. This augments right ventricular afterload due to backward transmission of the V wave, contributing to right heart failure that is independent of the pulmonary vasculature. Failure to account for the V wave during hemodynamic assessment overestimates the severity of pulmonary vascular disease present.
中文摘要:左房僵硬化会增大左房V波,使肺动脉压力升高程度与左室舒张末压不成比例。本研究描述射血分数保留的心力衰竭中,以显著V波所定义的左房僵硬化的病理生理、诊断和临床意义。这项回顾性队列研究纳入静息时二尖瓣反流程度低于中度的射血分数保留的心力衰竭患者,行有创血流动力学运动试验。以肺动脉楔压V波超过平均肺动脉楔压≥10 mm Hg定义左房有效僵硬度增高。研究用既往提出的V波校正肺动脉楔压公式,与肺动脉楔压波形的压力-时间面积进行验证,以探讨V波对跨肺压力梯度的影响。比较有无显著V波患者的临床、超声心动图、血流动力学和结局资料。与无显著V波者(n=844,79%)相比,有显著V波者(n=225,21%)年龄更大、女性更多,左房肌病更重,表现为左房容积指数更大(42.2±15.0 对 32.5±13.0 mL/m2,P<0.001)、左房储备应变更低(16.4±7.5% 对 23.2±8.3%,P<0.001)、心房颤动更多(61.3% 对 22.9%,P<0.001)、左房有效储备僵硬度更高(0.59±0.25 对 0.23±0.24 mm Hg/mL,P<0.001)。有显著V波者的肺动脉收缩压明显高于无显著V波者(54±16 对 38±12 mm Hg,P<0.001),但舒张末肺动脉楔压-肺动脉压力梯度无差异(3±5 对 3±4 mm Hg,P=0.950)。将V波纳入肺动脉楔压后,与A波中点肺动脉楔压相比,其与直接测得的肺动脉楔压压力-时间积分相关性更好(R2=0.96 对 R2=0.86,比较P<0.001)。在有显著V波者中,按V波校正跨肺压力梯度后,合并毛细血管前和毛细血管后肺动脉高压的患病率由60.2%降至29.3%。尽管有无显著V波者的校正肺血管阻力相似,有显著V波者的表观肺动脉顺应性明显更低(3.03±1.56 对 4.90±2.27 mL/mm Hg,P<0.001),使右室后负荷增加,这些变化伴有更严重的右室功能障碍、三尖瓣反流、心肺运动储备减低,以及因心力衰竭住院或死亡风险增加(校正风险比2.09,95%置信区间1.53-2.86,P<0.001)。超过五分之一的射血分数保留的心力衰竭患者存在超过舒张末肺动脉楔压的显著V波。V波向后传递使右室后负荷增加,促成不依赖肺血管床的右心衰竭。血流动力学评估时未考虑V波会高估肺血管疾病的严重程度。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42530239
Cardiac remodelling drives heart failure (HF), yet microstructural drivers in human tissue remain poorly defined due to the limited resolution of clinical imaging. This study sought to quantitatively assess cardiomyocyte morphometry and its relationship with clinical phenotypes. We developed MyoSAM, a deep learning framework for quantitative morphometric characterization of H&E-stained whole-slide images (N = 334 patients). Cardiomyocyte size was quantified using the myocyte maximum inscribed circle (MMIC) radius, along with measures of nuclear size and perinuclear-halo size, interstitial and macrodomain stromal fractions. Independent associations between these histological features and clinical variables were assessed using multivariable regression and patient-level linear mixed-effects models to account for clustering of cellular measurements within individuals. MMIC radius was the strongest histological predictor of left ventricular mass index (LVMI; P < 0.001) and was positively correlated with clinical HF (Pearson's r = 0.77, P < 0.001). In severe coronary artery disease, the association between LVMI and MMIC radius was significantly attenuated (P = 0.001), indicating that myocyte hypertrophy was diminished despite increased mass; instead, remodelling shifted towards greater interstitial stromal expansion (P = 0.025). Males exhibited larger MMIC radii than females (fold-changes 1.08, P = 0.003). Distinct aetiology-specific signatures emerged: anthracycline-treated hearts showed large MMIC radii and perinuclear halos with minimal stroma, while non-ischaemic cardiomyopathy exhibited the greatest nuclear enlargement and stromal macrodomain expansion. Computational pathology enables high-resolution characterization of myocardial remodelling, revealing distinct microstructural phenotypes across sex, coronary disease burden, and HF aetiology that may improve cardiac phenotyping and risk stratification.
中文摘要:心脏重构驱动心力衰竭(HF),但受临床影像分辨率限制,人体组织中的微结构驱动因素仍不明确。本研究旨在定量评估心肌细胞形态计量及其与临床表型的关系。我们开发了MyoSAM,一种用于H&E染色全切片图像定量形态计量表征的深度学习框架(N=334例患者)。心肌细胞大小以心肌细胞最大内切圆(MMIC)半径量化,并测量细胞核大小、核周晕大小、间质及大区域基质分数。采用多变量回归和患者水平线性混合效应模型评估这些组织学特征与临床变量的独立关联,以考虑个体内细胞测量的聚簇。MMIC半径是左心室质量指数(LVMI)最强的组织学预测因子(P<0.001),并与临床HF正相关(Pearson r=0.77,P<0.001)。在严重冠状动脉疾病中,LVMI与MMIC半径的关联显著减弱(P=0.001),提示尽管质量增加,心肌细胞肥大却减轻;重构转向间质基质扩张增加(P=0.025)。男性MMIC半径大于女性(倍数变化1.08,P=0.003)。出现了病因特异性特征:蒽环类治疗心脏显示大MMIC半径和核周晕,基质极少;非缺血性心肌病则表现为最明显的细胞核增大和基质大区域扩张。计算病理学能够高分辨率表征心肌重构,揭示跨性别、冠状动脉疾病负担和HF病因的独特微结构表型,可能改善心脏表型分型和风险分层。

基础研究 (4篇)

Ageing research reviews IF 15.5 2026-10-12 PMID: 42863579
Heart failure with preserved ejection fraction (HFpEF) contributes to nearly 50% of the global heart failure (HF) cases, and remains a major clinical challenge because of its heterogeneous pathophysiology, substantial residual morbidity, and limited mechanism-based treatment options. HFpEF is increasingly recognized as a heterogeneous multisystem syndrome closely associated with aging, cardiometabolic comorbidities, and chronic low-grade inflammation. Cellular senescence and the senescence-associated secretory phenotype (SASP) have emerged as potential mechanisms linking several of these systemic stressors to cardiovascular dysfunction. By paracrine and endocrine communication, SASP creates a self-reinforcing circuit in the myocardium. However, the biological consequences of cellular senescence are highly context-, cell type-, and stage-dependent, and transient senescence may exert adaptive or tissue-protective effects under certain conditions. Moreover, much of the current evidence linking senescence to HFpEF remains preclinical or associative, and HFpEF-specific human data are still limited. This review systematically assesses the current evidence linking cellular senescence and SASP to HFpEF and examines the therapeutic potential and limitations of senolytics and senomorphics.
中文摘要:射血分数保留的心力衰竭(HFpEF)约占全球心力衰竭病例的近50%,因其病理生理异质性、显著残余发病率和有限的基于机制的治疗选择,仍是重大临床挑战。HFpEF日益被视为一种异质性多系统综合征,与衰老、心脏代谢合并症和慢性低度炎症密切相关。细胞衰老及衰老相关分泌表型(SASP)已成为将多种全身应激因素与心血管功能障碍联系起来的潜在机制。通过旁分泌和内分泌通讯,SASP在心肌中形成自我强化的回路。然而,细胞衰老的生物学后果高度依赖背景、细胞类型和阶段,短暂性衰老在某些条件下可能发挥适应性或组织保护作用。当前将衰老与HFpEF联系起来的多数证据仍为临床前或相关性证据,HFpEF特异性人体数据仍有限。该综述系统评估细胞衰老和SASP与HFpEF相关的现有证据,并考察衰老细胞清除药物和衰老表型调节药物的治疗潜力与局限。
European heart journal IF 45.3 2026-10-10 PMID: 42855844
Palmitic acid (PA), the most abundant saturated fatty acid (SFA), is positively associated with heart failure (HF) risk. However, its role and mechanism underlying HF remain unclear. This study aimed to investigate the effects of a PA-enriched diet and potential therapeutic targets in HF. The association between plasma SFAs and HF was investigated in a cohort of 232 592 UK Biobank participants. Mice were randomly categorized into three groups, where they were fed a PA-enriched, olive oil-enriched, or control diet for 4 weeks, followed by a 4-week dietary adaptation period on the control diet. A pressure overload model was established by transverse aortic constriction in these mice and cardiac-specific lysine demethylase 5A (Kdm5A)-knockout mice. The UK Biobank database revealed an association between high plasma SFA levels and increased HF risk. Our in vitro and in vivo results demonstrated that short-term PA treatment promoted cardiac hypertrophy and HF without further exposure to high levels of PA, indicating a pro-hypertrophic memory in cardiomyocytes. Mechanistically, PA promoted palmitoylation-driven KDM5A degradation via the ubiquitination pathway, thereby up-regulating histone 3 lysine 4 tri-methylation (H3K4me3). KDM5A/H3K4me3 promoted a pro-hypertrophic memory in cardiomyocytes, thus causing cardiac hypertrophy via a monocarboxylate transporter 4 (MCT4)-induced metabolic imbalance. Furthermore, KDM5A agonist D18 ameliorated this PA-mediated cardiac hypertrophy and HF. A PA-enriched diet promotes pro-hypertrophic memory in cardiomyocytes, cardiac hypertrophy, and HF via KDM5A/H3K4me3/MCT4. The application of D18 may represent a promising therapeutic approach for PA-mediated cardiac hypertrophy and HF.
中文摘要:棕榈酸(PA)是最丰富的饱和脂肪酸(SFA),与心力衰竭(HF)风险呈正相关,但其在HF中的作用及机制仍不清楚。研究旨在探讨富含PA饮食的影响及HF的潜在治疗靶点。在232 592名英国生物银行参与者队列中分析血浆SFA与HF的关联。小鼠随机分为三组,分别喂食富含PA、富含橄榄油或对照饮食4周,随后在对照饮食下进行4周饮食适应。通过横向主动脉缩窄在这些小鼠及心脏特异性赖氨酸去甲基化酶5A(Kdm5A)敲除小鼠中建立压力超负荷模型。英国生物银行数据库显示高血浆SFA水平与HF风险增加相关。体外和体内结果均显示,短期PA处理可促进心脏肥厚和HF,且无需继续暴露于高水平PA,提示心肌细胞存在促肥厚记忆。机制上,PA通过泛素化途径促进棕榈酰化驱动的KDM5A降解,从而上调组蛋白3赖氨酸4三甲基化(H3K4me3)。KDM5A/H3K4me3促进心肌细胞促肥厚记忆,并通过单羧酸转运体4(MCT4)诱导的代谢失衡导致心脏肥厚。KDM5A激动剂D18可改善PA介导的心脏肥厚和HF。富含PA饮食通过KDM5A/H3K4me3/MCT4促进心肌细胞促肥厚记忆、心脏肥厚和HF。D18的应用可能为PA介导的心脏肥厚和HF提供有前景的治疗策略。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42592849
Inflammation plays a central role in the pathophysiology of heart failure (HF), and contributes to disease progression, morbidity, and mortality. However, the relationships between inflammatory cytokines and different HF subtypes are complex, heterogeneous, and bidirectional. In this review, we examine inflammatory pathways, biomarker profiles, and comorbidities in HF with reduced, mildly reduced, and preserved ejection fraction and summarize evidence on the use of high-sensitivity C-reactive protein as a biomarker for systemic inflammation in HF. We provide insights into emerging methodologies for biomarker discovery in HF and discuss the use of animal models to elucidate underlying mechanisms and test potential treatment strategies. Finally, we provide an overview of the therapeutic landscape, touching on past challenges and future opportunities for the development of targeted anti-inflammatory therapies in HF.
中文摘要:炎症在心衰病理生理中居核心地位,参与疾病进展、发病和死亡。炎症细胞因子与不同心衰亚型之间的关系复杂、异质且呈双向。本综述考察射血分数降低、轻度降低和保留型心衰中的炎症通路、生物标志物谱和合并症,总结高敏C反应蛋白作为心衰全身炎症生物标志物的证据。提供心衰生物标志物发现新兴方法的见解,讨论动物模型用于阐明机制和测试潜在治疗策略。最后概述治疗格局,涉及靶向抗炎治疗开发中的既往挑战与未来机会。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42578283
Liver sinusoidal endothelial cells (LSECs) dysfunction was demonstrated to represent an early and persistent event in chronic heart failure (CHF), preceding congestive hepatopathy and contributing to the pathophysiology of the disease. However, it remains unknown whether classical CHF pharmacotherapy would reverse LSEC defenestration. Herein, we characterized the therapeutic effects of angiotensin-converting enzyme inhibitor (ACE-I)-perindopril-and sodium-glucose cotransporter 2 inhibitor (SGLT2-I)-empagliflozin-on the cardiohepatic axis and, in particular, on LSEC defenestration in the murine model of CHF. Untreated 6-month-old Tgαq*44 mice exhibited impaired systolic and diastolic cardiac function, impaired liver perfusion, and LSEC defenestration. Perindopril (2 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) significantly improved the left ventricular (LV) and right ventricular (RV) systolic function and ameliorated liver perfusion in vivo in Tgαq*44 mice. Perindopril also displayed a pronounced hepatoprotective effect, as evidenced by proteomic analysis of isolated hepatocytes, reduced total bilirubin, and gamma-glutamyltransferase; however, the number of LSEC fenestrations was unaffected in Tgαq*44 mice treated with perindopril. Empagliflozin (300 mg/kg, 8 weeks of treatment, 4- to 6-month-old Tgαq*44 mice) not only significantly improved LV and RV systolic function and ameliorated liver perfusion but also improved diastolic cardiac function and significantly reduced the defenestration of LSECs. LSEC defenestration was primarily driven by cardiac diastolic dysfunction, not by impaired liver perfusion or hepatocyte function, and was independent of biomarkers of congestive hepatopathy in the murine model of CHF in Tgαq*44 mice. As fully reversed by SGLT2-I, but not by ACE-I, LSEC defenestration emerges as a target in the treatment of the cardiohepatic axis in CHF, which is not uniformly improved by CHF pharmacotherapy.
中文摘要:肝窦内皮细胞(LSECs)功能障碍已被证明是慢性心力衰竭(CHF)的早期且持续事件,先于淤血性肝病并参与疾病病理生理。然而,经典CHF药物治疗是否可逆转LSEC开窗化仍未知。本研究在CHF小鼠模型中表征血管紧张素转换酶抑制剂(ACE-I)培哚普利和钠-葡萄糖协同转运蛋白2抑制剂(SGLT2-I)恩格列净对心肝轴尤其是LSEC开窗化的治疗作用。未治疗6月龄Tgαq*44小鼠显示收缩和舒张心功能受损、肝灌注受损和LSEC开窗化。培哚普利(2 mg/kg,治疗8周,4至6月龄Tgαq*44小鼠)显著改善Tgαq*44小鼠左心室(LV)和右心室(RV)收缩功能并改善在体肝灌注。培哚普利还显示明显肝保护作用,表现为分离肝细胞蛋白质组分析、总胆红素和γ-谷氨酰转移酶降低;但培哚普利治疗Tgαq*44小鼠的LSEC窗孔数未受影响。恩格列净(300 mg/kg,治疗8周,4至6月龄Tgαq*44小鼠)不仅显著改善LV和RV收缩功能并改善肝灌注,还改善舒张心功能并显著减少LSECs开窗化。在Tgαq*44小鼠CHF模型中,LSEC开窗化主要由心脏舒张功能障碍驱动,而非肝灌注受损或肝细胞功能,且独立于淤血性肝病生物标志物。由于SGLT2-I可完全逆转而ACE-I不能,LSEC开窗化成为CHF心肝轴治疗靶点,而CHF药物治疗对其改善并不一致。

2心肌梗死/ACS (8篇)

临床研究 (4篇)

European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 40742910
This study aimed to determine the prevalence of severe obesity [body mass index (BMI) ≥ 40 kg/m²] among patients with ST-elevation myocardial infarction (STEMI) and clarify its association with age, temporal trends, and outcomes. Consecutive patients admitted to a German heart centre between 2006 and 2022 for STEMI were categorized into five BMI groups according to the World Health Organization classification. Among the 11 629 STEMI patients, 269 (2.3%) had severe obesity. These patients were more likely to be female, have diabetes, and were on average 8.6 years younger than normal-weight patients (57.8 ± 12 vs. 66.4 ± 14 years, P < 0.01). The prevalence of severe obesity increased from 1.9 to 2.6% (2006-13 vs. 2013-22, P = 0.014), with the increase being a greater in females than in males (2.5-3.7%, P = 0.052). In younger patients (<55 years), prevalence rates increased by 128% in females (4.9-11.3%, P < 0.01) and 71% in men (2.2-3.7%, P < 0.01). Severe obesity did not affect treatment outcomes or in-hospital adverse event rates but was associated with higher 30-day [14.2% vs. 9.2%; adjusted hazard ratio (HR), 1.99; 95% confidence interval (CI), 1.4-3.0; P < 0.01] and 5-year mortality rates (30.6% vs. 20.6%; adjusted HR, 2.03; 95% CI, 1.4-2.9; P < 0.01). The significant increase in the prevalence of severe obesity among patients with STEMI, particularly among females and younger individuals, underscores the urgent need for more effective prevention and treatment strategies to improve their long-term prognosis.
中文摘要:该研究旨在明确ST段抬高型心肌梗死(STEMI)患者中重度肥胖[体重指数(BMI)≥40 kg/m²]的患病率,并阐明其与年龄、时间趋势及结局的关系。2006年至2022年连续收治于德国一家心脏中心的STEMI患者按世界卫生组织分类分为5个BMI组。11 629例STEMI患者中269例(2.3%)存在重度肥胖。这些患者女性更多、糖尿病比例更高,平均年龄较正常体重患者小8.6岁(57.8±12岁 vs. 66.4±14岁,P<0.01)。重度肥胖患病率从1.9%升至2.6%(2006—2013年 vs. 2013—2022年,P=0.014),女性增幅大于男性(2.5%—3.7%,P=0.052)。在年轻患者(<55岁)中,女性患病率增加128%(4.9%—11.3%,P<0.01),男性增加71%(2.2%—3.7%,P<0.01)。重度肥胖未影响治疗结局或院内不良事件发生率,但与更高的30天死亡率(14.2% vs. 9.2%;校正风险比HR 1.99;95%置信区间CI 1.4—3.0;P<0.01)和5年死亡率(30.6% vs. 20.6%;校正HR 2.03;95%CI 1.4—2.9;P<0.01)相关。STEMI患者中重度肥胖患病率显著上升,尤其在女性和年轻人群中,这凸显出需要更有效的预防和治疗策略以改善其长期预后。
ACS sensors IF 10.9 2026-10-12 PMID: 42861732
Developing a miniaturized, portable device for multiplexed detection of a library of protein biomarkers from microliter blood sample is critical for early disease screening in many scenarios, such as home healthcare and emergency care. However, major challenges remain, including multiplexed detection without cross-interference, system-level miniaturization, reliable flow manipulation, and simple user operation. Here, we present a miniaturized, multilayer structured vertical flow paper device that enables one-step, multiplexed, spontaneous detection of biomarkers in microliter blood for screening of heart disease, kidney disease, and inflammation. The device is designed with a multilayer membrane structure that integrates 3D-printed glass fiber membranes, wax-printed nitrocellulose membranes, and cellulose absorption membranes, enabling autonomous wicking of the sample through the device while concurrently distributing the sample into multiple equal parts and executing the sandwich immunoassay and washing steps. Simultaneous quantification of 12 biomarkers is achieved, and clinical performance is validated using clinical samples from patients with acute myocardial infarction (AMI), acute kidney disease (AKD), or sepsis. The device requires about 60 μL of sample, delivers results in 15 min, and is also compact (12.5 cm3). Overall, this platform provides a novel and universal strategy for miniaturized multiplexed immunoassays for rapid clinical screening.
中文摘要:开发一种小型化、便携式设备,用于从微升血液中多重检测一组蛋白标志物,对家庭医疗和急诊救治等场景下的疾病早期筛查十分关键。该方向仍面临多重检测无交叉干扰、系统级小型化、可靠液体操控和用户操作简便等挑战。这里提出一种小型化多层结构垂直流纸基装置,可在微升血液中一步式、多重、自驱动检测标志物,用于心脏病、肾病和炎症筛查。装置采用多层膜结构,整合3D打印玻璃纤维膜、蜡打印硝酸纤维素膜和纤维素吸水膜,使样本自主毛细导流通过装置,同时将样本等分到多个区域并完成夹心免疫分析和洗涤步骤。该装置可同时定量12种标志物,并使用急性心肌梗死、急性肾病或脓毒症患者的临床样本验证临床性能。检测约需60 μL样本,15分钟出结果,体积仅12.5立方厘米。该平台为小型化多重免疫分析用于快速临床筛查提供了新颖且通用的策略。
Clinical reviews in allergy & immunology IF 11.5 2026-10-11 PMID: 42859290
Kounis syndrome (KS) is a hypersensitivity-associated acute coronary syndrome. Food-associated KS remains poorly characterized, and its clinical presentation may be mimicked by non-immune food-related toxic reactions. To characterize the food exposures, clinical and cardiovascular presentations, allergological assessment, potential cofactors, KS phenotypes, management, and outcomes reported in food-associated KS. PubMed, Scopus, and Web of Science Core Collection were searched from inception to August 22, 2026. Original case reports, case series, and sufficiently informative conference reports describing objective coronary involvement temporally associated with a food or food-derived exposure were included. Patient-level data were synthesized qualitatively. KS diagnostic certainty, coronary phenotype, food causality, and presumed mechanism were assessed separately. Planned sensitivity analyses restricted the synthesis to confirmed or suspected food allergy, definite or probable KS, and cases without epinephrine administration before coronary onset or its first objective documentation. The synthesis included 50 publications or reports describing 53 unique patients. Food-related mechanisms comprised confirmed food allergy in 20 patients, clinically suspected food allergy in 26, scombroid poisoning in six, and a Coprinopsis atramentaria-alcohol interaction in one. The reported coronary spectrum ranged from transient vasospasm and nonobstructive presentations to plaque-related myocardial infarction, native-coronary thrombosis, and stent or graft thrombosis. Type I was the most frequently assigned phenotype. Allergological assessment, paired acute and baseline tryptase measurements, treatment chronology, and long-term follow-up were inconsistently reported. The main cardiovascular patterns remained broadly consistent across the planned sensitivity analyses. Food-associated KS encompasses a heterogeneous spectrum of allergic coronary presentations. Clinically similar non-immune food-related toxic reactions, including scombroid poisoning, should be recognized as differential diagnoses and analyzed separately from true allergic KS. Diagnosis requires integration of exposure chronology, objective cardiovascular findings, coronary substrate, allergological evidence, potential cofactors, and competing exposures. Intramuscular epinephrine remains the first-line treatment for anaphylaxis, and temporal precedence should not be interpreted as evidence that epinephrine caused the coronary event.
中文摘要:Kounis综合征(KS)是一种与超敏反应相关的急性冠脉综合征。食物相关KS的临床特征仍不充分,其临床表现可被非免疫性食物相关毒性反应所模仿。旨在描述食物相关KS中报告的食物暴露、临床与心血管表现、过敏学评估、潜在辅因子、KS表型、处理及结局。检索PubMed、Scopus和Web of Science核心合集,时间自建库至2026年8月22日。纳入原始病例报告、病例系列及信息充分的会议报告,这些报告描述了与食物或食物来源暴露在时间上相关的客观冠状动脉受累。对患者层面数据进行定性综合。分别评估KS诊断确定性、冠状动脉表型、食物因果性及推测机制。预设敏感性分析将综合范围限制于确诊或疑似食物过敏、肯定或很可能KS,以及在冠状动脉事件发生前或其首次客观记录前未使用肾上腺素者。综合纳入50篇出版物或报告,描述53例独特患者。食物相关机制包括20例确诊食物过敏、26例临床疑似食物过敏、6例鲭鱼中毒及1例墨汁鬼伞(Coprinopsis atramentaria)与酒精相互作用。报告的冠状动脉谱从短暂性血管痉挛和非阻塞性表现,到斑块相关心肌梗死、自体冠状动脉血栓形成及支架或移植物血栓形成。I型是最常被赋予的表型。过敏学评估、急性期与基线类胰蛋白酶配对检测、治疗时间顺序及长期随访的报告不一致。在预设敏感性分析中,主要心血管表现模式总体保持一致。食物相关KS涵盖异质性的过敏性冠状动脉表现谱。临床相似的非免疫性食物相关毒性反应(包括鲭鱼中毒)应被识别为鉴别诊断,并与真正过敏性KS分开分析。诊断需要整合暴露时间顺序、客观心血管发现、冠状动脉基础、过敏学证据、潜在辅因子及竞争性暴露。肌内注射肾上腺素仍是过敏反应的一线治疗,时间上的先后关系不应被解释为肾上腺素导致冠状动脉事件的证据。
European journal of preventive cardiology IF 10.0 2026-10-11 PMID: 42858957
Current guidelines recommend targeting systolic blood pressure (SBP) below 130 mmHg in patients at high cardiovascular risk, including after acute coronary syndrome (ACS), although evidence specific to the post-ACS setting remains limited. We evaluated the prognostic value of SBP measured 1 year after ACS on subsequent cardiovascular outcomes. The ELIPS cohort prospectively enrolled ACS patients across four Swiss tertiary-care centers (2009-2017). Patients alive at 1 year with available SBP measurements were included. The association between SBP at 1 year and 3-point major adverse cardiovascular events (MACE; cardiovascular death, non-fatal stroke/transient ischemic attack, or non-fatal myocardial infarction) was modeled using restricted cubic splines, adjusted for age, sex, renal function, cardiovascular risk factors, index-event type, coronary revascularization, cardiac rehabilitation, heart-failure history, and antihypertensive medication classes. Among 2,074 patients (age 63±12 years; 82% male; 53% STEMI), 229 MACE events occurred over a median follow-up of 4.0 years (2.7 per 100 patient-years). The SBP-MACE relationship was nonlinear and J-shaped (P-non-linearity=0.007), with lowest risk between ∼130 and 140 mmHg (formally estimated nadir 138 mmHg [95%CI 116-152]). Above 140 mmHg, each 5-mmHg increase was associated with a borderline increase in MACE risk (adjusted HR 1.08; 95%CI 1.00-1.17). The pattern was broadly consistent across sex, age and hypertension status, with a possible interaction with diabetes that could not be excluded (P-interaction=0.08). In this large, predominantly male, well-characterized post-ACS cohort, SBP measured 1 year after ACS showed a J-shaped association with cardiovascular risk, with lowest risk at 130-140 mmHg.
中文摘要:当前指南建议高心血管风险患者包括急性冠脉综合征(ACS)后患者将收缩压(SBP)控制在130 mmHg以下,但针对ACS后场景的证据仍有限。我们评估ACS后1年测得的SBP对后续心血管结局的预后价值。ELIPS队列前瞻性纳入瑞士四家三级医疗中心的ACS患者(2009-2017)。纳入1年时存活且有SBP测量值的患者。采用限制性立方样条建模1年时SBP与3点主要不良心血管事件(MACE;心血管死亡、非致死性卒中/短暂性脑缺血发作或非致死性心肌梗死)的关联,并校正年龄、性别、肾功能、心血管危险因素、指数事件类型、冠状动脉血运重建、心脏康复、心力衰竭病史及抗高血压药物类别。在2,074例患者中(年龄63±12岁;82%男性;53% STEMI),中位随访4.0年期间发生229例MACE事件(每100患者年2.7例)。SBP与MACE关系呈非线性且为J形(非线性P=0.007),风险最低约在130至140 mmHg之间(正式估计最低点138 mmHg [95%CI 116-152])。高于140 mmHg时,每增加5 mmHg与MACE风险边缘性升高相关(校正HR 1.08;95%CI 1.00-1.17)。该模式在性别、年龄和高血压状态间大体一致,与糖尿病的可能交互作用不能排除(交互作用P=0.08)。在这个以男性为主、特征描述充分的大型ACS后队列中,ACS后1年测得的SBP与心血管风险呈J形关联,风险最低在130-140 mmHg。

基础研究 (4篇)

Science advances IF 13.9 2026-10-16 PMID: 42886791
Macrophages play a key role in cardiac injury and repair after myocardial infarction (MI). Salt-inducible kinase 2 (SIK2), a member of the adenosine monophosphate-activated protein kinase family, is notably up-regulated in monocytes/macrophages of patients with MI and animal models. In this study, we investigated the role of SIK2 in macrophage-mediated inflammation and efferocytosis following MI. Macrophage-specific SIK2 deletion reduces infarct size and improves healing post-MI. Furthermore, SIK2-knockout macrophages decrease proinflammatory factor expression and enhance efferocytosis, thereby increasing repair factors expression. SIK2 associates with tumor necrosis factor receptor-associated factor 2 (TRAF2), promoting its phosphorylation and K63 polyubiquitylation, which exacerbates inflammation and hinders efferocytosis via the P38 and nuclear factor κB pathways. In contrast, the SIK2T175A mutation exhibits no effect. Macrophage-specific SIK2 overexpression worsens cardiac changes after MI, whereas P38 inhibition reduces this effect. In addition, pharmacological inactivation of SIK2 substantially enhances cardiac repair after MI in mice. These findings highlight the crucial role of macrophage SIK2 in the regulation of inflammation and efferocytosis via TRAF2 polyubiquitination in MI, thereby presenting potential therapeutic targets.
中文摘要:巨噬细胞在心肌梗死(MI)后的心脏损伤与修复中起关键作用。盐诱导激酶2(SIK2)是腺苷酸活化蛋白激酶家族成员,在MI患者及动物模型的单核/巨噬细胞中明显上调。本研究探讨SIK2在MI后巨噬细胞介导的炎症与胞葬作用中的角色。巨噬细胞特异性敲除SIK2可缩小梗死面积并改善MI后愈合。SIK2敲除巨噬细胞降低促炎因子表达并增强胞葬作用,进而提高修复因子表达。SIK2与肿瘤坏死因子受体相关因子2(TRAF2)结合,促进其磷酸化及K63多泛素化,通过P38与核因子κB通路加剧炎症并阻碍胞葬作用。SIK2T175A突变则无此效应。巨噬细胞特异性过表达SIK2加重MI后心脏改变,抑制P38可减轻该效应。药物性失活SIK2显著增强小鼠MI后心脏修复。这些发现表明巨噬细胞SIK2通过TRAF2多泛素化调控MI中的炎症与胞葬作用,提示潜在治疗靶点。
Nature IF 56.1 2026-10-14 PMID: 42875490
In acute myocardial infarction and acute kidney injury, capillary no-reflow denotes that capillary blood flow is still blocked despite successful arterial reperfusion. This is associated with substantially increased mortality and reinfarction risk; nevertheless, no targeted therapy exists so far1,2. Because capillary no-reflow is driven by smooth muscle myosin-mediated hypercontraction of capillary pericytes, we developed R(+)2501, a myosin-specific and capillary-selective vasodilator. In reperfused animal models of acute myocardial infarction and acute kidney injury, direct in vivo imaging showed that R(+)2501 rapidly restored capillary flow, an effect sustained even after rapid drug clearance. Ex vivo experiments confirmed reversal of pericyte constriction directly. Restoration of capillary blood flow, together with clearance of trapped neutrophils, linked resolution of capillary no-reflow to attenuation of an early driver of reperfusion injury. R(+)2501 enhanced capillary perfusion while preserving coronary autoregulation and systemic haemodynamics, and markedly improved survival during acute reperfusion. We further found that acute myocardial infarction induced renal capillary no-reflow, which was reversed by R(+)2501, suggesting that capillary no-reflow contributes to the pathophysiology of cardiorenal syndrome type I. These findings establish pericyte-targeted smooth muscle myosin inhibition as a therapeutic strategy to restore microvascular perfusion and halt the ischaemic cascade across organs, while defining a specific physiological role for capillaries and pericytes in circulatory regulation.
中文摘要:在急性心肌梗死和急性肾损伤中,毛细血管无复流指动脉再灌注成功后毛细血管血流仍受阻,这与死亡率和再梗死风险显著升高相关,但迄今尚无靶向治疗。毛细血管无复流由平滑肌肌球蛋白介导的毛细血管周细胞过度收缩驱动,因此我们开发了R(+)2501,一种肌球蛋白特异性且毛细血管选择性的血管扩张剂。在急性心肌梗死和急性肾损伤的再灌注动物模型中,直接活体成像显示R(+)2501迅速恢复毛细血管血流,且该效应在药物快速清除后仍持续。离体实验直接证实周细胞收缩被逆转。毛细血管血流的恢复以及滞留中性粒细胞的清除,将毛细血管无复流的缓解与再灌注损伤早期驱动因素的减轻联系起来。R(+)2501增强毛细血管灌注,同时保留冠状动脉自身调节和全身血流动力学,并显著提高急性再灌注期间的生存率。我们还发现急性心肌梗死可诱导肾毛细血管无复流,R(+)2501可将其逆转,提示毛细血管无复流参与I型心肾综合征的病理生理。这些发现确立以周细胞为靶点的平滑肌肌球蛋白抑制作为一种治疗策略,可恢复微血管灌注并阻止跨器官的缺血级联反应,同时界定毛细血管和周细胞在循环调节中的特定生理作用。
Circulation IF 41.3 2026-10-13 PMID: 42639656
Myocardial infarction can cause a massive loss of functional cardiomyocytes, yet effective strategies to stimulate cardiac regeneration remain lacking. A key barrier to adult cardiomyocyte proliferation appears to be cytokinesis inhibition. This study aimed to determine whether combining proliferation stimulators with the removal of cytokinesis-inhibitory constraints could unlock regenerative potential after myocardial infarction. Transcriptomic profile from 5 regeneration models, including Aurkb-tdTomato cytokinesis reporter mice and Myh6-MerCreMer;mosaic analysis with double markers (MADM), and cross-species comparative analysis were used to explore the regulatory networks for cardiomyocyte proliferation. MADM mice were used to evaluate cardiac regeneration by quantifying after cytokinesis new cardiomyocytes and clonal clusters. Integrative multimodel analysis revealed a dual regulatory control system for cardiomyocyte proliferation, along with key associated genes and transcriptional regulators. Nfyb was identified as an activator and Nr3c1 as a repressor of cardiomyocyte proliferation. Nfyb overexpression enhanced cardiomyocyte proliferation and post-myocardial infarction cardiac repair through propelling cell-cycle gene transcription. Nr3c1 inhibition promoted cardiomyocyte proliferation, improved cardiac function, and reduced infarct size. A spatiotemporally controlled adeno-associated virus 9 system combining drug-inducible Nfyb overexpression and CRISPR/enOsCas12f1-mediated Nr3c1 deletion efficiently induces cardiomyocyte proliferation. Clonal analysis using MADM mice showed that the dual intervention synergistically increased new cardiomyocyte formation (28% clustered, >28-fold versus control). The enhanced regenerative effect of the dual intervention was demonstrated in post-myocardial infarction mice and human engineered heart tissues. This work documents a dual-control paradigm of cardiomyocyte proliferation and establishes Nfyb/Nr3c1 cointervention as a putative new therapy to induce and control cardiac regeneration after injury.
中文摘要:心肌梗死可导致功能性心肌细胞大量丢失,但促进心脏再生的有效策略仍然缺乏。成年心肌细胞增殖的主要障碍之一似乎是胞质分裂受抑。本研究旨在确定将增殖刺激因素与解除胞质分裂抑制性约束相结合,能否释放心肌梗死后的再生潜能。研究利用5种再生模型的转录组图谱,包括Aurkb-tdTomato胞质分裂报告小鼠和Myh6-MerCreMer;双标记嵌合分析(MADM)小鼠,并结合跨物种比较分析,探索心肌细胞增殖的调控网络。采用MADM小鼠量化胞质分裂后新形成的心肌细胞及克隆簇,以评估心脏再生。整合多模型分析揭示了心肌细胞增殖的双重调控控制系统,以及关键相关基因和转录调控因子。Nfyb被鉴定为心肌细胞增殖的激活因子,Nr3c1为抑制因子。过表达Nfyb通过推动细胞周期基因转录增强心肌细胞增殖并促进心肌梗死后心脏修复。抑制Nr3c1可促进心肌细胞增殖、改善心功能并缩小梗死面积。一种时空可控的腺相关病毒9系统,将药物诱导的Nfyb过表达与CRISPR/enOsCas12f1介导的Nr3c1缺失相结合,可有效诱导心肌细胞增殖。MADM小鼠克隆分析显示,双重干预协同增加新生心肌细胞形成(28%呈簇状,较对照增加逾28倍)。双重干预增强的再生效应在心肌梗死后小鼠和人工程心脏组织中得到验证。该工作记录了心肌细胞增殖的双重控制范式,并将Nfyb/Nr3c1共同干预确立为一种潜在新疗法,用于诱导并控制损伤后的心脏再生。
Advanced healthcare materials IF 11.0 2026-10-12 PMID: 42865063
Myocardial ischemia-reperfusion injury (MIRI) remains a major obstacle to functional recovery after myocardial infarction, primarily driven by excessive reactive oxygen species (ROS) generation, mitochondrial dysfunction, and apoptosis. In this study, we developed a straightforward hydrothermal method to synthesize Astragalus membranaceus-derived carbon dots (AM-CDs), using this medicinal herb, known for its cardiovascular protective effects, as a biomass precursor. The resulting AM-CDs exhibited broad-spectrum ROS-scavenging activity and pronounced biological effects against oxidative stress, inflammation, and apoptosis. In vitro experiments revealed that AM-CDs restored mitochondrial membrane potential and reduced DNA damage, as indicated by decreased γ-H2AX expression. Furthermore, AM-CDs downregulated pro-inflammatory cytokine mRNA expression in LPS-stimulated macrophages. In a rat model of MIRI, direct intramyocardial administration of AM-CDs resulted in a significant reduction in infarct size, improved left ventricular ejection fraction and fractional shortening in a dose-dependent manner, and exhibited no notable systemic toxicity. Transcriptomic and protein analyses further demonstrated that AM-CDs downregulate pro-apoptotic proteins and modulate the PI3K-AKT and NF-κB-apoptosis signaling pathways, thereby disrupting the vicious cycle of oxidative stress, inflammation, and cell death. Collectively, these findings indicate that AM-CDs offer a promising therapeutic approach that integrates traditional medicine with nanotechnology to provide effective cardioprotection against MIRI.
中文摘要:心肌缺血再灌注损伤(MIRI)仍是心肌梗死后功能恢复的主要障碍,其核心驱动因素包括活性氧(ROS)过度生成、线粒体功能障碍和细胞凋亡。本研究采用简便水热法,以具有心血管保护作用的中药黄芪作为生物质前体,合成黄芪来源碳点(AM-CDs)。所得AM-CDs表现出广谱ROS清除活性,并在抗氧化应激、炎症和凋亡方面显示出明显生物学效应。体外实验显示,AM-CDs恢复线粒体膜电位并减少DNA损伤,表现为γ-H2AX表达下降。AM-CDs还下调LPS刺激巨噬细胞中促炎细胞因子mRNA表达。在大鼠MIRI模型中,心肌内直接给予AM-CDs使梗死面积显著缩小,左心室射血分数和缩短分数呈剂量依赖性改善,未观察到明显全身毒性。转录组和蛋白分析进一步表明,AM-CDs下调促凋亡蛋白并调控PI3K-AKT与NF-κB-凋亡信号通路,从而打断氧化应激、炎症和细胞死亡之间的恶性循环。这些结果提示,AM-CDs将传统医学与纳米技术结合,为MIRI提供有效心脏保护,具有潜在治疗价值。

3高血压 (8篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-16 PMID: 42885348
This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo. COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5mg daily or placebo for six months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and six months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. Of 183 screened, 150 were randomized (75 per group). Mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 137.6 (±15.6) mmHg. At six months, cfPWV did not differ between groups (between-group difference in ΔcfPWV -0.1m/s, 95% CI: -0.5 to 0.3m/s, p=0.53). Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, p=0.018. hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP -39.8%, 95% CI: -59.1 to -11.4%, p=0.010). Left ventricular mass index or cardiac biomarkers did not differ between groups. Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP.
中文摘要:本试验比较秋水仙碱这一抗炎治疗与安慰剂对心血管结构和功能的影响,通过动脉僵硬度、血压和生化指标评估。COHERENT为随机、双盲、安慰剂对照试验,纳入接受药物治疗的高血压成人且无心血管疾病,观察秋水仙碱对动脉僵硬度的影响。符合条件的患者按1:1随机接受秋水仙碱0.5mg每日一次或安慰剂,共六个月。基线及六个月时行动脉僵硬度评估、超声心动图和生物标志物检测。主要终点为颈-股脉搏波速度(cfPWV)变化。次要终点包括血压、左心室质量指数以及心脏和炎症生物标志物变化。筛查183例,随机150例(每组75例)。平均年龄64.5(±8.0)岁,女性53例(35.3%),平均收缩压137.6(±15.6)mmHg。六个月时cfPWV两组无差异(ΔcfPWV组间差-0.1 m/s,95% CI -0.5至0.3 m/s,p=0.53)。安慰剂组诊室收缩压下降幅度显著大于秋水仙碱组(Δ诊室收缩压组间差5.7 mmHg,95% CI 1.0至10.5 mmHg,p=0.018)。秋水仙碱组hsCRP较安慰剂组显著下降(hsCRP百分比变化组间差-39.8%,95% CI -59.1至-11.4%,p=0.010)。左心室质量指数或心脏生物标志物两组无差异。接受药物治疗且无心血管疾病的高血压患者使用秋水仙碱六个月未影响动脉僵硬度。秋水仙碱显著降低hsCRP。

基础研究 (7篇)

Pharmacological research IF 12.2 2026-10-15 PMID: 42880616
Hypertension leads to concomitant injuries in the kidney and vasculature, yet the molecular mechanisms underlying this coordinated pathology remain incompletely understood. Here, we identify activation of the CYP4A/20-HETE/GPR75 axis as being associated with coordinated renal and vascular injury in hypertension. In hypertension, this pathway was concurrently activated in the liver, kidney, and vasculature and was associated with renal fibrosis, endothelial dysfunction, and oxidative stress. Pharmacological inhibition of CYP4A attenuated these pathological changes, supporting a functional contribution of this axis to hypertensive organ injury. Genetic and pharmacological evidence further demonstrated that FGF21 acts as an endogenous negative regulator of CYP4A/20-HETE signaling. Mechanistically, FGF21 restored expression of the nuclear receptor NR1D1, which was suppressed under hypertensive conditions, and this effect was associated with reduced CYP4A expression independently of ERK1/2 signaling. The functional relevance of the FGF21-NR1D1 axis was supported by the observation that NR1D1 antagonism largely abolished the protective effects of FGF21. Thus, these findings elucidate a mechanistic axis linking FGF21-NR1D1 signaling to the CYP4A/20-HETE/GPR75 pathway and suggest that modulation of this pathway may represent a potential therapeutic strategy for hypertensive renal and vascular injury.
中文摘要:高血压可导致肾脏与血管同时受损,这种协同性病理改变的分子机制仍未完全明确。本研究识别出CYP4A/20-HETE/GPR75轴的激活与高血压时肾脏和血管的协同损伤相关。在高血压状态下,该通路在肝脏、肾脏和血管中同时被激活,并与肾纤维化、内皮功能障碍和氧化应激相关。药理学抑制CYP4A可减轻这些病理改变,支持该轴对高血压器官损伤具有功能性作用。遗传学和药理学证据进一步表明,FGF21是CYP4A/20-HETE信号的内源性负性调节因子。机制上,FGF21可恢复高血压条件下受抑制的核受体NR1D1表达,这一效应与CYP4A表达降低相关,且不依赖ERK1/2信号。NR1D1拮抗可在很大程度上消除FGF21的保护作用,支持FGF21-NR1D1轴的功能相关性。这些发现阐明了一条连接FGF21-NR1D1信号与CYP4A/20-HETE/GPR75通路的机制轴,并提示调节该通路可能成为高血压肾与血管损伤的潜在治疗策略。
Food chemistry IF 10.4 2026-10-15 PMID: 42603411
NaCl is essential for human physiology, but excessive intake is linked to various health problems, including hypertension and cardiovascular disease. Thus, reducing NaCl in processed meats is increasingly demanded; however, NaCl is critical for key quality attributes (e.g., water-holding capacity and texture) and its characteristic flavor, creating a challenge to lower sodium without compromising product quality. Here, dry-aged beef crust was enzymatically hydrolyzed to develop a natural salt replacer for low-sodium sausages, and optimal conditions were explored by protease type (Flavourzyme, Protamex, and Neutrase, used individually or in combination) and reaction time. The hydrolysate treated by Flavourzyme (for 180 min) showed strong saltiness and weak bitterness in sensory and electronic-tongue analyses with high contents of taste-active metabolites. Replacing 17-33% of NaCl in sausages maintained color, water-holding capacity, texture, and saltiness while reducing bitterness. These findings support dry-aged beef crust hydrolysate as a natural NaCl replacer for low-sodium meat products.
中文摘要:NaCl对人体生理必不可少,但摄入过量与高血压和心血管疾病等多种健康问题相关。加工肉制品减NaCl的需求不断增加;NaCl对关键品质属性(如持水力和质构)及特征风味至关重要,因此在不损害产品品质的前提下降低钠含量存在挑战。本研究对干式熟成牛肉外壳进行酶解,开发用于低钠香肠的天然盐替代物,并按蛋白酶种类(Flavourzyme、Protamex和Neutrase,单独或联合使用)和反应时间探索最优条件。经Flavourzyme处理180 min的水解物在感官和电子舌分析中表现出较强咸味和较弱苦味,并含有较高含量的呈味活性代谢物。在香肠中替代17-33%的NaCl可保持色泽、持水力、质构和咸味,同时降低苦味。这些结果支持干式熟成牛肉外壳水解物作为低钠肉制品的天然NaCl替代物。
Acta biomaterialia IF 10.4 2026-10-14 PMID: 42874756
The microstructural and micromechanical properties of the arterial extracellular matrix (ECM) are central to vascular cell behavior but are disrupted by disease and aging. Elastin and fibrillar collagens provide essential cues, yet the effects of disease-associated ECM remodeling on smooth muscle function remain poorly defined. Here, we imaged fibrillar ECM components across layers of healthy and hypertensive arteries in a large animal model and quantified their stiffness with submicron and piconewton resolution. These animal-derived data guided the fabrication of artery-mimetic hydrogels using image-derived 3D projection micro-stereolithography (µSTL) and thiol-ene clickable bioinks. The resulting hydrogels replicated fibril features down to 2 µm with emulated curvatures and tunable stiffness spanning physiological to pathological ranges (1-35 kPa). Systematic optimization of printing parameters, including light intensity, exposure time, monomer concentration, crosslinker type, optical configurations, and hydrogel swelling solutions, ensured high-fidelity structural replication. Vascular smooth muscle cells cultured on these hydrogels revealed that diseased ECM conditions promoted hypertrophy, impaired contractility, and reduced calcium responsiveness. Quantitative PCR showed reduced expression of contractile markers (MYH11, SMTN) and marked upregulation of PTK2 (focal adhesion kinase) on hypertensive-mimetic matrices, implicating focal adhesion-dependent mechanotransduction in this response. This image-guided biofabrication platform enables precise engineering of vascular microenvironments for mechanistic studies of remodeling, therapeutic testing, and modeling of complex vascular disease states. STATEMENT OF SIGNIFICANCE: Arterial extracellular matrix stiffens and reorganizes in hypertension, yet in vitro models rarely reproduce these micron-scale changes. We measured layer-specific stiffness and fibrillar architecture in arteries from normotensive and hypertensive steers, a large animal model with fattening-induced hypertension. These data were directly translated into projection micro-stereolithography of thiol-ene hydrogels. The resulting matrices, high-fidelity 3D hydrogel prints, reproduced fibrillar features down to 2 µm with emulated curvatures and tunable stiffness spanning 1-35 kPa. Vascular smooth muscle cells cultured on hypertensive-mimetic matrices exhibited hypertrophic morphology, reduced calcium responsiveness and agonist-induced contractility, altered contractile-marker expression, and increased PTK2 expression, linking disease-associated matrix remodeling to altered mechanotransduction. This measurement-to-fabrication workflow provides a physiologically informed platform for mechanistic studies of vascular remodeling and evaluation of therapeutic responses.
中文摘要:动脉细胞外基质(ECM)的微结构和微力学性质是血管细胞行为的重要基础,但会随疾病和衰老发生破坏。弹性蛋白和纤维状胶原提供关键线索,疾病相关ECM重塑对平滑肌功能的影响仍不清楚。研究在大动物模型中成像了健康与高血压动脉各层的纤维状ECM成分,并以亚微米和皮牛级分辨率量化其刚度。这些动物来源数据指导了动脉仿生水凝胶的制备,采用图像衍生的3D投影微立体光刻(µSTL)和硫醇-烯可点击生物墨水。所得水凝胶复现了低至2 µm的纤维特征,模拟曲率并可调刚度覆盖生理至病理范围(1–35 kPa)。对打印参数的系统优化,包括光强、曝光时间、单体浓度、交联剂类型、光学配置和水凝胶溶胀溶液,保证了高保真结构复制。在这些水凝胶上培养的血管平滑肌细胞显示,病变ECM条件促进肥大、损害收缩性并降低钙反应性。定量PCR显示,在高血压仿生基质上收缩标志物(MYH11、SMTN)表达降低,PTK2(黏着斑激酶)显著上调,提示黏着斑依赖的机械转导参与该反应。该图像引导的生物制造平台能够精确构建血管微环境,用于重塑机制研究、治疗测试和复杂血管疾病状态建模。意义声明:动脉ECM在高血压中变硬并重组,但体外模型很少重现这些微米尺度变化。我们测量了血压正常和高血压阉牛的层特异性刚度和纤维架构,该大动物模型通过育肥诱导高血压。这些数据直接转化为硫醇-烯水凝胶的投影微立体光刻打印。所得基质为高保真3D水凝胶打印物,复现低至2 µm的纤维特征,模拟曲率,刚度可在1–35 kPa调节。在高血压仿生基质上培养的血管平滑肌细胞呈现肥大型形态、钙反应性和激动剂诱导收缩性降低、收缩标志物表达改变以及PTK2表达增加,将疾病相关基质重塑与机械转导改变联系起来。该从测量到制造的流程为血管重塑机制研究和治疗反应评估提供了生理学依据的平台。
Molecular biomedicine IF 13.0 2026-10-13 PMID: 42867591
Aberrant cyclic stretch serves as a critical driver of vascular remodeling in hypertension, yet the underlying molecular mechanisms remain largely unknown. Here, we studied the role of a novel circRNA, termed circ_2465 (circLyst), in vascular remodeling in both human and rodent samples under high cyclic stretch. Next-generation sequencing data revealed that 165 circRNAs were differentially expressed in the thoracic aortas of spontaneously hypertensive rats (SHRs) compared with normotensive Wistar-Kyoto rats (WKYs), of which 60 circRNAs were significantly upregulated while 105 circRNAs were significantly downregulated. CircLyst, verified as a novel circRNA by ribonuclease R (RNase R) digestion and Actinomycin D assays, was induced in the thoracic aortas of SHRs and stably located in the cytoplasm as detected by fluorescence in situ hybridization (FISH). This elevation was confirmed in hypertensive patients and was recapitulated in vascular smooth muscle cells (VSMCs) exposed to high cyclic stretch in vitro. Mechanistically, oxidative stress, mediated by NADPH oxidases NOX1 and NOX4, induced circLyst expression. CircLyst then functioned as a sponge for miR-298-5p, derepressing its target gene Col23a1, thereby promoting VSMC proliferation and migration-key events in vascular remodeling. Importantly, both systemic and VSMC-specific targeting of circLyst attenuated pathological remodeling and blunted hypertension in animal models. Collectively, our findings establish the oxidative-stress-driven circLyst/miR-298-5p/Col23a1 axis as a critical regulator of vascular remodeling and highlight circLyst as a potential therapeutic target for hypertensive vascular disease.
中文摘要:异常周期性牵张是高血压血管重构的重要驱动因素,其分子机制仍不清楚。研究检测了高周期性牵张下人和啮齿类样本中新型环状RNA circ_2465(circLyst)在血管重构中的作用。二代测序显示,自发性高血压大鼠(SHR)胸主动脉与正常血压Wistar-Kyoto大鼠(WKY)相比有165个环状RNA差异表达,其中60个显著上调、105个显著下调。经核糖核酸酶R消化和放线菌素D实验证实为新型环状RNA的circLyst在SHR胸主动脉中表达升高,荧光原位杂交显示其稳定定位于细胞质。这一升高在高血压患者中得到确认,并在体外高周期性牵张处理的血管平滑肌细胞(VSMC)中重现。机制上,NADPH氧化酶NOX1和NOX4介导的氧化应激诱导circLyst表达。circLyst随后作为miR-298-5p的海绵,解除对其靶基因Col23a1的抑制,促进VSMC增殖和迁移,这些是血管重构的关键事件。在动物模型中,全身性和VSMC特异性靶向circLyst均减轻病理性重构并削弱高血压。这些发现确立氧化应激驱动的circLyst/miR-298-5p/Col23a1轴是血管重构的关键调控因素,并提示circLyst是高血压血管病的潜在治疗靶点。
Circulation IF 41.3 2026-10-13 PMID: 42639676
Hypertension is a major risk factor for cardiovascular diseases. RNA N6-methyladenosine (m6A) modification is closely linked to hypertension pathogenesis, but key m6A-related factors that regulate blood pressure remain unclear. This study aims to identify these regulators and evaluate their therapeutic potential. We assessed RNA m6A changes and METTL (methyltransferase-like) expression in hypertensive aortas via methylated RNA immunoprecipitation sequencing and RNA sequencing (RNA-seq). Global Mettl7b knockout mice and vascular smooth muscle cell (VSMC)-specific Mettl7b knockin and knockout mice were used to evaluate its in vivo role. Downstream target genes were identified via methylated RNA immunoprecipitation sequencing, enhanced cross-linking and immunoprecipitation sequencing, and RNA-seq. METTL7B activators were screened using molecular docking and surface plasmon resonance and validated in vivo via intraperitoneal injection. Under hypertensive stress, METTL7B expression positively correlated with global RNA m6A content, exhibiting concurrent depletion in VSMCs. In vitro biochemical assays revealed that recombinant METTL7B significantly increased RNA m6A levels. Crucially, METTL7B overexpression in METTL3 knockout cells robustly upregulated m6A levels, definitively establishing METTL7B as a novel, METTL3-independent RNA m6A methyltransferase. Physiologically, VSMC-specific Mettl7b ablation exacerbated angiotensin II-induced hypertensive pathogenesis, structural arterial remodeling, and vascular tone, whereas its overexpression exerted potent vasoprotective effects. Mechanistically, METTL7B recruited HNRNPH1 to catalyze m6A deposition at the 3' untranslated region of FILIP1L mRNA, facilitating its maturation. Importantly, the expression of FILIP1L was positively correlated with blood pressure reduction in humans and mice. Elevated FILIP1L downregulated the expression of its binding protein FLNA (Filamin A), reducing F-actin polymerization, attenuating VSMC contractility, and ultimately lowering blood pressure. Furthermore, FILIP1L overexpression reversed the detrimental effects of Mettl7b knockout on hypertension and vascular remodeling, whereas these effects were not rescued by the mutation of FILIP1L's m6A site. Elucidating the upstream pathology, we found that stress-induced KLF4 directly bound the METTL7B promoter, transcriptionally repressing its expression. Finally, the Food and Drug Administration-approved drug netarsudil exerted preventive and therapeutic effects on hypertension and vascular remodeling by activating METTL7B; notably, these therapeutic benefits were completely abolished in VSMC-specific Mettl7b knockout mice. Collectively, our study identifies a novel RNA m6A methyltransferase, METTL7B. The METTL7B-HNRNPH1-FILIP1L axis mitigates hypertension by regulating VSMC dedifferentiation and vascular tone. Targeted activation of METTL7B may emerge as a promising strategy for hypertension.
中文摘要:高血压是心血管疾病的重要危险因素。RNA N6-甲基腺苷(m6A)修饰与高血压发病密切相关,但调控血压的关键m6A相关因子仍不清楚。本研究旨在识别这些调控因子并评估其治疗潜力。通过甲基化RNA免疫沉淀测序和RNA测序(RNA-seq),评估高血压主动脉中的RNA m6A变化及METTL(甲基转移酶样)表达。使用全局Mettl7b敲除小鼠以及血管平滑肌细胞(VSMC)特异性Mettl7b敲入和敲除小鼠评估其在体内的作用。通过甲基化RNA免疫沉淀测序、增强型交联免疫沉淀测序和RNA-seq识别下游靶基因。利用分子对接和表面等离子体共振筛选METTL7B激活剂,并通过腹腔注射在体内验证。在高血压应激下,METTL7B表达与全局RNA m6A含量呈正相关,并在VSMC中同时降低。体外生化实验显示,重组METTL7B显著提高RNA m6A水平。关键的是,在METTL3敲除细胞中过表达METTL7B可显著上调m6A水平,明确确立METTL7B是一种新的、不依赖METTL3的RNA m6A甲基转移酶。生理上,VSMC特异性缺失Mettl7b加重血管紧张素II诱导的高血压发病、动脉结构重塑和血管张力,而过表达则产生强效血管保护作用。机制上,METTL7B招募HNRNPH1催化FILIP1L mRNA的3′端非翻译区m6A沉积,促进其成熟。FILIP1L表达在人和小鼠中与血压降低呈正相关。升高的FILIP1L下调其结合蛋白FLNA(细丝蛋白A)的表达,减少F-actin聚合,减弱VSMC收缩性,最终降低血压。FILIP1L过表达可逆转Mettl7b敲除对高血压和血管重塑的不利影响,而突变FILIP1L的m6A位点不能产生这种挽救作用。追溯上游病理过程,应激诱导的KLF4直接结合METTL7B启动子并转录抑制其表达。最后,美国食品药品监督管理局批准的药物奈他舒地尔通过激活METTL7B对高血压和血管重塑发挥预防和治疗作用;在VSMC特异性Mettl7b敲除小鼠中,这些治疗获益完全消失。总体而言,本研究识别了一种新的RNA m6A甲基转移酶METTL7B。METTL7B-HNRNPH1-FILIP1L轴通过调控VSMC去分化和血管张力减轻高血压。靶向激活METTL7B可能成为高血压治疗的有前景策略。
Biosensors & bioelectronics IF 11.8 2026-10-12 PMID: 42863205
Post-translational modifications (PTMs) on G protein-coupled receptor kinase 4 (GRK4) are implicated in hypertension pathogenesis, their label-free analysis at the single-chemical-group level remains challenging. Here, we construct a γ-cyclodextrin/silicon nitride (γ-CD/SiNx) hybrid nanopore by controlled dielectric breakdown followed by electrophoretic insertion of a single γ-CD molecule into a size-matched SiNx pore, and use it to discriminate PTMs on GRK4-derived oligopeptides. By recording ionic current blockades (ΔI/Io) and dwell times in 1 M KCl at 200 mV, the angstrom-scale hydrophobic cavity of γ-CD provides high spatial resolution: the platform resolves peptides differing by few-residue substitutions and distinguishes palmitoylation, single/multiple phosphorylation, and acetylation on identical 15-residue sequences. Palmitoylated peptides show enhanced capture rates and longer dwell times (2.2 ± 0.1 ms) than unmodified controls (1.0 ± 0.1 ms); mono-phosphorylation reduces normalized current blockade amplitude (ΔI/Io = 0.51 ± 0.02) whereas tri-phosphorylation increases it (ΔI/Io = 0.65 ± 0.02); positional phosphorylation isomers and peptide mixtures are resolved by combined amplitude and dwell-time readout. This label-free single-molecule platform offers a proof-of-concept route toward PTM profiling; validation under physiological conditions and in biological matrices is required before diagnostic application.
中文摘要:G蛋白偶联受体激酶4(GRK4)的翻译后修饰(PTMs)与高血压发病机制相关,在单个化学基团水平进行无标记分析仍具挑战。我们通过可控介电击穿,随后电泳将单个γ-环糊精分子插入尺寸匹配的氮化硅孔,构建γ-环糊精/氮化硅(γ-CD/SiNx)杂合纳米孔,并用其区分GRK4衍生寡肽上的PTMs。在1 M KCl、200 mV下记录离子电流阻断(ΔI/Io)和停留时间,γ-CD的埃级疏水腔提供高空间分辨率:该平台可分辨仅差几个残基替换的肽,并区分相同15残基序列上的棕榈酰化、单/多磷酸化及乙酰化。棕榈酰化肽较未修饰对照表现出更高捕获率和更长停留时间(2.2 ± 0.1 ms vs 1.0 ± 0.1 ms);单磷酸化降低归一化电流阻断幅度(ΔI/Io = 0.51 ± 0.02),三磷酸化则使其升高(ΔI/Io = 0.65 ± 0.02);结合幅度与停留时间读数可分辨位置磷酸化异构体及肽混合物。该无标记单分子平台为PTM分析提供概念验证路径;在用于诊断前,需在生理条件和生物基质中验证。
American journal of respiratory and critical care medicine IF 21.7 2026-10-10 PMID: 42858161
Most patients with nonheritable forms of pulmonary arterial hypertension (PAH) lack identifiable pathogenic variants. Increasing evidence suggests that, in addition to high-impact predicted loss-of-function variants, rare missense coding variants may also contribute to disease pathogenesis. We identified ultra-rare missense variants in FOXF1 in two index cases with PAH. FOXF1 encodes a highly conserved transcription factor essential for lung vascular development. We sought to define the frequency of FOXF1 variants, characterize FOXF1 expression, and assess the functional relevance of FOXF1 alterations in PAH. Three independent international PAH cohorts were analyzed for predicted deleterious FOXF1 variants. FOXF1 expression was evaluated using bulk and single-cell RNA sequencing and immunofluorescence. Bioinformatic and chromatin-profiling approaches were used to identify potential downstream transcriptional targets, followed by promoter-reporter assays in vitro. Nine novel and one rare missense variants, one start-site variant, and one in-frame deletion in FOXF1 were identified across the three cohorts. FOXF1 expression was reduced in PAH lungs and localized predominantly to the endothelial cell compartment. Histopathological analysis revealed heterogeneous FOXF1 expression, with the lowest levels in phenotypically abnormal endothelial cells within complex vascular lesions. Single-cell analyses confirmed reduced endothelial FOXF1 expression in PAH, whereas broad FOXF1 downregulation across endothelial populations was not observed in other chronic lung diseases. Integration of CUT&Tag and ATAC-seq identified a canonical FOXF1-binding motif within the BMPR2 promoter. Promoter-reporter assays further supported FOXF1-dependent transcriptional regulation of BMPR2 and demonstrated reduced transcriptional activity of PAH-associated FOXF1 variants. Large-scale genomic and transcriptomic analyses support an association between FOXF1 dysregulation and PAH and identify BMPR2 as a potential downstream transcriptional target.
中文摘要:大多数非遗传性肺动脉高压(PAH)患者缺乏可识别的致病变异。越来越多证据提示,除高影响的预测功能丧失变异外,罕见错义编码变异也可能参与疾病发病。我们在两例PAH先证者中发现了FOXF1的超罕见错义变异。FOXF1编码一种对肺血管发育必需的高度保守转录因子。我们旨在确定FOXF1变异的频率、刻画FOXF1表达,并评估FOXF1改变在PAH中的功能相关性。分析了三个独立国际PAH队列中预测有害的FOXF1变异。使用bulk和单细胞RNA测序及免疫荧光评估FOXF1表达。采用生物信息学和染色质图谱分析识别潜在下游转录靶点,随后进行体外启动子报告基因实验。在三个队列中鉴定出FOXF1的9个新发现的错义变异和1个罕见错义变异、1个起始位点变异以及1个框内缺失。PAH肺组织中FOXF1表达降低,主要定位于内皮细胞区室。组织病理学分析显示FOXF1表达异质,复杂血管病变内表型异常内皮细胞中水平最低。单细胞分析证实PAH中内皮FOXF1表达降低,而其他慢性肺病未观察到内皮细胞群中FOXF1广泛下调。整合CUT&Tag和ATAC-seq在BMPR2启动子内识别出经典FOXF1结合基序。启动子报告基因实验进一步支持FOXF1依赖的BMPR2转录调控,并显示PAH相关FOXF1变异转录活性降低。大规模基因组和转录组分析支持FOXF1失调与PAH相关,并确定BMPR2为潜在下游转录靶点。

4脑卒中/脑血管病 (7篇)

临床研究 (5篇)

Stroke IF 11.1 2026-10-15 PMID: 42877955
Health literacy is a critical component of high-quality stroke care. Across the continuum from prevention through recovery, health literacy is strongly associated with functional outcomes and stroke-related morbidity. Despite its importance, it is often overlooked, leaving patients and caregivers overwhelmed by communication demands that exceed their capacity. These mismatches are especially pronounced among individuals with stroke-related cognitive or language impairments, limited English proficiency, socioeconomic disadvantage, or limited digital literacy. This scientific statement synthesizes current evidence on the role of health literacy and communication within stroke systems of care and identifies nurse-led opportunities to advance equity and patient-centered outcomes while recognizing this as a shared interprofessional responsibility. Nurse-led interventions, including teach-back-based education, dyadic psychoeducational programs, and tailored digital support, have demonstrated improvements in stroke knowledge, self-efficacy, quality of life, and caregiver preparedness. However, the literature is marked by methodological heterogeneity. Many studies are underpowered and infrequently use validated health literacy or communication measures. Future directions include standardized assessment of health literacy; literacy-sensitive, nurse-led, and interprofessional care models; workforce training in plain-language and culturally responsive communication; and organizational health literacy principles. Emerging technologies, including telehealth and artificial intelligence, offer promise for improving communication and personalization but require rigorous evaluation to minimize bias and ensure equity and usability.
中文摘要:健康素养是高质量卒中照护的关键组成部分。在从预防到康复的连续过程中,健康素养与功能结局和卒中相关疾病负担密切相关。尽管其重要性明确,健康素养常被忽视,使患者和照护者面对超出其能力的沟通要求而不堪重负。这种不匹配在伴有卒中相关认知或语言障碍、英语水平有限、社会经济处境不利或数字素养有限的人群中尤为突出。本科学声明综合了健康素养与沟通在卒中照护系统中的作用证据,并识别护士主导的促进公平和以患者为中心结局的机会,同时承认这是跨专业共同责任。护士主导的干预,包括基于回授法的教育、二元心理教育项目和量身定制的数字支持,已显示可改善卒中知识、自我效能、生活质量和照护者准备度。然而,文献存在方法学异质性。许多研究检验效能不足,且较少使用经过验证的健康素养或沟通测量工具。未来方向包括健康素养的标准化评估;对健康素养敏感的护士主导和跨专业照护模式;以简明语言和文化响应性沟通为重点的员工培训;组织健康素养原则。远程医疗和人工智能等新兴技术有望改善沟通和个性化,但需要严格评估以减少偏倚并确保公平性和可用性。
Stroke IF 11.1 2026-10-14 PMID: 42872327
Evidence of regional differences in clinical outcomes after intracerebral hemorrhage (ICH) is still scarce. We quantified differential outcomes and response to early intensive blood pressure lowering treatment by region in the Blood pressure in Acute Stroke Collaboration ICH data set. This was an observational analysis of pooled individual participant data from 16 completed randomized controlled trials of blood pressure-lowering treatment in acute ICH, based on the Blood pressure in Acute Stroke Collaboration data set. Generalized linear mixed models with inverse probability of treatment weighting (IPTW) were used to determine the association between regions (Asia [primarily East and South Asia] versus non-Asia) and clinical outcomes including neurological deterioration within 7 days, hematoma expansion at 24 hours (absolute ≥6 mL or relative ≥33%), and death or dependency (modified Rankin Scale scores, 3-6), major disability(modified Rankin Scale score, 3-5), death alone at 90 days. Among 6221 patients (age, 63.3±13.0 years; female 36.4%), 3494 (56.2%) were from Asia. ICH participants from Asia had a significantly reduced risk of death or dependency (unadjusted odds ratio [OR], 0.44 [95% CI, 0.39-0.51]; IPTW-weighted OR, 0.67 [95% CI, 0.58-0.77]); and major disability (unadjusted OR, 0.49 [95% CI, 0.42-0.56]; IPTW-weighted OR, 0.67 [95% CI, 0.57-0.78]) at 90 days, neurological deterioration (unadjusted OR, 0.63 [95% CI, 0.52-0.77]; IPTW-weighted OR, 0.70 [95% CI, 0.56-0.89]) within 7 days, in comparison to those from non-Asia regions. However, there were no differences for hematoma expansion (P=0.97) at 24 hours or death (P=0.23) at 90 days using IPTW. Additionally, there were no significant interactions between blood pressure-lowering treatment and region (Asia versus non-Asia) for either outcome using IPTW. Participants from East and South Asia had a favorable functional recovery and a lower risk of neurological deterioration compared with those from non-Asian regions after adjustment for confounders, with no differences in hematoma expansion at 24 hours after ICH. These findings suggest that future ICH studies on clinical outcomes should consider regional differences.
中文摘要:脑出血后临床结局是否存在地区差异,目前证据仍有限。我们利用血压在急性卒中协作组(BASC)脑出血数据集,量化不同地区患者的结局差异及对早期强化降血压治疗的反应。该研究为观察性分析,汇总16项已完成的急性脑出血降血压治疗随机对照试验的个体参与者数据,数据来源于BASC数据集。采用广义线性混合模型并结合逆概率治疗加权(IPTW),评估地区(亚洲,主要为东亚与南亚,对比非亚洲)与临床结局的关联,结局包括7天内神经功能恶化、24小时血肿扩大(绝对≥6 mL或相对≥33%)、90天死亡或依赖(改良Rankin量表评分3-6分)、重度残疾(改良Rankin量表评分3-5分)以及单纯死亡。共纳入6221例患者(年龄63.3±13.0岁,女性36.4%),其中3494例(56.2%)来自亚洲。与非亚洲地区患者相比,亚洲脑出血患者90天死亡或依赖风险显著降低(未校正比值比[OR] 0.44,95%置信区间[CI] 0.39-0.51;IPTW加权OR 0.67,95%CI 0.58-0.77),90天重度残疾风险降低(未校正OR 0.49,95%CI 0.42-0.56;IPTW加权OR 0.67,95%CI 0.57-0.78),7天内神经功能恶化风险降低(未校正OR 0.63,95%CI 0.52-0.77;IPTW加权OR 0.70,95%CI 0.56-0.89)。经IPTW分析,24小时血肿扩大(P=0.97)与90天死亡(P=0.23)未见地区差异。经IPTW分析,降血压治疗与地区(亚洲对比非亚洲)对各结局均无显著交互作用。校正混杂因素后,东亚与南亚患者的远期功能恢复较好,神经功能恶化风险较低,而脑出血后24小时血肿扩大未见差异。这些结果提示,未来针对脑出血临床结局的研究应考虑地区差异。
Stroke IF 11.1 2026-10-13 PMID: 42866880
Intravenous thrombolysis is a standard treatment for acute ischemic stroke but has traditionally been limited to 4.5 hours after symptom onset. This time-based restriction may exclude patients with salvageable brain tissue, especially those with wake-up or unknown-onset strokes. Multimodal imaging allows for the identification of viable penumbra beyond traditional treatment windows. This study compiles randomized evidence evaluating intravenous thrombolysis in imaging-selected patients treated after 4.5 hours. We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Cochrane Central were searched through February 2026 for randomized trials comparing intravenous thrombolysis (alteplase or tenecteplase) with best medical therapy in patients presenting beyond 4.5 hours or with wake-up/unknown-onset stroke selected by imaging. The primary outcome was excellent functional outcome at 90 days (modified Rankin Scale score 0-1). Secondary outcomes included functional independence (modified Rankin Scale score 0-2), symptomatic intracranial hemorrhage, and 90-day mortality. Fourteen trials involving 4192 participants were analyzed. Intravenous thrombolysis improved excellent functional outcomes (modified Rankin Scale score 0-1; risk ratio, 1.22 [95% CI, 1.16-1.29]) and functional independence (modified Rankin Scale score 0-2; risk ratio, 1.12 [95% CI, 1.06-1.18]). Both alteplase and tenecteplase contributed to these benefits. Thrombolysis increased the risk of symptomatic intracranial hemorrhage (risk ratio, 2.58 [95% CI, 1.58-4.22]) but did not significantly affect 90-day mortality (risk ratio, 1.15 [95% CI, 0.97-1.35]). In patients selected using advanced imaging, intravenous thrombolysis performed after 4.5 hours improves functional outcomes without increasing mortality, supporting a tissue-based rather than strictly time-based approach to treating acute ischemic stroke.
中文摘要:静脉溶栓是急性缺血性卒中的标准治疗,但传统上限于症状出现后4.5小时内。这种基于时间的限制可能排除仍存在可挽救脑组织的患者,尤其是醒后卒中或发病时间不明者。多模态影像可识别超出传统治疗时间窗的可存活缺血半暗带。本研究汇总评估影像筛选后4.5小时后接受静脉溶栓患者的随机证据。我们按PRISMA指南开展系统综述和荟萃分析。检索PubMed、Embase和Cochrane Central至2026年2月,纳入比较静脉溶栓(阿替普酶或替奈普酶)与最佳药物治疗的随机试验,对象为发病超过4.5小时或醒后/发病时间不明且经影像筛选的卒中患者。主要结局为90天极佳功能结局(改良Rankin量表评分0-1)。次要结局包括功能独立(改良Rankin量表评分0-2)、症状性颅内出血和90天死亡率。共分析14项试验、4192名受试者。静脉溶栓改善极佳功能结局(改良Rankin量表评分0-1;风险比1.22[95% CI 1.16-1.29])和功能独立(改良Rankin量表评分0-2;风险比1.12[95% CI 1.06-1.18])。阿替普酶和替奈普酶均对这些获益有贡献。溶栓增加症状性颅内出血风险(风险比2.58[95% CI 1.58-4.22]),但未显著影响90天死亡率(风险比1.15[95% CI 0.97-1.35])。在接受高级影像筛选的患者中,4.5小时后进行静脉溶栓可改善功能结局且不增加死亡率,支持以组织为基础而非严格以时间为基础的方法治疗急性缺血性卒中。
Circulation IF 41.3 2026-10-13 PMID: 42866879
OCEANIC-STROKE (XXX) showed that asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing bleeding in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack. We characterized bleeding categories, sites, and key subgroups. In the safety population, 12 254 participants received at least 1 dose of asundexian (n=6124) or placebo (n=6130). Bleeding was categorized by International Society on Thrombosis and Haemostasis criteria as major, clinically relevant nonmajor (CRNM), or minor. While-on-treatment analyses included events through 2 days after the last dose, with death and permanent discontinuation as competing risks. Major bleeding occurred in 117 (1.9%) participants with asundexian and 107 (1.7%) with placebo (cause-specific hazard ratio [csHR], 1.10 [95% CI, 0.85-1.44]; P=0.46). Major or CRNM bleeding occurred in 339 (5.5%) and 307 (5.0%), respectively (csHR, 1.12 [95% CI, 0.96-1.30]; P=0.16), and any bleeding in 763 (12.5%) and 752 (12.3%) (csHR, 1.02 [95% CI, 0.93-1.13]; P=0.65). Treatment effects for major and major or CRNM bleeding were consistent across prespecified subgroups, including planned dual antiplatelet therapy. Symptomatic intracranial hemorrhage occurred in 41 (0.7%) and 36 (0.6%) participants. Any gastrointestinal bleeding occurred in 186 (3.0%) and 147 (2.4%) (csHR, 1.28 [95% CI, 1.03-1.59]), and lower gastrointestinal bleeding in 102 (1.7%) and 59 (1.0%) (csHR, 1.75 [95% CI, 1.27-2.41]), primarily rectal bleeding. Any procedure-related bleeding and any mucosal bleeding did not differ significantly. Asundexian added to antiplatelet therapy reduced ischemic stroke without significantly increasing major, major or CRNM, or any bleeding. Lower gastrointestinal bleeding was more frequent with asundexian, whereas treatment effects on major and major or CRNM bleeding were consistent across prespecified subgroups. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05686070.
中文摘要:OCEANIC-STROKE(XXX)显示,在非心源性栓塞性缺血性卒中或高危短暂性脑缺血发作患者中,抗血小板治疗基础上加用 asundexian 可减少缺血性卒中,未显著增加出血。本研究分析出血类别、部位和关键亚组。安全性人群中,12254 例参与者至少接受 1 剂 asundexian(n=6124)或安慰剂(n=6130)。出血按国际血栓与止血学会标准分为大出血、临床相关非大出血(CRNM)或轻微出血。治疗期间分析纳入至末次给药后 2 天的事件,并将死亡和永久停药作为竞争风险。大出血在 asundexian 组发生 117 例(1.9%),安慰剂组 107 例(1.7%)(病因特异性风险比 csHR 1.10,95% CI 0.85-1.44;P=0.46)。大出血或 CRNM 出血分别发生 339 例(5.5%)和 307 例(5.0%)(csHR 1.12,95% CI 0.96-1.30;P=0.16),任何出血分别发生 763 例(12.5%)和 752 例(12.3%)(csHR 1.02,95% CI 0.93-1.13;P=0.65)。大出血及大出血或 CRNM 出血的治疗效应在预设亚组中一致,包括计划双联抗血小板治疗。症状性颅内出血分别发生 41 例(0.7%)和 36 例(0.6%)。任何胃肠道出血分别发生 186 例(3.0%)和 147 例(2.4%)(csHR 1.28,95% CI 1.03-1.59),下消化道出血分别发生 102 例(1.7%)和 59 例(1.0%)(csHR 1.75,95% CI 1.27-2.41),主要为直肠出血。任何操作相关出血和任何黏膜出血无显著差异。抗血小板治疗基础上加用 asundexian 减少缺血性卒中,未显著增加大出血、大出血或 CRNM 出血或任何出血。asundexian 组下消化道出血更常见,而大出血及大出血或 CRNM 出血的治疗效应在预设亚组中一致。URL: https://www.clinicaltrials.gov;唯一标识符:NCT05686070。
Circulation IF 41.3 2026-10-13 PMID: 42677492
Determining the source of thromboembolism in patients with acute ischemic stroke remains challenging because current diagnostic approaches rely largely on circumstantial and inferential associations rather than direct identification of the cause of stroke. Fluorine-18 GP1 ([18F]GP1) is a novel radiotracer that binds with high affinity and specificity to activated glycoprotein IIb/IIIa receptors on activated platelets. We aimed to determine whether hybrid [18F]GP1 positron emission tomography (PET) and computed tomography angiography could identify in vivo cardiovascular thromboembolism in patients with acute ischemic stroke and provide a mechanism-based assessment of stroke etiology. In a single-center prospective observational cohort study, 100 patients presenting with acute ischemic stroke underwent hybrid [18F]GP1 PET/computed tomography angiography within 21 days of symptom onset in addition to standard-of-care stroke investigations. Stroke etiology was classified using the causative classification system by an expert stroke physician blinded to [18F]GP1 PET findings. In parallel, [18F]GP1 PET/computed tomography angiography images were analyzed independently by readers who were blinded to all clinical data and causative classification system classification. We assessed whether [18F]GP1 PET/computed tomography angiography could identify the source of in vivo cardiovascular thromboembolism, influence stroke classification, and predict recurrent cerebrovascular events. Cardiovascular [18F]GP1 uptake indicative of thrombosis was identified in nearly two-thirds (n=63) of participants, changing stroke classification in over a quarter (n=26) of patients. In those with stroke of undetermined cause, the source of thrombus was identified in 18 of 41 (44%) participants, which included nonstenotic carotid atherothrombosis, native cardiac valve thrombosis, and paradoxical thromboembolism. During a median follow-up of 613 (interquartile interval, 251-788) days, recurrent stroke or transient ischemic attack occurred in 14 patients, 13 (93%) of whom had cardiovascular [18F]GP1 uptake at baseline. Cardiovascular [18F]GP1 uptake was associated with a 10.4-fold increased risk of recurrent events (95% CI, 1.35-79.40; P=0.024). Noninvasive thrombosis imaging is a novel technique that enables direct in vivo identification of thrombus formation and frequently reveals the source of thromboembolism in patients with acute ischemic stroke. This approach represents a shift from inference-based to mechanism-based stroke classification with potential implications for targeted prevention strategies and better patient outcomes. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT05636748.
中文摘要:急性缺血性卒中患者血栓栓塞来源的判断仍具挑战性,现有诊断方法在很大程度上依赖间接和推断性关联,而非直接识别卒中病因。氟-18 GP1([18F]GP1)是一种新型放射性示踪剂,可高亲和力、高特异性结合活化血小板表面的活化糖蛋白IIb/IIIa受体。研究旨在确定[18F]GP1正电子发射断层显像(PET)与计算机断层血管造影(CTA)混合成像能否识别急性缺血性卒中患者体内的心血管血栓栓塞,并对卒中病因提供基于机制的评估。在一项单中心前瞻性观察性队列研究中,100例急性缺血性卒中患者在症状发作21天内接受[18F]GP1 PET/CTA混合成像及标准卒中检查。卒中病因由一名对[18F]GP1 PET结果设盲的卒中专科医师采用病因分类系统判定。同期,[18F]GP1 PET/CTA图像由对所有临床数据和病因分类系统分类设盲的阅片者独立分析。研究评估[18F]GP1 PET/CTA能否识别体内心血管血栓栓塞来源、影响卒中分类并预测复发性脑血管事件。近三分之二参与者(n=63)检测到提示血栓形成的心血管[18F]GP1摄取,超过四分之一患者(n=26)的卒中分类因此改变。在病因未明卒中患者中,41例中有18例(44%)识别出血栓来源,包括非狭窄性颈动脉粥样硬化血栓形成、自体心脏瓣膜血栓和矛盾性血栓栓塞。中位随访613天(四分位间隔251–788天)期间,14例患者发生复发性卒中或短暂性脑缺血发作,其中13例(93%)基线时存在心血管[18F]GP1摄取。心血管[18F]GP1摄取与复发性事件风险增加10.4倍相关(95% CI,1.35–79.40;P=0.024)。无创血栓成像是一种新技术,可在体内直接识别血栓形成,并常能揭示急性缺血性卒中患者的血栓栓塞来源。该方法代表从推断性卒中分类向基于机制的卒中分类转变,可能对靶向预防策略和改善患者结局产生影响。网址:https://www.clinicaltrials.gov;唯一标识:NCT05636748。

基础研究 (2篇)

Advanced healthcare materials IF 11.0 2026-10-16 PMID: 42885941
Ischemic stroke (IS), caused by cerebral blood vessel occlusion, leads to ischemia, hypoxia, and irreversible brain tissue damage. Current treatments primarily rely on thrombolytic agents like alteplase, urokinase, and streptokinase for rapid reperfusion. However, these therapies are limited by narrow therapeutic windows, rapid clearance, poor blood-brain barrier (BBB) penetration, off-target effects, and the complex ischemic microenvironment. These have led to increased interest in nanomaterial-based platforms to improve the precision and efficacy of IS treatment. The IS microenvironment, characterized by oxidative stress, inflammation, ionic imbalance, acidosis, and BBB disruption, provides valuable cues for designing responsive nanomaterials. Nanomaterials engineered to respond to reactive oxygen species, pH, enzymes, light, ultrasound, or magnetic fields can enable targeted drug delivery, controlled release, and multi-modal interventions, enhancing therapeutic precision. This review discusses the IS microenvironment, limitations of traditional therapies, recent advances in intelligent nanomaterials for IS treatment, and the major barriers that currently limit clinical translation.
中文摘要:缺血性脑卒中由脑血管闭塞引起,导致缺血、缺氧和不可逆的脑组织损伤。当前治疗主要依赖阿替普酶、尿激酶和链激酶等溶栓药物实现快速再灌注,但这些疗法受限于治疗时间窗窄、清除快、血脑屏障穿透差、脱靶效应以及复杂的缺血微环境。基于纳米材料的平台因此受到更多关注,用于提高缺血性脑卒中治疗的精准性和疗效。缺血微环境以氧化应激、炎症、离子失衡、酸中毒和血脑屏障破坏为特征,为设计响应性纳米材料提供了线索。经工程化设计、可对活性氧、pH、酶、光、超声或磁场作出响应的纳米材料,能够实现靶向药物递送、控制释放和多模式干预,提升治疗精准性。本综述讨论缺血性脑卒中微环境、传统疗法的局限、智能纳米材料用于缺血性脑卒中治疗的最新进展,以及目前限制临床转化的主要障碍。
Molecular neurodegeneration IF 19.6 2026-10-15 PMID: 42881417
Distinguishing resident microglia from infiltrating myeloid cells in stroke scRNA-seq data remains challenging due to shared myeloid markers; SALL1 shows greater specificity for microglia compared with commonly used markers (e.g. TMEM119, CX3CR1, P2RY12), and combining SALL1 with these commonly used markers improves the ability to distinguish microglia from infiltrating myeloid populations in stroke‑associated scRNA‑seq datasets.
中文摘要:在卒中单细胞RNA测序数据中,由于髓系标记物存在共享,区分驻留小胶质细胞与浸润性髓系细胞仍有困难;与常用标记物(如TMEM119、CX3CR1、P2RY12)相比,SALL1对小胶质细胞的特异性更高,将SALL1与这些常用标记物联合使用,可提高在卒中相关scRNA-seq数据集中区分小胶质细胞与浸润性髓系细胞群体的能力。

5心肌病/心肌炎 (7篇)

临床研究 (3篇)

European heart journal IF 45.3 2026-10-13 PMID: 42864989
Dilated cardiomyopathy (DCM) presents with variable risk of life-threatening arrhythmias. Genetic diagnosis guides sudden death prevention strategies, but risk magnitude for arrhythmogenic genes remains unknown. This study leveraged the international Sarcomeric Human Cardiomyopathy Registry (SHaRe) to address this gap and improve risk stratification. Effects of pathogenic/likely pathogenic (P/LP) variants in genes associated with DCM and ventricular arrhythmia on clinical events were analysed in DCM-SHaRe patients. Patients were stratified by presence of a P/LP variant in a high-arrhythmogenic risk gene (LMNA, DSP, FLNC, RBM20, PLN, SCN5A, DES, TMEM43), a low-arrhythmogenic risk gene (TTN, TNNT2, MYH7, others), or gene-elusive. Outcomes included age-, sex-, and baseline left ventricular ejection fraction (LVEF)-adjusted risk of major ventricular arrhythmia (MVA), atrial fibrillation (AF), heart failure (HF), death, and their composite. Among 2660 genotyped adults with DCM (mean diagnosis age 47 ± 15 years, 39.8% female), 434 (16%) had P/LP variants in high-arrhythmogenic genes, 451 (17%) in low-arrhythmogenic genes, and 1775 (67%) were gene-elusive. Compared with gene-elusive patients, patients with high-arrhythmogenic P/LP variants showed increased MVA [hazard ratio (HR) 3.25, 95% confidence interval (CI) 2.63-4.01], AF (HR 2.42, 95% CI 1.96-2.98), HF (HR 2.46, 95% CI 1.89-3.19), and composite (HR 1.97, 95% CI 1.69-2.29) risk, which remained significant after adjusting for age, sex, and LVEF. Patients with high-arrhythmogenic P/LP variants and LVEF ≥ 50% maintained increased MVA (HR 2.36, 95% CI 1.59-3.51) and composite (HR 1.63, 95% CI 1.25-2.12) risk. Genetic testing enables powerful risk stratification for arrhythmias and HF in DCM independent of age, sex, or LVEF.
中文摘要:扩张型心肌病(DCM)患者发生危及生命性心律失常的风险存在差异。基因诊断可指导猝死预防策略,但心律失常相关基因所对应的风险强度仍不清楚。本研究利用国际Sarcomeric Human Cardiomyopathy Registry(SHaRe)填补这一空白并改进风险分层。在DCM-SHaRe患者中分析DCM及室性心律失常相关基因的致病/可能致病变异(P/LP)对临床事件的影响。患者按携带高心律失常风险基因(LMNA、DSP、FLNC、RBM20、PLN、SCN5A、DES、TMEM43)P/LP变异、低心律失常风险基因(TTN、TNNT2、MYH7及其他)P/LP变异或未检出相关基因变异进行分层。结局包括经年龄、性别和基线左心室射血分数(LVEF)校正后的主要室性心律失常(MVA)、心房颤动(AF)、心力衰竭(HF)、死亡及其复合结局风险。2660例接受基因分型的DCM成人中(平均诊断年龄47±15岁,女性39.8%),434例(16%)携带高心律失常风险基因P/LP变异,451例(17%)携带低心律失常风险基因P/LP变异,1775例(67%)未检出相关基因变异。与未检出相关基因变异者相比,携带高心律失常风险基因P/LP变异者的MVA风险升高(HR 3.25,95% CI 2.63-4.01)、AF风险升高(HR 2.42,95% CI 1.96-2.98)、HF风险升高(HR 2.46,95% CI 1.89-3.19)、复合结局风险升高(HR 1.97,95% CI 1.69-2.29),校正年龄、性别和LVEF后仍显著。携带高心律失常风险基因P/LP变异且LVEF≥50%的患者MVA风险(HR 2.36,95% CI 1.59-3.51)和复合结局风险(HR 1.63,95% CI 1.25-2.12)仍升高。基因检测可在DCM中实现对心律失常和HF的有力风险分层,且独立于年龄、性别或LVEF。
Progress in cardiovascular diseases IF 10.6 2026-10-11 PMID: 42860196
While serum neurofilament light chain (sNfL) has shown promise as a biomarker for the development of peripheral neuropathy (PN) in hereditary transthyretin (TTR) amyloidosis (vATTR), its role in all-comers with ATTR cardiomyopathy (ATTR-CM) is less well-defined, and it is unknown how CM severity and TTR stabilizer therapy affect sNfL in ATTR-CM. Study participants included those with ATTR-CM not on gene-silencer therapy referred to Oregon Health & Science University. The association between sNfL and baseline patient characteristics, including age, sex, body mass index (BMI), presence of PN, ATTR subtype, N-terminal pro b-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR) and tafamidis treatment, were evaluated utilizing linear regression. 66 patients (age: 78.5 ± 6.9 years, 6.1% female, 16.7% with diabetes mellitus, 10.6% vATTR-CM, 43.9% with PN symptoms, 30.3% receiving tafamidis at baseline) were included. There was no difference in sNfL levels when stratified by ATTR subtype (p = 0.168), PN symptoms (p = 0.881), or tafamidis treatment measured categorically (p = 0.418). In 17 patients (17.6% vATTR-CM) with available paired pre-tafamidis and on-tafamidis samples, there was no difference in sNfL level. In our univariable and multivariable analysis, NT-proBNP and eGFR were associated with sNfL. In ATTR-CM, cardiomyopathy severity and renal dysfunction impact sNfL more than presence of PN or other clinical factors.
中文摘要:血清神经丝轻链(sNfL)作为遗传性转甲状腺素蛋白(TTR)淀粉样变性(vATTR)中外周神经病(PN)发生的生物标志物已显现潜力,但其在全部ATTR心肌病(ATTR-CM)患者中的作用尚不明确,ATTR-CM中心肌病严重程度和TTR稳定剂治疗如何影响sNfL也未知。研究对象为转诊至Oregon Health & Science University、未接受基因沉默剂治疗的ATTR-CM患者。采用线性回归评估sNfL与基线患者特征的关联,包括年龄、性别、体重指数(BMI)、PN是否存在、ATTR亚型、N末端B型利钠肽原(NT-proBNP)、估算肾小球滤过率(eGFR)和tafamidis治疗。共纳入66例患者(年龄78.5±6.9岁,女性6.1%,糖尿病16.7%,vATTR-CM 10.6%,有PN症状43.9%,基线时接受tafamidis 30.3%)。按ATTR亚型(p=0.168)、PN症状(p=0.881)或tafamidis治疗分类(p=0.418)分层时,sNfL水平无差异。在17例有配对tafamidis治疗前和治疗中样本的患者(vATTR-CM 17.6%)中,sNfL水平无差异。单变量和多变量分析中,NT-proBNP和eGFR与sNfL相关。在ATTR-CM中,心肌病严重程度和肾功能不全对sNfL的影响大于PN存在或其他临床因素。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42669063
Inflammatory cardiomyopathy (iCMP) is a leading cause of heart failure, with limited therapeutic options. Excessive cytokine levels are implicated in adverse outcomes, but their pathomechanism in iCMP is poorly understood. We sought to identify key cytokines involved in severe iCMP and elucidate their potential contribution to cardiomyocyte injury. Cytokines were analysed in patients with severe biopsy-proven iCMP (n = 63; LVEF ≤ 35%) and validated in a national cohort (n = 425). In vitro experiments examined the effect of the top cytokines observed in severe iCMP with regards to production of reactive oxygen species (ROS) and calcium homeostasis in induced human pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and human aortic endothelial cells (HAECs). Three proteins (COLEC-12, CRIM-1, IL-6) were associated with severe iCMP. In iPSC-CMs, these proteins increased ROS (H2DCFDA assay) and intracellular Ca2+ levels (Fluo-4AM assay), indicating cellular stress. Effects were less pronounced in HAEC. Finally, real-world data from electronic medical records suggested a possible cardioprotective effect of clinically available inhibitors targeting these cytokines, although these findings remain exploratory and require confirmation in controlled studies. COLEC-12, CRIM-1, and IL-6 are elevated in severe iCMP and induce oxidative stress and calcium dysregulation in cultured cardiomyocytes. These findings highlight their potential as possible future therapeutic targets. ClinicalTrials.gov Identifier: NCT04265040, NCT02187263.
中文摘要:炎症性心肌病(iCMP)是心力衰竭的主要原因之一,治疗选择有限。细胞因子水平过高与不良结局相关,但其在iCMP中的病理机制了解甚少。我们试图识别参与重度iCMP的关键细胞因子,并阐明它们对心肌细胞损伤的可能作用。分析了经活检证实的重度iCMP患者(n=63;LVEF≤35%)的细胞因子,并在一个全国队列(n=425)中验证。体外实验检测重度iCMP中观察到的居前细胞因子对诱导多能干细胞来源心肌细胞(iPSC-CMs)和人主动脉内皮细胞(HAECs)中活性氧(ROS)生成及钙稳态的影响。三种蛋白(COLEC-12、CRIM-1、IL-6)与重度iCMP相关。在iPSC-CMs中,这些蛋白增加ROS(H2DCFDA检测)和细胞内Ca2+水平(Fluo-4AM检测),提示细胞应激。在HAEC中效应较弱。最后,来自电子病历的真实世界数据提示,针对这些细胞因子的临床可用抑制剂可能具有心脏保护作用,不过这些发现仍属探索性,需在对照研究中确认。COLEC-12、CRIM-1和IL-6在重度iCMP中升高,并在培养的心肌细胞中诱导氧化应激和钙调节异常。这些发现凸显其作为未来潜在治疗靶点的可能性。ClinicalTrials.gov标识:NCT04265040、NCT02187263。

基础研究 (4篇)

Journal of advanced research IF 17.1 2026-10-14 PMID: 42874998
Doxorubicin (DOX) is a key chemotherapeutic agent for hematologic malignancies and many solid tumors, but its clinical use is limited by doxorubicin-induced cardiotoxicity (DIC). DIC may present as subclinical myocardial injury, arrhythmias, left ventricular dysfunction, cardiomyopathy, or heart failure. DOX can disrupt organelle function through topoisomerase IIβ (Top2β)-mediated DNA damage and transcriptional stress, oxidative stress, disrupted iron homeostasis, and calcium imbalance. Mitochondrial and endoplasmic/sarcoplasmic reticulum (ER/SR) injury are therefore central pathological features of DIC. This review summarizes current evidence on mitophagy and ER-phagy in DIC, with emphasis on discrepancies in reported findings across different experimental settings, potential crosstalk mechanisms, and the translational limitations of targeting these pathways for cardioprotection. Current studies suggest that mitophagy in DIC follows a checkpoint-dependent pattern. Depending on DOX dose, exposure duration, and lysosomal degradative capacity, mitophagy may remove damaged mitochondria, but it may also worsen mitochondrial injury when initiation is insufficient, activation is excessive, or flux is stalled. In contrast, direct evidence for ER-phagy in DIC remains limited. This evidence is mainly derived from CCPG1-mediated protective ER-phagy in chronic fractionated DOX models and FAM134B-associated ER-phagy-related injury signals in acute high-dose injury models. Thus, the functional divergence of ER-phagy in DIC requires confirmation in additional experimental models with rigorous autophagic flux assessment. Mitochondria-associated ER membranes (MAMs) may coordinate mitophagy and ER-phagy by regulating calcium transfer, autophagosome formation, and receptor localization. Overall, current evidence does not support indiscriminate activation or inhibition of mitophagy and ER-phagy. Instead, future interventions may need to preserve flux-complete organelle clearance while avoiding excessive or stalled autophagic signaling. In addition, this framework may help generate research hypotheses that integrate cardioprotection with preservation of antitumor efficacy. However, most evidence comes from cell and animal studies, and further validation in human myocardial tissue and confirmation of cardiac target engagement are still needed.
中文摘要:多柔比星(DOX)是血液系统恶性肿瘤和多种实体瘤的重要化疗药物,但多柔比星诱导的心脏毒性(DIC)限制其临床应用。DIC可表现为亚临床心肌损伤、心律失常、左心室功能障碍、心肌病或心力衰竭。DOX可通过拓扑异构酶IIβ(Top2β)介导的DNA损伤与转录应激、氧化应激、铁稳态紊乱和钙失衡破坏细胞器功能。线粒体与内质网/肌浆网(ER/SR)损伤因此成为DIC的核心病理特征。本综述总结DIC中线粒体自噬与内质网自噬的现有证据,重点讨论不同实验条件下报道结果的差异、可能的交互机制以及靶向这些通路进行心脏保护转化的局限。现有研究提示,DIC中的线粒体自噬呈检查点依赖模式。依据DOX剂量、暴露时长和溶酶体降解能力,线粒体自噬既可清除受损线粒体,也可在启动不足、激活过度或自噬流受阻时加重线粒体损伤。相比之下,DIC中内质网自噬的直接证据仍有限。这些证据主要来自慢性分次DOX模型中CCPG1介导的保护性内质网自噬,以及急性高剂量损伤模型中FAM134B相关的内质网自噬损伤信号。因此,内质网自噬在DIC中的功能分化仍需在更多实验模型中通过严格的自噬流评估加以确认。线粒体相关内质网膜(MAMs)可能通过调控钙转运、自噬体形成和受体定位协调线粒体自噬与内质网自噬。现有证据不支持对线粒体自噬和内质网自噬进行无差别激活或抑制。未来干预或需在保持自噬流完整的前提下完成细胞器清除,同时避免过度或停滞的自噬信号。这一框架还可能帮助形成兼顾心脏保护与保留抗肿瘤疗效的研究假设。然而,多数证据来自细胞和动物研究,仍需在人心肌组织中进一步验证,并确认心脏靶点结合。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42858243
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease in which most patients carry (likely) pathogenic variants in desmosomal genes, most commonly in plakophilin-2 (PKP2). While the genetic causes are well described, the molecular mechanisms driving disease progression-particularly in response to exercise-remain poorly understood. To investigate disease-driving pathways in ACM, we used PKP2 mutant human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and myocardial tissue from ACM patients. Transcriptomic profiling revealed consistent downregulation of oxidative phosphorylation (OXPHOS) genes in PKP2 mutant hiPSC-CMs, which was confirmed in explanted ACM hearts carrying PKP2 variants. Reduced expression of OXPHOS-related genes was associated with lower PPARGC1A expression and decreased mitochondrial spare capacity in PKP2 mutant hiPSC-CMs. The reduction in PPARGC1A expression appeared to result, at least in part, from decreased AMPKα protein levels, a known activator of PPARGC1A previously shown to localize at the intercalated disc, as PKP2 mutant cells failed to increase PPARGC1A expression following treatment with AICAR, an AMPK activator. To directly assess whether increasing PPARGC1A expression could compensate for this defect, we overexpressed PPARGC1A, which partially restored OXPHOS gene expression and improved contractility in PKP2 mutant cells. Our study identifies a novel transcriptional mechanism linking PKP2 loss to reduced mitochondrial function via decreased PGC1α signaling, partially through reduced AMPKα levels. Disruption of this axis reduces OXPHOS gene expression and mitochondrial function in PKP2 mutant hiPSC-CMs, potentially impairing the heart's ability to meet increased energy demands during stress, and offering a mechanistic explanation for the detrimental effects of exercise in ACM. Furthermore, these findings highlight PGC1α induction as a potential therapeutic strategy to restore OXPHOS gene expression and mitochondrial adaptability in ACM.
中文摘要:致心律失常性心肌病(ACM)是一种遗传性心脏病,多数患者携带桥粒基因的(可能)致病性变异,最常见的是plakophilin-2(PKP2)变异。其遗传病因已有较充分描述,但推动疾病进展的分子机制,尤其是运动应答中的机制,仍不清楚。为研究ACM的致病通路,我们使用了PKP2突变型人诱导多能干细胞来源心肌细胞(hiPSC-CMs)和ACM患者心肌组织。转录组分析显示,PKP2突变型hiPSC-CMs中氧化磷酸化(OXPHOS)基因持续下调,并在携带PKP2变异的ACM离体心脏中得到证实。OXPHOS相关基因表达降低与PPARGC1A表达下降及PKP2突变型hiPSC-CMs线粒体储备能力降低相关。PPARGC1A表达下降似乎至少部分源于AMPKα蛋白水平降低;AMPKα是PPARGC1A的已知激活因子,既往显示定位于闰盘,因为PKP2突变细胞在接受AMPK激活剂AICAR处理后未能提高PPARGC1A表达。为直接评估提高PPARGC1A表达能否补偿这一缺陷,我们过表达PPARGC1A,结果部分恢复了PKP2突变细胞的OXPHOS基因表达并改善了收缩力。该研究识别出一种新的转录机制,将PKP2缺失与线粒体功能下降联系起来,其通过降低PGC1α信号实现,部分经由AMPKα水平降低。该轴的破坏降低PKP2突变型hiPSC-CMs的OXPHOS基因表达和线粒体功能,可能损害心脏在应激时满足能量需求增加的能力,并为运动在ACM中的不利影响提供机制解释。这些发现还提示,诱导PGC1α可作为恢复ACM中OXPHOS基因表达和线粒体适应性的潜在治疗策略。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42578286
Chronic kidney disease (CKD) is associated with uraemic cardiomyopathy characterized by early metabolic dysfunction. Elevated myocardial intracellular sodium (Naᵢ) has emerged as a driver of cardiometabolic remodelling, however, its role in CKD and therapeutic modulation remains unclear. We investigated whether dual sodium-glucose cotransporter (SGLT)1/2 inhibition with sotagliflozin (SOTA) targets Naᵢ and improves cardiac metabolism in CKD. CKD was induced in male Wistar rats by 5/6 nephrectomy and assessed after 4 weeks. Cardiac phenotype was evaluated using in vivo echocardiography and ex vivo Langendorff perfusion combined with 23Na and 31P NMR spectroscopy. CKD hearts exhibited preserved systolic but impaired diastolic function and a marked elevation in myocardial Naᵢ, identifying Naᵢ overload as an early feature of uraemic cardiomyopathy. Cardiac metabolomic profiling and flux modelling demonstrated widespread suppression of central carbon metabolism, redox imbalance despite preserved PCr/ATP. In silico electrophysiological simulations predicted Naᵢ-driven Ca2+ dysregulation consistent with in vivo diastolic dysfunction. Chronic SOTA treatment (3 weeks, in vivo) normalized myocardial Naᵢ and partially reversed metabolic remodelling. Acute SOTA exposure (20 min, Langendorff-perfusion) similarly reduced Naᵢ in CKD hearts but not in controls, indicating a direct, disease-selective myocardial effect. Naᵢ normalization was accompanied by improved redox state and restoration of mitochondrial metabolic flux, without changes in expression of canonical Na + -handling proteins. Myocardial Naᵢ overload emerges as an early and potentially modifiable feature of uraemic cardiomyopathy. Dual SGLT1/2 inhibition with SOTA directly lowers Naᵢ and improves cardiac metabolic homeostasis, supporting Naᵢ as a mechanistically relevant and potentially targetable pathway in CKD-related cardiac remodelling.
中文摘要:慢性肾脏病(CKD)与以早期代谢功能障碍为特征的尿毒症性心肌病相关。心肌细胞内钠(Naᵢ)升高已成为心脏代谢重塑的驱动因素,但其在CKD中的作用及治疗性调控仍不清楚。研究探讨以索格列净(SOTA)双重抑制钠-葡萄糖协同转运蛋白(SGLT)1/2是否靶向Naᵢ并改善CKD心脏代谢。通过5/6肾切除术在雄性Wistar大鼠中诱导CKD,4周后评估。采用在体超声心动图和离体Langendorff灌注联合²³Na与³¹P核磁共振波谱评估心脏表型。CKD心脏收缩功能保留但舒张功能受损,心肌Naᵢ显著升高,提示Naᵢ超载是尿毒症性心肌病的早期特征。心脏代谢组学分析和通量建模显示中心碳代谢广泛受抑、氧化还原失衡,而PCr/ATP保持。计算机电生理模拟预测Naᵢ驱动的Ca²⁺失调,与在体舒张功能障碍一致。慢性SOTA治疗(在体3周)使心肌Naᵢ正常化并部分逆转代谢重塑。急性SOTA暴露(Langendorff灌注20分钟)同样降低CKD心脏Naᵢ,但不降低对照心脏Naᵢ,表明存在直接的疾病选择性心肌效应。Naᵢ正常化伴随氧化还原状态改善和线粒体代谢通量恢复,而经典Na⁺处理蛋白表达未见变化。心肌Naᵢ超载是尿毒症性心肌病早期且可能可修饰的特征。SOTA双重抑制SGLT1/2可直接降低Naᵢ并改善心脏代谢稳态,支持Naᵢ作为CKD相关心脏重塑中具有机制相关性且可能可靶向的通路。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42573153
In Duchenne muscular dystrophy (DMD), connexin-43 (Cx43) delocalizes from intercalated discs to the lateral membrane of cardiomyocytes, where it forms undocked hemichannels. β-adrenergic stress induces lethal arrhythmias in DMDmdx mice that correlate with increased Cx43 S-nitrosylation and excessive hemichannel opening. Here, we aimed to determine whether S-nitrosylation of Cx43 at cysteine 271 directly contributes to β-adrenergic stress-induced arrhythmias and myocardial injury in DMD. To define the role of Cx43 S-nitrosylation in DMD cardiomyopathy, we generated DMDmdx knock-in mice carrying a cysteine-to-serine substitution at residue 271, a critical S-nitrosylation site involved in NO-dependent Cx43 hemichannel activation (DMDmdx:C271S+/-). Following β-adrenergic stimulation, DMDmdx mice exhibited a higher incidence of arrhythmogenic events and increased triggered activity in isolated cardiomyocytes compared with DMDmdx:C271S+/- mice, which more closely resembled wild-type mice. Optical mapping of isolated hearts showed that DMDmdx mice developed abnormal Ca2+ transients, prolonged action potentials, and episodes of conduction block. These abnormalities were normalized in DMDmdx:C271S+/- mice and attenuated by treatment with the Cx43 hemichannel inhibitor Gap19. Moreover, β-adrenergic stress evoked severe myocardial injury and bradycardia in DMDmdx mice, both of which were significantly attenuated in DMDmdx:C271S+/- mice. Notably, Gap19-treated DMDmdx mice were protected against myocardial injury, further supporting a direct role for Cx43 hemichannels in DMD-associated cardiac damage. These findings reveal, for the first time, a mechanistic link between Cx43 hemichannel activity, arrhythmogenesis, and myocardial injury in DMD. We conclude that S-nitrosylation of Cx43 is a fundamental NO-mediated mechanism driving β-adrenergic stress-induced arrhythmias and myocardial injury in DMDmdx mice through pathological opening of Cx43 hemichannels.
中文摘要:在杜氏肌营养不良症(DMD)中,连接蛋白43(Cx43)从闰盘移位至心肌细胞侧膜,并在该处形成未对接的半通道。β肾上腺素能应激可在DMDmdx小鼠中诱发致死性心律失常,且与Cx43 S-亚硝基化增加和半通道过度开放相关。本研究旨在确定Cx43第271位半胱氨酸的S-亚硝基化是否直接参与DMD中β肾上腺素能应激诱发的心律失常和心肌损伤。为界定Cx43 S-亚硝基化在DMD心肌病中的作用,我们构建了在271位点携带半胱氨酸至丝氨酸替换的DMDmdx敲入小鼠(DMDmdx:C271S+/-),该位点是参与NO依赖性Cx43半通道激活的关键S-亚硝基化位点。β肾上腺素能刺激后,DMDmdx小鼠的致心律失常事件发生率高于DMDmdx:C271S+/-小鼠,分离心肌细胞中的触发活动也增多,而DMDmdx:C271S+/-小鼠更接近野生型小鼠。离体心脏光学标测显示,DMDmdx小鼠出现异常钙瞬变、动作电位延长和传导阻滞发作。这些异常在DMDmdx:C271S+/-小鼠中恢复正常,并被Cx43半通道抑制剂Gap19减轻。β肾上腺素能应激在DMDmdx小鼠中引起严重心肌损伤和心动过缓,二者在DMDmdx:C271S+/-小鼠中均显著减轻。接受Gap19治疗的DMDmdx小鼠免于心肌损伤,进一步支持Cx43半通道在DMD相关心脏损伤中的直接作用。这些结果首次揭示了DMD中Cx43半通道活性、心律失常发生和心肌损伤之间的机制联系。结论是,Cx43 S-亚硝基化是一种基础性的NO介导机制,通过病理性开放Cx43半通道驱动DMDmdx小鼠中β肾上腺素能应激诱发的心律失常和心肌损伤。

6卒中/脑血管 (3篇)

临床研究 (3篇)

British journal of anaesthesia IF 10.3 2026-10-16 PMID: 42888145
Patients from more deprived backgrounds experience poorer postoperative outcomes. We analysed preoperative characteristics in UK Perioperative Quality Improvement Programme participants according to socioeconomic position to explore opportunities for targeted interventions. Participants were adults aged ≥18 yr undergoing major elective surgery at UK Perioperative Quality Improvement Programme sites. Socioeconomic position was determined using postcode data and the Index of Multiple Deprivation (IMD) standardised aggregate scale of area-level deprivation. Associations between IMD position and patient characteristics, health behaviours, and comorbidities were analysed using descriptive statistics with appropriate parametric and nonparametric testing. Of 55 938 participants included, quintile 1 (most deprived) represented the smallest subgroup (14.2%), with recruitment varying by region and site. Median age was 66 yr with IMD 1 participants 5 yr younger (62 yr) than IMD 5 (67 yr). Deprivation gradients (IMD 5 to 1) were seen for home ownership, occupation, and educational attainment. Prevalences of smoking, inactivity, and obesity increased from IMD 5 to 1. Higher prevalences of major long-term conditions including diabetes mellitus, heart failure, stroke, and ASA physical status 3-4 were observed in more deprived quintiles. Prevalence rates of dementia and renal impairment were similar across quintiles despite the age gradient. Notably, the proportions of patients living with frailty and disability increased with deprivation. Patients presenting for major surgery from more deprived backgrounds do so in poorer overall health. They can encounter barriers to both research participation and available preoperative support. Addressing this unmet need to prevent widening perioperative health inequalities requires interventions tailored to the patient's socioeconomic context.
中文摘要:来自较贫困背景的患者术后结局较差。为探索针对性干预的机会,我们按社会经济地位分析了英国围手术期质量改进计划参与者的术前特征。参与者为在英国围手术期质量改进计划站点接受大型择期手术的18岁及以上成人。社会经济地位依据邮编数据和多重剥夺指数(IMD)这一标准化的地区层面剥夺综合量表确定。采用描述性统计及适当的参数与非参数检验,分析IMD位置与患者特征、健康行为和合并症之间的关联。纳入的55 938名参与者中,第1五分位(最贫困)人数最少(14.2%),招募情况随地区和站点变化。中位年龄为66岁,IMD 1参与者比IMD 5参与者年轻5岁(62岁对67岁)。住房自有、职业和教育程度呈现剥夺梯度(IMD 5至1)。吸烟、缺乏活动和肥胖的患病率从IMD 5至1上升。较贫困五分位中,糖尿病、心力衰竭、卒中等主要长期疾病以及ASA 3-4级的患病率更高。尽管存在年龄梯度,痴呆和肾功能损害的患病率在各五分位间相近。衰弱和残疾患者比例随剥夺程度增加而上升。来自较贫困背景接受大型手术的患者整体健康状况更差。他们在研究参与和可获得的术前支持方面可能遇到障碍。为应对这一未满足需求、防止围手术期健康不平等扩大,需要根据患者社会经济背景制定干预措施。
Circulation IF 41.3 2026-10-13 PMID: 42741837
Gravitational gradients, ranging from the surface of the Earth (1 G) to the microgravity of spaceflight (0 G), including intermediate gravitational fields such as those on Mars (⅜ G), directly affect cardiovascular hemodynamics. We sought to track changes in cardiac structure and function over the course of long-duration spaceflight and compare them with responses to specific gravitational loads measured preflight and postflight in a uniquely simulated Martian gravitational load. We performed a prospective, within-subject, repeated-measures observational study of astronauts during flights to the International Space Station, with acquisition of echocardiographic variables during preflight supine rest and upright tilt at specific gravitational loads, including simulated Martian gravity (22° tilt; 0.38 G). Data were subsequently acquired during spaceflight onboard the International Space Station, upon landing on Earth, and after landing during exposure to simulated Martian gravity. Offline analyses of echocardiographic images were performed according to standardized methods, including myocardial deformation measurements. Thirteen astronauts (9 male) with a mean age of 49±4 years were included. The median spaceflight duration was 164 days (interquartile range, 126 to 169 days; median absolute deviation, 21 days). Significant reductions occurred in left ventricular (LV) end-diastolic volume, stroke volume, and myocardial deformation measures from preflight supine to early in-flight (14 days) measures in microgravity. These early in-flight values were similar in magnitude to those observed in the preflight upright Earth posture, with the exception of an increase in LV longitudinal strain magnitude (-14.5%±1.79% versus -16.9%±2.03%; P=0.006) and a reduction in LV global circumferential strain (-26.09%±1.76% versus -23.3%±3.22%; P=0.016). Throughout the subsequent duration of spaceflight, LV end-diastolic volume and LV stroke volume increased toward preflight supine values. After ≈6 months in space, when astronauts were exposed to simulated Martian gravity (⅜ G), no volumetric or hemodynamic measure evinced greater load or hemodynamic stress than upright posture on Earth before flight. In this small exploratory study, initial changes in LV chamber volumes, myocardial mechanics, cardiac output, and stroke volume with transition from Earth's gravitational loads to microgravity were transient and stabilized during flight. Given current countermeasures, prolonged spaceflight of up to 6 months does not result in large changes in cardiac structure or function within the context of normal posture variations on Earth. These adaptations generally return to baseline upon return to Earth, with no large changes in cardiac volumes or function relative to the upright posture on Earth in a simulated Martian gravity landing, suggesting that orthostatic intolerance may be unlikely to occur on Mars after a 6-month transport with appropriate exercise countermeasures.
中文摘要:从地球表面(1 G)到航天微重力(0 G)的重力梯度,包括火星等中间重力场(⅜ G),直接影响心血管血流动力学。研究旨在追踪长时间航天飞行期间心脏结构与功能变化,并与飞行前和飞行后在独特模拟火星重力负荷下测得的特定重力负荷反应比较。研究对前往国际空间站的宇航员开展前瞻性、受试者内、重复测量观察性研究,在飞行前仰卧静息和特定重力负荷下直立倾斜期间采集超声心动图变量,包括模拟火星重力(22°倾斜;0.38 G)。随后在国际空间站飞行期间、着陆地球时以及着陆后暴露于模拟火星重力期间采集数据。按标准化方法对超声心动图图像进行离线分析,包括心肌形变测量。纳入13名宇航员(9名男性),平均年龄49±4岁。航天飞行时长中位数164天(四分位距126至169天;中位绝对偏差21天)。从飞行前仰卧到飞行早期(14天)微重力下,左心室舒张末期容积、每搏量和心肌形变指标显著降低。这些飞行早期数值的幅度与飞行前地球直立姿势观察到的相似,例外是左心室纵向应变幅度增加(-14.5%±1.79% 对 -16.9%±2.03%,P=0.006)和左心室整体周向应变减低(-26.09%±1.76% 对 -23.3%±3.22%,P=0.016)。在随后整个航天飞行期间,左心室舒张末期容积和左心室每搏量增加,向飞行前仰卧值回升。在太空约6个月后,宇航员暴露于模拟火星重力(⅜ G)时,没有任何容积或血流动力学指标显示出比飞行前地球直立姿势更大的负荷或血流动力学应激。在这项小型探索性研究中,从地球重力负荷向微重力过渡时左心室腔容积、心肌力学、心输出量和每搏量的初始变化是短暂的,并在飞行期间稳定。在当前对抗措施下,长达6个月的长时间航天飞行未导致心脏结构或功能的较大变化,且处于地球正常姿势变化范围内。这些适应在返回地球后总体回到基线,在模拟火星重力着陆时相对于地球直立姿势未见心脏容积或功能的较大变化,提示在适当运动对抗措施下经过6个月运输后,火星上直立不耐受可能不太会发生。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 42207987
The Lancet Diabetes and Endocrinology Commission recently proposed the new definition of preclinical and clinical obesity. Our study aimed to investigate the associations of the novel obesity classifications with incident cardiovascular disease (CVD). In 459 102 UK Biobank participants enrolled between 2006 and 2010, we applied the new definitions of clinical and preclinical obesity, based on the presence of excess adiposity with or without organ dysfunction, to assess their associations with incident CVD and its subtypes. Participants were further stratified into a seven-category classification integrating the Lancet framework with traditional body mass index (BMI) categories. Multivariable Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CI) for each obesity classification in relation to CVD risk. Over a median follow-up of 11.0 years, a total of 51 640 cases of CVD incidence were recorded. Compared with those with no obesity, individuals with preclinical obesity exhibited modestly elevated risks of CVD (HR 1.11, 95% CI 1.08-1.15), while clinical obesity was associated with substantially higher risks of total CVD (HR 1.77, 95% CI 1.72-1.82) and all subtypes, including coronary heart disease (CHD), stroke, and heart failure. Furthermore, newly diagnosed preclinical and clinical obesity with BMI below the conventional obesity threshold also had elevated incident CVD risk, with strongest association for CHD. The new framework advances CVD risk stratification beyond BMI alone, emphasizing the importance of incorporating excess body fat and functional health assessments into obesity diagnosis. Stronger associations with clinical obesity highlight its utility as a cumulative disease burden classifier, identifying individuals at higher cardiovascular risk.
中文摘要:《柳叶刀·糖尿病与内分泌学》委员会最近提出了临床前肥胖和临床肥胖的新定义。本研究旨在探讨新的肥胖分类与心血管疾病(CVD)发病之间的关联。在2006至2010年纳入的459102名英国生物银行参与者中,我们依据是否存在器官功能障碍的过度脂肪蓄积,应用临床肥胖和临床前肥胖的新定义,评估其与CVD及其亚型发病的关联。参与者进一步按整合《柳叶刀》框架与传统体重指数(BMI)分类的七分类法分层。多变量Cox回归估计各肥胖分类与CVD风险的危害比(HR)和95%置信区间(CI)。中位随访11.0年期间,共记录51640例CVD发病。与无肥胖者相比,临床前肥胖者的CVD风险轻度升高(HR 1.11,95%CI 1.08-1.15),临床肥胖与总CVD及其所有亚型风险显著升高相关(HR 1.77,95%CI 1.72-1.82),包括冠心病、卒中和心力衰竭。新诊断的临床前肥胖和临床肥胖且BMI低于传统肥胖阈值者,其CVD发病风险也升高,其中与冠心病的关联最强。新框架在BMI之外推进了CVD风险分层,强调将过量体脂和功能健康评估纳入肥胖诊断的重要性。临床肥胖更强的关联凸显其作为累积疾病负担分类器的效用,可识别心血管风险更高的个体。

7冠心病/心绞痛 (3篇)

临床研究 (3篇)

Nature cardiovascular research IF 12.6 2026-10-13 PMID: 42869976
Invasive coronary angiography is the reference standard for diagnosing coronary artery disease, yet assessment is subjective, and existing artificial-intelligence tools typically assess stenosis in individual frames or videos and do not integrate the full multiview angiographic study. Here we show that DeepCORO-CLIP, trained on 203,808 angiographic videos and reports from 28,117 patients, interprets whole multiple-video angiograms at once. It detects obstructive stenoses (≥70%), with an area under the receiver operating characteristic curve (AUROC) of 0.89 internally and externally, and identifies chronic total occlusion (AUROC = 0.90 to 0.95), intra-coronary thrombus and calcification (AUROC = 0.90 to 0.91). It also predicts 1-year cardiovascular events (AUROC = 0.79, 95% CI of 0.74 to 0.84, versus 0.65 for a model derived using clinical variables) and left ventricular ejection fraction (mean absolute error 7.3% versus 8.8% for a previous model), both achieved using coronary angiography alone. In a blinded review of 365 evaluations across 288 angiograms, its reports were clinically usable in 76% of evaluations versus 88% for cardiologists, with comparable false positives (17% versus 14%, P = 0.38); residual missed stenoses reflected an adjustable threshold rather than an absent signal.
中文摘要:有创冠状动脉造影是诊断冠状动脉疾病的参考标准,但评估具有主观性,现有的人工智能工具通常只评估单帧或单个视频中的狭窄,未整合完整的多次造影检查。DeepCORO-CLIP基于28,117例患者的203,808段造影视频与报告训练,可一次性解读由多段视频组成的完整造影检查。它检测阻塞性狭窄(≥70%),内部和外部验证的受试者工作特征曲线下面积(AUROC)均为0.89,并可识别慢性完全闭塞(AUROC=0.90至0.95)、冠状动脉内血栓和钙化(AUROC=0.90至0.91)。它还能预测1年心血管事件(AUROC=0.79,95% CI为0.74至0.84;使用临床变量构建的模型为0.65)和左心室射血分数(平均绝对误差7.3%,既往模型为8.8%),两者均仅使用冠状动脉造影实现。在覆盖288份造影的365次评估的盲法复核中,其报告在76%的评估中具有临床可用性,心内科医生为88%,假阳性率相近(17%对14%,P=0.38);残余漏诊狭窄反映的是可调阈值,而非信号缺失。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 40197521
Obesity, traditionally measured using body mass index (BMI), is considered a significant risk factor for the development of cardiovascular disease (CVD). However, there have been mixed findings regarding the association between obesity and cardiovascular events in part due to the way it is measured. Major limitations exist with the use of BMI as it cannot assess body composition or fat distribution, and thus fails to account for the separate roles of muscle and fat mass (FM). The objective is to examine the relationship between various measures of body composition including FM, fat-free mass (FFM), waist-to-height ratio, waist circumference, and BMI, and coronary heart disease (CHD) events, from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort. MESA is a population-based cohort study of 6814 men and women, aged between 45 and 85 years, without clinically apparent CVD. FM and FFM at baseline (Exam 1) were estimated using multiplicative power equations formulated from bioelectrical impedance analysis (BIA) measurements. Multi-variable Cox regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for 10-year incident hard CHD events (non-fatal myocardial infarction, resuscitated cardiac arrest, and death resulting from CHD) for FM/FFM, waist-to-height ratio, waist circumference, and BMI. Higher FM was associated with higher risk of hard CHD events, with a HR of 1.64 (1.09-2.48) per standard deviation (SD) unit increase (P-value 0.019). FFM was associated with a lower risk of CHD, with a HR of 0.24 (0.08-0.76) per SD unit increase of FFM (P-value 0.014). The waist-to-height ratio had a HR of 1.21 (1.08-1.35) (P-value 0.001) per SD unit increase in the ratio and was significantly associated with a higher risk of hard CHD events, as was waist circumference with a HR of 1.14 (1.03-1.28) (P-value 0.016) per SD unit increase. BMI had a HR of 1.08 (0.97-1.21) (P-value 0.158) and was not significantly associated with a 10-year risk of hard CHD events. Higher FM, waist-to-height ratio, and waist circumference were associated with increased risk for hard CHD events while higher FFM was associated with decreased risk. This highlights the potential importance of lifestyle interventions to build muscle and minimize adiposity for the prevention of CVD and strengthens the call for the inclusion of alternative methodologies to define obesity and measure body composition in the clinical setting.
中文摘要:肥胖通常以体质指数衡量,被视为心血管疾病发生的重要危险因素。但肥胖与心血管事件之间的关联结果并不一致,部分原因在于测量方式。体质指数无法评估身体成分或脂肪分布,不能区分肌肉量与脂肪量的独立作用,存在明显局限。研究目的是利用多种族动脉粥样硬化研究队列,分析脂肪量、去脂体重、腰高比、腰围和体质指数等身体成分指标与冠心病事件的关系。MESA为基于人群的队列研究,纳入6814名45至85岁、无临床明显心血管疾病的男性和女性。基线检查时的脂肪量和去脂体重由生物电阻抗分析测量结果构建的乘法幂方程估算。采用多变量Cox回归模型估计脂肪量/去脂体重、腰高比、腰围和体质指数与10年新发硬性冠心病事件(非致死性心肌梗死、心脏骤停复苏成功和冠心病死亡)的风险比及95%置信区间。脂肪量较高与硬性冠心病事件风险升高相关,每增加1个标准差的风险比为1.64(1.09-2.48),P值为0.019。去脂体重与冠心病风险降低相关,每增加1个标准差的风险比为0.24(0.08-0.76),P值为0.014。腰高比每增加1个标准差的风险比为1.21(1.08-1.35),P值为0.001,与硬性冠心病事件风险升高显著相关;腰围每增加1个标准差的风险比为1.14(1.03-1.28),P值为0.016。体质指数的风险比为1.08(0.97-1.21),P值为0.158,与10年硬性冠心病事件风险无显著关联。脂肪量、腰高比和腰围较高与硬性冠心病事件风险增加相关,去脂体重较高与风险降低相关。这提示通过生活方式干预增加肌肉、减少脂肪堆积对预防心血管疾病可能具有重要性,也支持在临床环境中采用替代方法定义肥胖并测量身体成分。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 39957360
Visceral adipose tissue (VAT) has been related to coronary artery disease (CAD), but its association with recurrent major adverse cardiovascular events (MACE) in premature CAD (pCAD) has not been fully explored. Thus, we aimed to investigate the impact of VAT on recurrent MACE in patients with pCAD. This was a retrospective sub-analysis of 853 patients with pCAD from the GEA cohort study. Visceral adipose tissue was measured by computed tomography at baseline. The primary outcome was the recurrence of MACE over 5 years of follow-up. Likewise, the association of VAT with non-fatal and fatal MACE was analysed as a secondary outcome. Cox regression models were fitted and adjusted by confounders obtained at baseline to estimate adjusted hazard ratios (aHRs). The median age of the patients was 53 years, and 80% were male, with a median follow-up of 4.9 years. Overall, 10% of the patients had recurrent MACE (6.5% non-fatal and 3.6% fatal) with an incidence rate of 18.5 [95% confidence interval (CI): 18.0-19.0] events per 1000 person-years. Visceral adipose tissue was positively associated with MACE. Those in the upper tertile (VAT ≥ 194 cm²) had the highest risk for total (aHR: 2.71; 95% CI: 1.37-5.35; P = 0.004) and non-fatal (aHR: 3.58; 95% CI: 1.49-8.61; P = 0.004) MACE. Fatal MACE was not statistically associated (aHR: 2.13; 95% CI: 0.72-6.35; P = 0.174). Among patients with pCAD, VAT increased the risk of recurrent MACE despite adequate pharmacological treatment. These results suggest that VAT could be considered an emergent risk factor and a promising target for residual cardiovascular risk reduction. This study explores how visceral adipose tissue (VAT), a type of body fat located around internal organs, elevates the risk of recurrent cardiovascular events in patients with premature coronary artery disease (pCAD), even with optimal medical treatment.Key finding 1: Patients with elevated VAT levels faced a significantly higher risk of recurrent major cardiovascular events.Key finding 2: These results indicate that reducing VAT through lifestyle modifications or targeted interventions could decrease cardiovascular risks in patients with pCAD.
中文摘要:内脏脂肪组织(VAT)与冠状动脉疾病(CAD)相关,但其与早发冠心病(pCAD)患者复发性主要不良心血管事件(MACE)的关联尚未充分探讨。因此,我们旨在研究VAT对pCAD患者复发性MACE的影响。本研究为GEA队列研究中853例pCAD患者的回顾性子分析。基线时通过计算机断层扫描测量内脏脂肪组织。主要结局为5年随访期间MACE复发。同样,将VAT与非致死性和致死性MACE的关联作为次要结局分析。拟合Cox回归模型,并校正基线获得的混杂因素以估计校正风险比(aHRs)。患者中位年龄53岁,80%为男性,中位随访4.9年。总体10%的患者出现复发性MACE(6.5%非致死性,3.6%致死性),发生率为每1000人年18.5[95%置信区间(CI):18.0-19.0]次事件。内脏脂肪组织与MACE呈正相关。位于上三分位(VAT ≥ 194 cm²)者总MACE(aHR:2.71;95% CI:1.37-5.35;P = 0.004)和非致死性MACE(aHR:3.58;95% CI:1.49-8.61;P = 0.004)风险最高。致死性MACE无统计学关联(aHR:2.13;95% CI:0.72-6.35;P = 0.174)。在pCAD患者中,尽管接受了充分的药物治疗,VAT仍增加复发性MACE风险。这些结果提示VAT可被视为新兴危险因素,并作为降低残余心血管风险的有希望靶点。本研究探讨位于内脏器官周围的体脂类型内脏脂肪组织(VAT)如何升高早发冠心病(pCAD)患者复发性心血管事件风险,即使接受最佳药物治疗。关键发现1:VAT水平升高的患者面临显著更高的复发性主要心血管事件风险。关键发现2:这些结果表明,通过生活方式调整或靶向干预降低VAT可降低pCAD患者的心血管风险。

8心房颤动 (3篇)

临床研究 (2篇)

European journal of preventive cardiology IF 10.0 2026-10-12 PMID: 42861574
Regular physical activity (PA) may reduce atrial fibrillation (AF) risk in the general population, however, contemporary data suggests individuals engaging in the highest levels of PA may exhibit a paradoxical rise in AF risk. The point at which the dose-response curve reverses remains unclear. This meta-analysis aimed to assess the association between PA and AF across the full continuum of PA exposure. Four databases were searched (from January 1990 to June 2025). Eligible studies included those that reported PA exposure compared against a sedentary control group and assessed AF incidence or prevalence. PA exposures were standardised to metabolic equivalent of task hours per week (MET-hr/wk). Pooled odds ratios (ORs) were calculated using a weighted random-effects model. A weighted restricted cubic spline model of logarithmic odds was used to produce a dose-response curve. 37 studies were included (n = 1,298,291 individuals). In the general population, PA was associated with a reduction in odds of AF by 22% (22 studies; OR 0.78; 95% CI 0.68, 0.89). Athlete status was associated with an increase in the odds of AF (15 studies; OR 2.74; 95% CI 1.72, 4.39). Dose-response analysis (26 studies; n = 1,022,790 individuals) showed 26 MET-hr/wk of PA was associated with the greatest reduction in odds of AF, with doses beyond 78 MET-hr/wk associated with increased odds of AF; the equivalent of 6-7 hours per week of endurance training. PA and AF demonstrate a U-shaped relationship whereby beyond a quantitative dose threshold of 78 MET-hr/wk, the protective effect of exercise may reverse.
中文摘要:在一般人群中,规律的身体活动(PA)可能降低心房颤动(AF)风险,但近年数据提示,活动量最高的人群可能出现AF风险的反常升高。剂量-反应曲线在何处反转仍不清楚。本meta分析旨在评估PA与AF在全范围暴露水平上的关联。检索四个数据库(1990年1月至2025年6月)。纳入标准为报告PA暴露与久坐对照组比较并评估AF发病率或患病率的研究。PA暴露统一换算为每周代谢当量小时(MET-hr/wk)。采用加权随机效应模型计算合并比值比(OR)。以对数OR的加权限制性立方样条模型生成剂量-反应曲线。共纳入37项研究(n=1 298 291人)。在一般人群中,PA与AF风险降低22%相关(22项研究;OR 0.78;95%CI 0.68,0.89)。运动员身份与AF风险升高相关(15项研究;OR 2.74;95%CI 1.72,4.39)。剂量-反应分析(26项研究;n=1 022 790人)显示,PA为26 MET-hr/wk时AF风险的降低幅度最大,超过78 MET-hr/wk的剂量与AF风险升高相关,相当于每周6~7小时耐力训练。PA与AF呈U形关系,超过78 MET-hr/wk这一量化剂量阈值后,运动的保护作用可能反转。
Cardiovascular research IF 12.5 2026-10-10 PMID: 42669093
Adherence with a holistic or integrated care management of atrial fibrillation (AF) based on the AF better care (ABC) pathway has been associated with improved clinical outcomes. Two prospective randomized trials (mAFA and MIRACLE-AF) have evaluated this approach. The multicentre mAFA-II trial delivered the ABC pathway via mobile health using an mAFA App, while the MIRACLE-AF trial relied on village doctors supported by telehealth in rural communities. We conducted a pooled analysis of individual participant data to assess the overall efficacy of ABC pathway-based management in patients with AF. We combined patient-level data from the mAFA-II and MIRACLE-AF trials. The primary endpoint was defined as a composite of all-cause mortality, ischaemic stroke, haemorrhagic stroke, heart failure (HF), acute coronary syndrome (ACS), and major bleeding events. The secondary endpoints included individual components and two grouped outcomes: all stroke and HF/ACS. A one-stage marginal Cox proportional hazards model stratified by trial and with robust standard errors clustered at the site level was used, with adjustment for CHA2DS2-VASc and other clinically relevant baseline variables. Cumulative event rates were estimated using Kaplan-Meier methods. Subgroup and sensitivity analyses were conducted to assess the robustness of the findings. Between-trial heterogeneity was further explored using a two-stage approach, incorporating trial-level effect estimates and inverse-variance weighting. We studied 4363 patients with AF [mean age 70.3 (SD 12.8) years; 60.5% male]. During 0.8 [SD 0.4] years of follow-up, the primary endpoint occurred in 329 (7.5%). Kaplan-Meier curves demonstrated lower cumulative incidence of events in the intervention group. On multivariable mixed-effects Cox models, the intervention group demonstrated a significantly lower risk of the primary endpoint compared to the control group (adjusted hazard ratio: 0.72; 95% confidence interval: 0.56-0.93). Subgroup analyses suggested potential effect modification, whereas sensitivity analyses consistently supported the primary findings. A two-stage analysis showed directionally consistent effects across trials for the primary endpoint. In this pooled individual participant data from two prospective randomized trials, ABC pathway-based integrated care was associated with improved clinical outcomes in patients with AF vs. usual care, with the observed benefit primarily driven by reductions in HF/ACS-related events rather than classical AF-specific outcomes, supporting further implementation studies and context-specific adoption in clinical practice.
中文摘要:基于心房颤动ABC路径的整体或整合管理依从性与临床结局改善相关。mAFA和MIRACLE-AF两项前瞻性随机试验评估了该策略。多中心mAFA-II试验通过mAFA应用程序以移动健康方式实施ABC路径,MIRACLE-AF试验则在农村社区依托远程医疗支持乡村医生实施。本研究汇总个体参与者数据,评估以ABC路径为基础的管理对心房颤动患者的总体疗效。研究合并mAFA-II与MIRACLE-AF的患者水平数据。主要终点为全因死亡、缺血性卒中、出血性卒中、心力衰竭、急性冠脉综合征和重大出血事件的复合终点。次要终点包括各单一组分及两个分组结局:全部卒中和心力衰竭/急性冠脉综合征。采用按试验分层的单阶段边际Cox比例风险模型,并以中心水平聚类稳健标准误,校正CHA2DS2-VASc及其他临床相关基线变量。采用Kaplan-Meier法估计累积事件率。开展亚组和敏感性分析评估结果稳健性。进一步采用两阶段方法探索试验间异质性,纳入试验水平效应估计并行逆方差加权。共纳入4363例心房颤动患者,平均年龄70.3岁(标准差12.8),男性占60.5%。随访0.8年(标准差0.4)期间,329例(7.5%)发生主要终点。Kaplan-Meier曲线显示干预组事件累积发生率较低。多变量混合效应Cox模型显示,与对照组相比,干预组主要终点风险显著降低(校正风险比0.72;95%置信区间0.56-0.93)。亚组分析提示可能存在效应修饰,敏感性分析一致支持主要发现。两阶段分析显示各试验主要终点效应方向一致。在这项来自两项前瞻性随机试验的汇总个体参与者数据中,与常规照护相比,以ABC路径为基础的整合管理与心房颤动患者临床结局改善相关,观察到的获益主要由心力衰竭/急性冠脉综合征相关事件减少驱动,而非经典的心房颤动特异性结局,支持进一步开展实施研究并在临床实践中结合具体情境采用。

基础研究 (1篇)

Journal of advanced research IF 17.1 2026-10-12 PMID: 42863786
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia worldwide, and environmental factors are increasingly recognized as contributors to its complex pathogenesis. The tire antioxidant N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine (6PPD) and its oxidation product 6PPD-quinone (6PPD-Q) are emerging environmental contaminants with reported cardiotoxicity; however, their molecular relationship with AF remains unclear. This study aimed to identify potential molecular targets and pathways that link 6PPD/6PPD-Q exposure to AF using an integrated network toxicology and machine learning strategy. Multicohort atrial microarray datasets from patients with AF were integrated to identify AF-related genes using differential expression analysis, weighted gene coexpression network analysis, and GeneCards database screening. Putative targets of 6PPD/6PPD-Q were predicted using multiple in silico databases and intersected with AF-related genes. Network toxicology, enrichment analysis, machine learning with SHAP interpretation, single-cell RNA sequencing, and molecular docking were utilized to identify and characterize hub genes. Key targets were validated using qRT-PCR and western blotting in human cardiac fibroblasts. A mouse exposure model was further used to assess AF inducibility, duration, and cardiac gene expression in vivo. Sixteen putative AF-associated target genes of 6PPD/6PPD-Q were identified. Machine learning analysis highlighted four hub genes as key candidate hubs. Single-cell RNA analysis revealed cell type-specific expression, with enrichment in cardiomyocytes and vascular structural cells. Molecular docking predicted favorable binding interactions between 6PPD/6PPD-Q and the key target proteins. In vitro exposure to 6PPD or 6PPD-Q at the tested concentrations upregulated the mRNA and protein levels of all four candidate genes. In vivo exposure significantly increased pacing-induced AF inducibility, prolonged AF duration, and upregulated the expression of all these genes in cardiac tissues. These findings suggest that 6PPD and 6PPD-Q may contribute to AF by targeting specific genes and signaling pathways, with DDR1, BCHE, HTR2B, and KCNJ3 identified as core exposure-related hubs.
中文摘要:心房颤动(AF)是全球最常见的持续性心律失常,环境因素在其复杂发病机制中的作用日益受到重视。轮胎抗氧化剂N-(1,3-二甲基丁基)-N'-苯基对苯二胺(6PPD)及其氧化产物6PPD-醌(6PPD-Q)是新兴环境污染物,已有心脏毒性报道,但其与AF的分子联系仍不清楚。本研究旨在通过整合网络毒理学与机器学习策略,识别将6PPD/6PPD-Q暴露与AF联系起来的潜在分子靶点与通路。整合来自AF患者的多队列心房芯片数据集,采用差异表达分析、加权基因共表达网络分析和GeneCards数据库筛选识别AF相关基因。利用多个计算机数据库预测6PPD/6PPD-Q的潜在靶点,并与AF相关基因取交集。运用网络毒理学、富集分析、带SHAP解释的机器学习、单细胞RNA测序和分子对接识别并刻画枢纽基因。在人心脏成纤维细胞中用qRT-PCR和western blotting验证关键靶点。进一步使用小鼠暴露模型在体内评估AF可诱发性、持续时间及心脏基因表达。共识别出16个6PPD/6PPD-Q的假定AF相关靶基因。机器学习分析突出4个枢纽基因作为关键候选枢纽。单细胞RNA分析显示细胞类型特异性表达,在心肌细胞和血管结构细胞中富集。分子对接预测6PPD/6PPD-Q与关键靶蛋白具有良好结合相互作用。在所测试浓度下,体外暴露于6PPD或6PPD-Q上调了全部4个候选基因的mRNA和蛋白水平。体内暴露显著增加起搏诱发的AF可诱发性,延长AF持续时间,并上调心脏组织中这些基因的表达。这些发现提示,6PPD和6PPD-Q可能通过靶向特定基因和信号通路促进AF,其中DDR1、BCHE、HTR2B和KCNJ3被确定为核心暴露相关枢纽。

9心律失常(非房颤) (2篇)

基础研究 (2篇)

Science advances IF 13.9 2026-10-16 PMID: 42886781
Temporary cardiac pacing is indispensable for bridging transient bradyarrhythmic indications over days to weeks, yet existing systems remain constrained by device dimensions, surgical complexity, patient burden, and intrinsic operational principles. Here, these challenges are addressed through a millimeter-scale capsule power system with magnetically gated activation via a reed switch, which eliminates the stringent orientation and implantation-depth requirements of optically controlled approaches. In contrast to conventional reed switch-based pacemakers, this capsule system extends the functionality of the reed switch by integrating electrode materials directly onto its surface, thereby enabling a monolithic miniaturized architecture. Pulsed magnetic fields wirelessly actuate intermittent switching, enabling controlled discharge, with robust cardiac pacing demonstrated in large animals. A proof-of-concept closed-loop system is further realized, establishing the feasibility of future integration with a wearable electronic module to enable autonomous electrotherapy upon arrhythmia detection. Collectively, this strategy addresses a key limitation in temporary pacing and may provide a versatile framework for the development of temporary electrotherapeutic systems across cardiac, neural, and regenerative applications.
中文摘要:临时心脏起搏对于在数天至数周内桥接短暂性缓慢性心律失常适应证不可或缺,但现有系统受器件尺寸、手术复杂性、患者负担及固有工作原理限制。这里通过一种毫米级胶囊电源系统应对这些挑战,该系统利用磁簧开关实现磁门控激活,从而消除光控方法对方向和植入深度的严格要求。与传统基于磁簧开关的起搏器不同,该胶囊系统将电极材料直接集成到磁簧开关表面,扩展其功能,形成单片式小型化架构。脉冲磁场无线驱动间歇开关,实现受控放电,并在大型动物中展示稳健的心脏起搏。进一步实现概念验证闭环系统,为未来与可穿戴电子模块整合、在检测到心律失常时实现自主电疗建立可行性。该策略解决临时起搏的关键限制,并可能为心脏、神经和再生应用中的临时电治疗系统开发提供通用框架。
Pharmacology & therapeutics IF 13.5 2026-10-13 PMID: 42869137
Sinoatrial node dysfunction (SND) is a major cause of bradyarrhythmia, chronotropic incompetence, tachy-brady syndrome, and a common indication for permanent pacemaker implantation, particularly in older adults. Although SND has diverse etiologies, this review focuses on aging-associated intrinsic SND, while considering other common causes where they inform differential diagnosis, arrhythmogenic mechanisms, or therapeutic development. Although current medical interventions provide effective rhythm support, they does not correct the molecular and tissue-level processes that drive sinoatrial node (SAN) degeneration. The review integrates current knowledge of SAN biology with mechanisms underlying SND, including fibrosis, ion-channel and calcium-clock remodeling, mitochondrial dysfunction, cellular senescence, impaired β-adrenergic signaling, genetic susceptibility, and epigenetic or epitranscriptomic regulation. We further discuss how these mechanisms contribute to impaired impulse generation, SAN exit block, reduced chronotropic reserve, and increased susceptibility to atrial arrhythmia. We discuss approaches for studying the molecular and cellular mechanisms and evaluating therapeutic strategies using emerging animal models, human pluripotent stem cell-derived SAN-like pacemaker cells, organoids, assembloids, and single-cell and spatial omics platforms . Finally, we highlight translational opportunities, including senescence-directed, metabolic, antifibrotic, autonomic, gene-based, regenerative, and biological pacing strategies. A mechanism-guided classification of SND may support future precision therapies that complement conventional pacing by linking dominant rhythm phenotypes to targetable biological drivers, molecular and functional pharmacodynamic markers, and human-relevant models of pacemaker failure.
中文摘要:窦房结功能障碍(SND)是缓慢性心律失常、变时功能不全和慢快综合征的重要原因,也是永久起搏器植入的常见适应证,在老年人中尤为多见。SND病因多样,本综述聚焦与衰老相关的内源性SND,并在有助于鉴别诊断、致心律失常机制或治疗开发时讨论其他常见病因。当前医学干预虽能提供有效的节律支持,却不能纠正驱动窦房结(SAN)退变的分子和组织层面过程。综述将SAN生物学现有认识与SND机制整合,包括纤维化、离子通道与钙钟重构、线粒体功能障碍、细胞衰老、β肾上腺素能信号受损、遗传易感性以及表观遗传或表观转录调控。文中进一步讨论这些机制如何导致冲动生成受损、SAN出口阻滞、变时储备下降和房性心律失常易感性增加。讨论利用新兴动物模型、人多能干细胞来源的SAN样起搏细胞、类器官、组装体以及单细胞和空间组学平台研究分子与细胞机制、评估治疗策略的方法。转化机会涵盖靶向衰老、代谢、抗纤维化、自主神经、基因、再生和生物起搏策略。以机制为导向的SND分类可能支持未来精准治疗,通过将主要节律表型与可靶向生物学驱动因素、分子和功能药效学标志物以及人相关起搏器衰竭模型相联系,补充常规起搏治疗。

10PCI/血运重建 (2篇)

临床研究 (2篇)

European heart journal IF 45.3 2026-10-16 PMID: 42880972
Intracoronary imaging has become an important tool for the in vivo assessment of coronary atherosclerosis and for guiding percutaneous coronary intervention. By enabling high-resolution visualization of coronary anatomy, these modalities allow for more accurate lesion characterization, precise stent sizing, and optimized procedural strategies. In recent years, multiple randomized controlled trials have demonstrated that imaging-guided percutaneous coronary intervention reduces major adverse cardiac events (including cardiac death, myocardial infarction, and repeat revascularization), particularly in complex clinical and anatomical settings. This state-of-the-art review synthesizes contemporary evidence supporting the use of intravascular ultrasound and optical coherence tomography to guide percutaneous coronary intervention and improve clinical outcomes, drawing from recent trial data and current guideline recommendations. Special emphasis is placed on complex lesion subsets, such as left main coronary artery disease and other complex bifurcation lesions, calcified lesions, long lesions, and scenarios involving patients at heightened risk, such as those with acute coronary syndrome. Finally, this review considers the strengths and limitations of intracoronary imaging, as well as unresolved questions and priority areas for future research aimed at further improving patient outcomes.
中文摘要:冠状动脉内成像已成为在体内评估冠状动脉粥样硬化并指导经皮冠状动脉介入治疗的重要工具。这些技术能够高分辨率显示冠状动脉解剖,从而更准确地刻画病变、精确选择支架尺寸并优化手术策略。近年来,多项随机对照试验表明,成像指导的经皮冠状动脉介入治疗可减少主要不良心脏事件(包括心源性死亡、心肌梗死和再次血运重建),在复杂临床和解剖情形中尤为明显。本综述汇总支持使用血管内超声和光学相干断层扫描指导经皮冠状动脉介入治疗并改善临床结局的当代证据,依据近期试验数据和当前指南推荐。重点讨论复杂病变亚组,如左主干冠状动脉病变及其他复杂分叉病变、钙化病变、长病变,以及急性冠脉综合征等高风险患者情形。最后讨论冠状动脉内成像的优势与局限,以及尚未解决的问题和未来研究优先领域,以进一步改善患者结局。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 41284738
To assess the association between body mass index (BMI) and 10-year clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. This is a pooled analysis of five randomized trials with 10-year follow-up. All-cause death was the primary outcome. Secondary outcomes were cardiovascular death, myocardial infarction (MI), definite stent thrombosis (ST), and repeat revascularization. A total of 9486 patients were analysed divided into four BMI groups (underweight [n = 92], normal-weight [n = 2785], overweight [n = 4296], and obese [n = 2313]). After 10 years, the risk of all-cause death was significantly higher in underweight patients than in those of normal weight (adjusted hazard ratio [HRadj], 1.58; 95% confidence interval [CI], 1.01-2.47). Compared with normal-weight patients, overweight patients had a significantly lower risk of all-cause death (HRadj, 0.84; 95% CI, 0.78-0.90) and cardiovascular death, while the difference was not significant for obese patients. Overweight and obese patients had a significantly higher risk of definite ST within 30 days, while obese patients had a significantly lower risk of TLR than normal-weight patients. There was a U-shaped, non-linear association between BMI, all-cause death, and cardiovascular death. The baseline BMI of patients undergoing PCI with DES may have important implications for long-term secondary prevention strategies. Further dedicated studies are needed to overcome the limitations of the current analysis.
中文摘要:评估体重指数(BMI)与接受经皮冠状动脉介入治疗(PCI)并植入药物洗脱支架(DES)患者10年临床结局之间的关联。该分析汇总了5项随机试验的10年随访数据。主要结局为全因死亡,次要结局包括心血管死亡、心肌梗死(MI)、明确支架血栓(ST)和再次血运重建。共分析9486例患者,按BMI分为4组:低体重组(n=92)、正常体重组(n=2785)、超重组(n=4296)和肥胖组(n=2313)。10年后,低体重患者的全因死亡风险显著高于正常体重患者(校正风险比[HRadj]为1.58,95%置信区间[CI]为1.01-2.47)。与正常体重患者相比,超重患者的全因死亡风险(HRadj为0.84,95%CI为0.78-0.90)和心血管死亡风险显著更低,而肥胖患者的差异不显著。超重和肥胖患者30天内明确ST风险显著更高,肥胖患者的靶病变血运重建(TLR)风险显著低于正常体重患者。BMI与全因死亡、心血管死亡之间呈U形非线性关联。接受PCI并植入DES患者的基线BMI可能对长期二级预防策略有重要影响。仍需进一步专门研究以克服当前分析的局限性。

11基础/转化 (2篇)

临床研究 (2篇)

Ageing research reviews IF 15.5 2026-10-14 PMID: 42874807
Population ageing has increased the burden of cardiovascular disease, cognitive decline and frailty in older adults. These conditions are often studied separately, yet increasing evidence suggests that the ageing heart, vasculature and brain are biologically interconnected. Using a hybrid design that combines a systematic literature search with narrative synthesis, this review summarizes current knowledge on heart-brain co-ageing, with emphasis on phenotypic heterogeneity, molecular mechanisms and translational interventions. Heart-brain co-ageing is characterized by partially coupled but non-synchronous ageing trajectories of cardiac, vascular and brain function. Major clinical phenotypes include vascular-dominant ageing, cardiac-output-related brain vulnerability, arrhythmia-associated thromboinflammatory injury, frailty-cognitive decline and metabolic-inflammatory co-ageing. These phenotypes differ in risk profiles, dominant mechanisms and potential biomarkers. Candidate shared mechanisms include cellular senescence, chronic low-grade inflammation, mitochondrial dysfunction, oxidative stress, endothelial impairment, blood-brain barrier disruption, epigenetic remodelling, telomere attrition, non-coding ribonucleic acid regulation, Klotho signalling, nicotinamide adenine dinucleotide metabolism and microbiome-derived metabolic signalling. Advances in multimodal imaging, circulating biomarkers, biological ageing clocks and multi-omics profiling provide new opportunities for risk stratification, although clinical standardization remains limited. Heart-brain co-ageing should not be regarded as the simple coexistence of cardiovascular and neurological diseases, but as a dynamic multi-organ ageing process shaped by shared biological drivers, interorgan interactions and organ-specific vulnerability, and we propose it as a testable conceptual framework with explicit operational criteria that distinguish coupled from parallel organ ageing. Future research should integrate longitudinal phenotyping, mechanism-based biomarkers and stratified clinical trials to develop precision interventions that preserve both cardiovascular and brain health in older adults.
中文摘要:人口老龄化加重了老年人心血管疾病、认知衰退和衰弱的负担。这些情况常被分开研究,但越来越多证据提示,衰老的心脏、血管和大脑在生物学上相互关联。采用系统文献检索与叙述性综合相结合的混合设计,总结心脏-大脑共同衰老的现有认识,重点涉及表型异质性、分子机制和转化干预。心脏-大脑共同衰老表现为心脏、血管和脑功能部分耦合但不同步的衰老轨迹。主要临床表型包括血管主导型衰老、心输出量相关的脑易损性、心律失常相关的血栓炎症性损伤、衰弱-认知衰退以及代谢-炎症共同衰老。这些表型在风险特征、主导机制和潜在生物标志物方面存在差异。候选共享机制包括细胞衰老、慢性低度炎症、线粒体功能障碍、氧化应激、内皮损伤、血脑屏障破坏、表观遗传重塑、端粒磨损、非编码核糖核酸调控、Klotho信号、烟酰胺腺嘌呤二核苷酸代谢和微生物组来源的代谢信号。多模态成像、循环生物标志物、生物学衰老时钟和多组学分析的进展为风险分层提供了新机会,但临床标准化仍然有限。心脏-大脑共同衰老不应被视为心血管疾病和神经系统疾病的简单共存,而应被视为由共享生物学驱动因素、器官间相互作用和器官特异性易损性塑造的动态多器官衰老过程;将其提出为一个可检验的概念框架,并给出明确的操作标准,以区分耦合性器官衰老与平行性器官衰老。未来研究应整合纵向表型分型、基于机制的生物标志物和分层临床试验,以开发精准干预,维护老年人的心血管和大脑健康。
Circulation IF 41.3 2026-10-13 PMID: 42862908
Chronic liver disease is an increasingly prevalent and heterogeneous syndrome with important consequences for cardiovascular function. As the global burdens of chronic liver disease and cirrhosis continue to rise, cardiovascular disease has emerged as a major driver of overall morbidity and mortality in affected patients. Despite the growing recognition of the intersectionality between hepatology and cardiology care clinically, cardiovascular disease risk among patients with liver disease is underrecognized. This state-of-the-art review summarizes the current understanding of the bidirectional interactions between the liver and the cardiovascular system. Shared mechanisms-including inflammation, endothelial injury, and neurohormonal overactivation-that contribute to the development of adverse myocardial remodeling, atherosclerotic cardiovascular disease, heart failure, arrhythmias, pulmonary vascular syndromes, and cirrhosis-associated cardiovascular syndromes are reviewed. A specific focus is placed on metabolic dysfunction-associated steatotic liver disease, the most common form of chronic liver disease, while highlighting the distinct cardiovascular manifestations associated with other types of chronic liver disease. These include alcohol-associated liver disease and infiltrative diseases that affect the liver and heart with cardiovascular implications across the spectrum from early stages of liver disease through cirrhosis. We discuss practical approaches to detecting liver disease, including the assessment of liver fibrosis noninvasively in individuals at risk. We discuss the approach to assessing cardiovascular risk through cardiac imaging, biomarkers, and cardiac functional testing once chronic liver disease is detected. Management considerations for commonly encountered cardiovascular conditions and a critical appraisal of the evolving evidence supporting cardiometabolic therapies in patients with chronic liver disease are discussed to underscore potential cardiovascular and liver benefits. Critical evidence gaps and future research priorities are identified, including the development and evaluation of liver-informed cardiovascular risk models, incorporation of cardiovascular end points into liver disease trials, and implementation of integrated cardiohepatometabolic care pathways. Improved recognition of chronic liver disease and related cardiovascular disease risk represents a major opportunity to facilitate earlier disease detection, enhance risk stratification, and improve outcomes across the spectrum of chronic liver disease.
中文摘要:慢性肝病是一种日益常见且异质性很强的综合征,对心血管功能产生重要影响。随着全球慢性肝病和肝硬化负担持续上升,心血管疾病已成为这类患者总体发病和死亡的主要驱动因素。临床实践中肝病学与心脏病学诊疗交叉日益受到认识,但肝病患者的心血管疾病风险仍被低估。该前沿综述总结当前对肝脏与心血管系统双向相互作用的认识。共同机制包括炎症、内皮损伤和神经激素过度激活,这些机制促成不良心肌重构、动脉粥样硬化性心血管疾病、心力衰竭、心律失常、肺血管综合征和肝硬化相关心血管综合征。重点讨论代谢功能障碍相关脂肪性肝病这一最常见的慢性肝病形式,同时突出其他类型慢性肝病所具有的不同心血管表现,包括酒精相关性肝病以及同时累及肝脏和心脏的浸润性疾病,其心血管影响贯穿肝病早期至肝硬化全程。讨论检测肝病的实用方法,包括在高危个体中无创评估肝纤维化。讨论在发现慢性肝病后通过心脏影像、生物标志物和心脏功能检查评估心血管风险的路径。讨论常见心血管情况的处理考虑,并对支持慢性肝病患者使用心脏代谢治疗的新证据进行批判性评价,以强调可能的心血管和肝脏获益。识别关键证据空白和未来研究重点,包括开发与评价结合肝脏信息的心血管风险模型、将心血管终点纳入肝病试验,以及实施心-肝-代谢整合诊疗路径。提高对慢性肝病及相关心血管疾病风险的认识,为促进更早发现疾病、加强风险分层并改善慢性肝病全程结局提供重要机会。

12心脏瓣膜病/TAVR (1篇)

临床研究 (1篇)

European journal of heart failure IF 10.3 2026-10-16 PMID: 42886864
GLP-1 receptor agonists reduce major adverse cardiovascular events among patients with diabetes, overweight, and obesity. Whether these benefits extend to patients undergoing aortic valve replacement (AVR) for severe aortic stenosis (AS) remains unknown. Thus, we investigated the association between GLP-1 receptor agonist treatment and cardiovascular outcomes after AVR. Nationwide population-based cohort study including consecutive patients with severe AS undergoing TAVI or SAVR in Western Denmark between January, 2016 and April, 2022. Patients were followed until death, emigration, crossover, or end of follow up on May 12, 2026. Propensity score-matching was performed to balance confounding. The primary outcome was a composite of all-cause mortality, heart failure hospitalization, or aortic valve reoperation. Secondary outcomes included all-cause mortality, heart failure hospitalization, aortic valve reoperation, with analyses accounting for the competing risk of death. Among 5259 eligible patients undergoing AVR, 292 propensity score-matched patients were included in the final analyses. During a mean follow up of 4.8±2.4 years, GLP-1 receptor agonist treatment was associated with a lower risk of the primary composite outcome compared with controls (HR 0.69, 95%CI 0.50-0.96, p=0.029). GLP-1 receptor agonist treatment was also associated with lower risk of all-cause mortality (HR 0.66, 95%CI 0.46-0.95, p=0.025). In competing risk analyses accounting for death, lower risks were observed for heart failure hospitalization (HR 0.67, 95%CI 0.48-0.93, p=0.018), and aortic valve reoperation (HR 0.69, 95%CI 0.49-0.98, p=0.037). Treatment with GLP-1 receptor agonists was associated with lower risk of cardiovascular outcomes including mortality following AVR among patients with severe AS.
中文摘要:GLP-1受体激动剂可降低糖尿病、超重和肥胖患者的主要不良心血管事件。这些获益是否延伸至因重度主动脉瓣狭窄接受主动脉瓣置换术的患者尚不明确。本研究考察GLP-1受体激动剂治疗与主动脉瓣置换术后心血管结局之间的关联。研究为全国性人群队列研究,纳入2016年1月至2022年4月丹麦西部连续接受经导管主动脉瓣植入或外科主动脉瓣置换的重度主动脉瓣狭窄患者。随访至死亡、移居、交叉转换或2026年5月12日随访结束。采用倾向评分匹配平衡混杂因素。主要结局为全因死亡、心力衰竭住院或主动脉瓣再手术的复合终点。次要结局包括全因死亡、心力衰竭住院和主动脉瓣再手术,分析时考虑死亡的竞争风险。5259例符合条件的主动脉瓣置换患者中,292例倾向评分匹配患者进入最终分析。平均随访4.8±2.4年,GLP-1受体激动剂治疗与主要复合结局风险降低相关(HR 0.69,95%CI 0.50-0.96,p=0.029)。GLP-1受体激动剂治疗也与全因死亡风险降低相关(HR 0.66,95%CI 0.46-0.95,p=0.025)。在考虑死亡的竞争风险分析中,心力衰竭住院(HR 0.67,95%CI 0.48-0.93,p=0.018)和主动脉瓣再手术(HR 0.69,95%CI 0.49-0.98,p=0.037)风险均较低。在重度主动脉瓣狭窄患者中,GLP-1受体激动剂治疗与主动脉瓣置换术后心血管结局(包括死亡)风险降低相关。

13脑血管病 (1篇)

临床研究 (1篇)

Stroke IF 11.1 2026-10-16 PMID: 42885481
White matter hyperintensities (WMH) are a common brain magnetic resonance imaging marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. We sought to identify circulating proteins that lie upstream of WMH and influence related clinical manifestations. We conducted a 4-stage proteogenomic study. Stage 1 tested a WMH polygenic risk score against 2923 plasma proteins in 52 560 UK Biobank participants (mean age, 56.8 years, 53.9% female, 94.0% White), and candidate proteins against WMH volume in the neuroimaging subset (n=5443; mean age 54.2 years, 53.5% female). Stage 2 applied bidirectional Mendelian randomization, colocalization, and local genetic correlation using cis protein quantitative trait locus and cis expression quantitative trait locus instruments from plasma, vascular, and brain tissue. Stage 3 analyzed single-nucleus RNA sequencing of 8 postmortem periventricular white matter samples (4 WMH lesions, 4 controls; mean age, 81 years; 50% female). Stage 4 tested circulating and genetically predicted protein levels against general cognitive ability. Stages 1 and 2 converged on CTSB (cathepsin B) and ECHDC3 (enoyl-coenzyme A hydratase domain-containing 3). Higher plasma CTSB was associated with lower WMH volume (β=-0.09 [95% CI, -0.13 to -0.05]; n=5260), and Mendelian randomization estimates were directionally consistent across all 5 instrument sets (plasma protein quantitative trait locus β=-0.052 [95% CI, -0.064 to -0.040]), with concordant effects on white matter microstructure, perivascular spaces, and lacunar stroke. Single-nucleus RNA sequencing showed CTSB downregulation within lesions, predominantly in astrocytes (log2 fold change=-1.70) and oligodendrocytes (log2 fold change=-0.48; both false discovery rate P<1×10-20). Higher plasma CTSB (β=0.061 [95% CI, 0.010-0.112]; n=5193) and a cis protein quantitative trait locus polygenic score (β=0.031 [95% CI, 0.009-0.054]; n=8884) predicted better cognitive performance. ECHDC3 showed no consistent association beyond stage 1. Multimodal proteogenomic evidence nominates CTSB as a lesion-suppressed protein associated with lower WMH burden and better cognition, and a candidate therapeutic target for cerebral small vessel disease.
中文摘要:白质高信号(WMH)是脑小血管病常见的脑磁共振成像标志物,也是卒中和痴呆的重要危险因素,但调控病灶形成的分子机制仍未完全阐明。我们试图识别位于WMH上游并影响相关临床表现的循环蛋白。研究开展了四阶段蛋白基因组学分析。第1阶段在52 560名英国生物银行参与者(平均年龄56.8岁,女性53.9%,白人94.0%)中检验WMH多基因风险评分与2923种血浆蛋白的关联,并在神经影像亚组(n=5443;平均年龄54.2岁,女性53.5%)中检验候选蛋白与WMH体积的关联。第2阶段利用来自血浆、血管和脑组织的顺式蛋白数量性状位点及顺式表达数量性状位点工具,进行双向孟德尔随机化、共定位和局部遗传相关性分析。第3阶段分析8份死后脑室周围白质样本(4份WMH病灶,4份对照;平均年龄81岁;女性50%)的单核RNA测序。第4阶段检验循环蛋白及遗传预测蛋白水平与一般认知能力的关联。第1和第2阶段共同指向CTSB(组织蛋白酶B)和ECHDC3(烯酰辅酶A水合酶结构域包含3)。较高的血浆CTSB与较低的WMH体积相关(β=-0.09 [95% CI, -0.13至-0.05];n=5260),孟德尔随机化估计在全部5组工具中方向一致(血浆蛋白数量性状位点β=-0.052 [95% CI, -0.064至-0.040]),并对白质微结构、血管周围间隙和腔隙性卒中有一致效应。单核RNA测序显示病灶内CTSB下调,主要见于星形胶质细胞(log2倍数变化=-1.70)和少突胶质细胞(log2倍数变化=-0.48;错误发现率P均<1×10⁻²⁰)。较高血浆CTSB(β=0.061 [95% CI, 0.010-0.112];n=5193)和顺式蛋白数量性状位点多基因评分(β=0.031 [95% CI, 0.009-0.054];n=8884)预测更好的认知表现。ECHDC3在第1阶段之外未见一致关联。多模态蛋白基因组学证据提示CTSB是一种受病灶抑制的蛋白,与较低WMH负荷和较好认知相关,并可能成为脑小血管病的候选治疗靶点。

14动脉粥样硬化 (1篇)

基础研究 (1篇)

Cell IF 45.1 2026-10-15 PMID: 42849439
Controlling hyperlipidemia has reduced but not eliminated atherosclerotic cardiovascular disease (ASCVD) as a major cause of human mortality. Here, we report that loss of the immunoregulatory gene GTPase of immunity-associated protein 6 (Gimap6) in mice causes an inflammatory vasculopathy and accelerated atherosclerosis in the absence of hyperlipidemia. These vascular abnormalities cause progressive cardiac ischemia, myocardial infarction, and heart failure, culminating in early death. GIMAP6 loss precipitates early endothelial barrier failure and a mitochondrial reactive oxygen species (ROS)-PPARγ-CD36 lipid-influx cascade that lowers the threshold for foam-cell formation and induces IL-6/MCP-1/TNF-mediated inflammation. Human hypomorphic GIMAP6 variants, including the African-ancestry-enriched V65I allele, are associated with altered monocyte redox balance, increased CD36-mediated lipid uptake, and early ASCVD. Thus, GIMAP6 is a crucial safeguard for vascular integrity that restrains endothelial dysfunction, macrophage foam cell generation, and inflammation that can cause lethal ASCVD independently of systemic hyperlipidemia.
中文摘要:控制高脂血症已降低动脉粥样硬化性心血管疾病(ASCVD)作为人类主要死亡原因的比重,但并未消除该病。小鼠免疫调节基因GTP酶免疫相关蛋白6(Gimap6)缺失可在无高脂血症的情况下引起炎症性血管病和加速性动脉粥样硬化。这些血管异常导致进行性心脏缺血、心肌梗死和心力衰竭,最终引起早死。GIMAP6缺失促使早期内皮屏障功能衰竭,并启动线粒体活性氧(ROS)-PPARγ-CD36脂质内流级联,该级联降低泡沫细胞形成阈值并诱导IL-6/MCP-1/TNF介导的炎症。人类GIMAP6亚效变异,包括非洲血统中富集的V65I等位基因,与单核细胞氧化还原平衡改变、CD36介导的脂质摄取增加及早期ASCVD相关。GIMAP6是维持血管完整性的关键保障,可抑制内皮功能障碍、巨噬细胞泡沫细胞生成和炎症,从而在不依赖全身高脂血症的情况下防止致死性ASCVD。

15冠心病/PCI (1篇)

临床研究 (1篇)

Science translational medicine IF 15.6 2026-10-14 PMID: 42873893
Aging is characterized by progressive functional decline, yet metabolomic signatures across the human life span remain incompletely defined. Here, we profiled plasma metabolomes from 18,476 participants aged 1 to 96 years across six centers in China using nano-assisted laser desorption/ionization mass spectrometry (LDI-MS) and identified 56 representative age-associated metabolites. In a healthy cohort, we developed a stacking ensemble model to estimate metabolomic age and quantified metabolomic age acceleration (mAA) as each individual's deviation from chronological age. Higher mAA was associated with health deterioration and unfavorable lifestyles. During follow-up from 2019 to 2025, individuals with accelerated mAA showed increased risk of incident chronic diseases, such as fatty liver disease, hypertension, and diabetes, as well as increased all-cause mortality. In a disease cohort, we further developed a mortality-linked metabolomic metric (age deviation) that quantified individualized departures from age-expected mortality risk inferred from plasma metabolites. Age deviation was associated with established composite health measures and increased with multisystem disease involvement and higher multimorbidity burden. Together, these findings support the potential of plasma metabolomic profiling as a scalable, life span-wide approach for deriving clinically interpretable metabolomic aging metrics associated with health status, chronic disease risk, and mortality.
中文摘要:衰老表现为功能的渐进性衰退,但贯穿人类全生命周期的代谢组学特征仍未充分界定。研究对中国六家中心18,476名1至96岁的参与者,采用纳米辅助激光解吸电离质谱(LDI-MS)测定血浆代谢组,识别出56种代表性年龄相关代谢物。在健康队列中,构建堆叠集成模型估算代谢组年龄,并以个体偏离实际年龄的程度量化代谢组年龄加速(mAA)。mAA较高者伴随健康状况变差和不利的生活方式。2019至2025年随访期间,mAA加速者的新发慢性病风险升高,包括脂肪肝、高血压和糖尿病,全因死亡率也上升。在疾病队列中,进一步构建与死亡关联的代谢组指标(年龄偏差),量化个体血浆代谢物所推断的年龄预期死亡风险的偏离程度。年龄偏差与已有的综合健康指标相关,并随多系统疾病累及和共病负担增加而升高。上述结果支持将血浆代谢组学作为可扩展、覆盖全生命周期的途径,用于得到与健康状况、慢性病风险和死亡相关的、具临床可解释性的代谢组衰老指标。

16心源性休克 (1篇)

临床研究 (1篇)

European heart journal IF 45.3 2026-10-14 PMID: 42870411
Cardiogenic shock (CS) remains a heterogeneous syndrome associated with persistently high mortality despite advances in temporary mechanical circulatory support. One recent randomized controlled trial suggested a mortality benefit of a percutaneous microaxial flow pump in a cohort of patients with ST-elevation myocardial infarction complicated by CS, whereas routine veno-arterial extracorporeal membrane oxygenation in populations with acute myocardial infarction complicated by CS has not improved survival and is associated with higher complication rates. These findings underscore the importance of phenotype-driven patient selection, incorporating the Society for Cardiovascular Angiography and Interventions (SCAI) and Shock Academic Research Consortium (SHARC) classifications to guide device selection, timing, escalation, and de-escalation. This clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology (ESC) updates the 2020 expert consensus document and provides updated practical guidance based on the recent evidence on the use of temporary mechanical circulatory support in acute myocardial infarction complicated by CS. Emphasis is placed on patient/device selection according to recent evidence, multidisciplinary shock teams, regionalized hub-and-spoke systems, structured protocols for escalation and futility, and the integration of contemporary trial data and best practices to optimize outcomes in this high-risk population.
中文摘要:心源性休克(CS)仍是异质性综合征,尽管临时机械循环支持取得进展,其死亡率持续偏高。一项近期随机对照试验提示,经皮微轴流泵在ST段抬高型心肌梗死合并CS患者队列中可带来生存获益;而在急性心肌梗死合并CS人群中常规使用静脉-动脉体外膜氧合未改善生存,并与更高的并发症发生率相关。这些结果强调表型驱动的患者选择的重要性,需结合心血管造影与介入学会(SCAI)及休克学术研究联盟(SHARC)分类指导装置选择、时机、升级与降级。这份来自欧洲经皮心血管介入协会(EAPCI)与欧洲心脏病学会(ESC)下属急性心血管监护协会(ACVC)的临床共识声明更新了2020年专家共识文件,并基于临时机械循环支持用于急性心肌梗死合并CS的最新证据提供更新后的实践指导。重点包括依据近期证据进行患者与装置选择、多学科休克团队、区域化枢纽-分支体系、升级与无效治疗的规范化流程,以及整合当代试验数据与最佳实践以优化这一高危人群的结局。

17神经退行病 (1篇)

基础研究 (1篇)

Ageing research reviews IF 15.5 2026-10-13 PMID: 42869105
With the global aging population, age-related neurodegenerative diseases and cerebrovascular diseases have become major public health challenges. As a modifiable lifestyle strategy, dietary intervention shows significant potential in delaying brain aging and reducing the risk of neurodegenerative and cerebrovascular diseases. Caloric restriction (CR) and dietary restriction (DR), two important nutritional intervention approaches, exhibit substantial neuroprotective potential through multiple mechanisms. This review systematically summarizes the mechanisms of CR and DR in brain aging and related diseases, focusing on: (1) modulating gene expression and epigenetic modifications; (2) regulating proteostasis and autophagy; (3) inhibiting neuroinflammation to delay inflammaging; (4) improving mitochondrial function and oxidative homeostasis; and (5) optimizing nutrient-sensing pathways and metabolism. Additionally, this review discusses the mechanistic evidence of CR and DR in disease models such as Alzheimer's Disease (AD), Parkinson's Disease (PD), stroke, and Vascular Dementia (VaD). Despite promising preclinical findings, their clinical translation faces challenges including individual variability, safety concerns, and uncertainty regarding mechanism prioritization. Future research should focus on conducting more high-quality clinical trials, integrating multi-omics technologies with precision nutrition strategies to promote the practical application of CR and DR in advancing healthy brain aging.
中文摘要:随着全球人口老龄化,年龄相关的神经退行性疾病和脑血管疾病已成为重要的公共卫生挑战。饮食干预作为可改变的生活方式策略,在延缓脑老化、降低神经退行性疾病和脑血管疾病风险方面显示出显著潜力。热量限制(CR)和饮食限制(DR)是两类重要的营养干预方式,通过多种机制表现出较强的神经保护潜力。本综述系统总结CR和DR在脑老化及相关疾病中的作用机制,重点包括:(1)调节基因表达与表观遗传修饰;(2)调控蛋白稳态与自噬;(3)抑制神经炎症以延缓炎性衰老;(4)改善线粒体功能与氧化稳态;(5)优化营养感应通路与代谢。文中还讨论了CR和DR在阿尔茨海默病(AD)、帕金森病(PD)、卒中及血管性痴呆(VaD)等疾病模型中的机制证据。尽管临床前研究结果具有前景,其临床转化仍面临个体差异、安全性问题以及机制优先性不明确等挑战。未来研究应开展更多高质量临床试验,并将多组学技术与精准营养策略相结合,推动CR和DR在促进健康脑老化中的实际应用。

18脑小血管病 (1篇)

临床研究 (1篇)

Acta neuropathologica IF 10.3 2026-10-13 PMID: 42867637
Cerebral small vessel disease (cSVD) is a leading cause of stroke and vascular cognitive impairment, yet the cellular mechanisms underlying microvascular dysfunction in human disease remain incompletely understood. In particular, the relationship between pericyte alterations and endothelial activation, two key features of blood-brain barrier dysfunction, remains unresolved. Here, we performed a quantitative single-vessel analysis of the human cortical microvasculature across increasing cSVD severity and ageing. Using multiplex immunohistochemistry combined with spectral unmixing and automated image analysis, we analysed 11,409 microvascular fragments from post-mortem brain tissue derived from 20 cases. Endothelial cells, pericytes, and endothelial activation were assessed using PECAM-1, PDGFRβ, and VCAM-1, respectively. Microvascular density and diameter differed between cortical grey matter and the underlying white matter, with white matter vessels being less dense and wider in controls. While vessel diameter remained stable across cSVD severity groups, microvascular density increased with cSVD severity and age in the white matter. At the molecular level, PDGFRβ signal decreased markedly with increasing cSVD severity, consistent with reduced pericyte coverage. This reduction was observed in both grey and white matter and correlated with disease severity and age. Notably, intermediate severity groups displayed marked heterogeneity, with vessels exhibiting either preserved or markedly reduced PDGFRβ signal. In parallel, endothelial markers PECAM-1 and VCAM-1 increased significantly with disease severity, reflecting endothelial activation. Unsupervised Gaussian mixture clustering of marker expression identified three vascular states characterised by (i) preserved PDGFRβ signal with low endothelial activation, (ii) reduced PDGFRβ signal without endothelial activation, and (iii) reduced PDGFRβ signal combined with endothelial activation. These clusters broadly aligned with neuropathological severity but revealed heterogeneity not captured by post-mortem diagnosis alone. Together, these findings suggest that pericyte alterations and endothelial activation are partially dissociated processes in human cSVD and identify distinct microvascular phenotypes across disease severity. These cross-sectional observations provide a framework for future longitudinal and experimental studies to determine their temporal and mechanistic relationships.
中文摘要:脑小血管病(cSVD)是卒中和血管性认知障碍的重要原因,但人类疾病中微血管功能障碍的细胞机制仍未完全明确。周细胞改变与内皮活化是血脑屏障功能障碍的两个关键特征,二者之间的关系尚未解决。我们对随cSVD严重程度和年龄增加的人类皮质微血管进行了单血管定量分析。采用多重免疫组化结合光谱解混和自动图像分析,分析了来自20例尸检脑组织的11,409个微血管片段。分别用PECAM-1、PDGFRβ和VCAM-1评估内皮细胞、周细胞和内皮活化。皮质灰质与下方白质的微血管密度和直径不同,对照者白质血管密度较低且较宽。各cSVD严重程度组的血管直径保持稳定,白质微血管密度随cSVD严重程度和年龄增加而升高。分子水平上,PDGFRβ信号随cSVD严重程度增加而明显下降,符合周细胞覆盖减少。这种下降见于灰质和白质,并与疾病严重程度和年龄相关。中间严重程度组表现出明显异质性,血管要么保留PDGFRβ信号,要么PDGFRβ信号明显降低。同时,内皮标志物PECAM-1和VCAM-1随疾病严重程度显著升高,反映内皮活化。对标志物表达进行无监督高斯混合聚类,识别出三种血管状态:(i)PDGFRβ信号保留且内皮活化低;(ii)PDGFRβ信号降低但无内皮活化;(iii)PDGFRβ信号降低并伴内皮活化。这些聚类大体与神经病理严重程度一致,但揭示了仅凭尸检诊断未捕捉到的异质性。这些发现提示,在人cSVD中周细胞改变与内皮活化是部分分离的过程,并识别出随疾病严重程度不同的微血管表型。这些横断面观察为未来纵向和实验研究确定二者的时间与机制关系提供了框架。

19心肌病 (1篇)

临床研究 (1篇)

Circulation IF 41.3 2026-10-13 PMID: 42866868
In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performance with guideline definitions. In a multicenter cohort study (8 centers, 4 countries), 1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy (derivation, n=722; validation, n=379) underwent standardized echocardiography with blinded core laboratory analysis, including MR measures (vena contracta width, effective regurgitant orifice area, regurgitant volume, and regurgitant fraction). All-cause mortality and time to first heart failure hospitalization (HFH) served as end points. Prognostic thresholds were derived from spline analysis, validated externally, and compared with American Heart Association/American College of Cardiology, European Society of Cardiology/European Association for Cardiothoracic Surgery, and American Society of Echocardiography definitions. During a median follow-up of 24.9 months (interquartile range, 12.0-42.0), 314 patients (28.5%) died and 244 (22.2%) experienced HFH. All MR metrics independently predicted mortality and HFH (all P<0.05). Spline-derived thresholds identified intermediate risk at vena contracta width ≥3.0 mm, effective regurgitant orifice area ≥0.10 cm2, regurgitant volume ≥15 mL, and regurgitant fraction ≥20% and high risk at effective regurgitant orifice area >0.25 cm2, regurgitant volume >38 mL, and regurgitant fraction >35%. Compared with guideline grading (≈12%-13%), the composite MR grading scheme classified a significantly higher proportion (21%) as severe MR and provided superior discrimination for clinical outcomes at 12 and 24 months in both the derivation and validation cohort. After multivariable adjustment, only the composite MR grading scheme remained strongly predictive for both mortality (hazard ratio, 1.20 [1.07-1.36]) and HFH (hazard ratio, 1.21 [1.05-1.38]). Quantitative MR thresholds in transthyretin amyloid cardiomyopathy are substantially lower than current guideline cutoffs. A validated, risk-based composite MR grading scheme improves prediction of both mortality and HFH, better reflecting the restrictive low-flow pathophysiology of transthyretin amyloid cardiomyopathy and supporting disease-specific MR grading. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06836011.
中文摘要:在转甲状腺素蛋白淀粉样心肌病中,由于限制性低流量的血流动力学,常规(半)定量超声心动图标准可能低估二尖瓣反流(MR)的严重程度。研究旨在定义并验证疾病特异性的MR风险阈值,并将其预后判断能力与指南定义进行比较。在一项多中心队列研究(8个中心、4个国家)中,1101例新诊断的转甲状腺素蛋白淀粉样心肌病患者(推导队列n=722;验证队列n=379)接受标准化超声心动图检查,并由核心实验室盲法分析,包括MR指标(缩流颈宽度、有效反流口面积、反流量和反流分数)。全因死亡和首次心力衰竭住院(HFH)时间作为终点。预后阈值由样条分析得出,经外部验证,并与美国心脏协会/美国心脏病学会、欧洲心脏病学会/欧洲心胸外科协会及美国超声心动图学会的定义进行比较。中位随访24.9个月(四分位距12.0-42.0),314例(28.5%)死亡,244例(22.2%)发生HFH。所有MR指标均独立预测死亡和HFH(均P<0.05)。样条分析得出的阈值将缩流颈宽度≥3.0 mm、有效反流口面积≥0.10 cm2、反流量≥15 mL和反流分数≥20%判定为中风险,将有效反流口面积>0.25 cm2、反流量>38 mL和反流分数>35%判定为高风险。与指南分级(约12%-13%)相比,复合MR分级方案将显著更高比例(21%)归为重度MR,并在推导队列和验证队列中对12个月和24个月临床结局均提供更优区分度。多变量校正后,仅复合MR分级方案对死亡(风险比1.20[1.07-1.36])和HFH(风险比1.21[1.05-1.38])仍具有强预测作用。转甲状腺素蛋白淀粉样心肌病中的定量MR阈值明显低于现行指南界值。经过验证的、基于风险的复合MR分级方案改善了对死亡和HFH的预测,更好地反映转甲状腺素蛋白淀粉样心肌病的限制性低流量病理生理,并支持采用疾病特异性MR分级。URL: https://www.clinicaltrials.gov;唯一标识符:NCT06836011。

20肺动脉高压 (1篇)

基础研究 (1篇)

Circulation IF 41.3 2026-10-13 PMID: 42677488
Pulmonary hypertension (PH) is a life-threatening cardiovascular disorder characterized by irreversible pulmonary vascular remodeling and poor prognosis. RNA pseudouridylation, the most evolutionarily conserved RNA epigenetic modification, and its catalytic enzyme pseudouridine synthase 7 (PUS7) remained uncharacterized in PH, representing a major gap in the understanding of the epigenetic pathogenesis of the disease. We generated the first single-base resolution pseudouridine (Ψ) landscape in lung tissues of patients with PH using bisulfite-induced deletion sequencing. PUS7 expression was analyzed in hypoxic pulmonary artery endothelial cells, the lung tissues of patients with PH, and SU5416-hypoxia rodent model. The functional roles of PUS7 were investigated through genetic manipulation (PUS7-deficiency cells, adeno-associated virus serotype-mediated overexpression, endothelial cell-specific knockdown, and heterozygous knockout mice) and pharmacological inhibition with NSC107512. Bisulfite-induced deletion sequencing revealed global Ψ dysregulation in the lung tissues of patients with PH. Among PUS family members, PUS7 was the most markedly upregulated in these tissues and in the hypoxic pulmonary artery endothelial cells. Both gene knockdown and pharmacological inhibition with NSC107512 ameliorated PH, whereas adeno-associated virus serotype-mediated PUS7 overexpression exacerbated disease progression. RNA immunoprecipitation sequencing and mutagenesis studies demonstrated that PUS7 bound to and catalyzed Ψ at position 688 of TGFBI (transforming growth factor β-induced protein) mRNA, thereby stabilizing TGFBI and activating phosphatidylinositol 3-kinase-protein kinase B signaling pathway. Furthermore, hypoxia-inducible factor 2α bound directly to the PUS7 promoter, establishing a hypoxia-inducible factor 2α/PUS7/TGFBI/phosphatidylinositol 3-kinase-protein kinase B positive feedback loop that drives PH pathogenesis. PUS7-mediated pseudouridylation serves as a novel epigenetic driver of PH through the hypoxia-inducible factor 2α/PUS7/TGFBI/phosphatidylinositol 3-kinase-protein kinase B axis, positioning PUS7 as a promising therapeutic target for this devastating disease.
中文摘要:肺动脉高压(PH)是一种危及生命的心血管疾病,特征为不可逆的肺血管重塑和预后不良。RNA假尿苷化是进化上最保守的RNA表观遗传修饰,其催化酶假尿苷合酶7(PUS7)在PH中尚未被阐明,这是理解该疾病表观遗传发病机制的主要空白。我们采用亚硫酸氢盐诱导缺失测序,首次在PH患者肺组织中绘制了单碱基分辨率的假尿苷(Ψ)图谱。在缺氧肺动脉内皮细胞、PH患者肺组织和SU5416-缺氧啮齿动物模型中分析PUS7表达。通过遗传操作(PUS7缺陷细胞、腺相关病毒血清型介导的过表达、内皮细胞特异性敲低和杂合敲除小鼠)以及NSC107512药理抑制研究PUS7的功能作用。亚硫酸氢盐诱导缺失测序揭示PH患者肺组织中Ψ全局失调。在PUS家族成员中,PUS7在这些组织及缺氧肺动脉内皮细胞中上调最明显。基因敲低和NSC107512药理抑制均改善PH,而腺相关病毒血清型介导的PUS7过表达加重疾病进展。RNA免疫沉淀测序和突变研究表明,PUS7结合并催化TGFBI(转化生长因子β诱导蛋白)mRNA第688位点的Ψ,从而稳定TGFBI并激活磷脂酰肌醇3-激酶-蛋白激酶B信号通路。此外,缺氧诱导因子2α直接结合PUS7启动子,建立缺氧诱导因子2α/PUS7/TGFBI/磷脂酰肌醇3-激酶-蛋白激酶B正反馈环路,驱动PH发病。PUS7介导的假尿苷化通过缺氧诱导因子2α/PUS7/TGFBI/磷脂酰肌醇3-激酶-蛋白激酶B轴成为PH的新型表观遗传驱动因素,使PUS7成为这种严重疾病的有前景治疗靶点。

21肝硬化心肌病 (1篇)

临床研究 (1篇)

Journal of hepatology IF 40.1 2026-10-12 PMID: 42863682
Cirrhotic cardiomyopathy (CCM), a clinically consequential comorbidity of cirrhosis, remains undefined and underappreciated in children. This study aimed to characterize myocardial structural, functional, morphometric, and histopathologic features in pediatric cirrhosis and objectively derive a reliable echocardiographic (2DE) metric to predict perioperative adverse events, including mortality. 2DE, morphometry, histopathology, and vasoactive-inotropic score (VIS) were compared between children with (n=226) and without (n=160) cirrhosis listed for liver transplantation (LT) over 2011-2021. Discriminatory performance of left ventricular mass index (height)2.7(LVMI g/m2.7) for predicting waitlist decompensation, composite serious adverse events post liver transplant and mortality was assessed using ROC analysis, with AUCs and optimal thresholds compared against PELD-Cr/MELD scores. LV mass was significantly higher in children with cirrhosis on 2DE and necropsy specimens compared to non-cirrhotic controls, with ∼25% demonstrating LV hypertrophy, with OR of 6.9 [CI 3,16], p< 0.0001. In the cirrhotic cohort, LVMI correlated with vasoactive needs under stress of LT (p <0.001) and was significantly higher in patients with WLD, CSAE, and non-survivors. In cirrhosis, LVMI values ≥ 88 g/m2.7, ≥ 91 g/m2.7, and ≥ 95 g/m2.7 were independently associated with WLD, CSAE, and mortality, when adjusting for PELD-Cr/MELD, bilirubin, and INR (p <0.01). Combining LVMI + PELD-Cr/MELD significantly outperformed PELD-Cr/MELD in discriminating both WLD and CSAE, whereas LVMI alone significantly outperformed PELD-Cr/MELD for CSAE and was comparable for WLD. All three models performed comparably in discriminating death. LVMI is a strong predictor of morbidity and mortality, serving as a prognostic marker in children with cirrhosis. Incorporating LVMI into PELD-Cr/MELD may enhance risk stratification and organ allocation.
中文摘要:肝硬化心肌病(CCM)是肝硬化具有临床后果的合并症,在儿童中仍未明确且认识不足。研究旨在描述儿童肝硬化的心肌结构、功能、形态学及组织病理学特征,并客观推导可靠的超声心动图(2DE)指标以预测围术期不良事件(包括死亡)。比较2011—2021年等待肝移植(LT)的肝硬化患儿(n=226)与非肝硬化患儿(n=160)的2DE、形态学、组织病理学及血管活性-正性肌力评分(VIS)。采用ROC分析评估左心室质量指数(以身高2.7次方标化,LVMI g/m2.7)对等待列表失代偿、肝移植后复合严重不良事件及死亡的判别能力,并将AUC和最佳阈值与PELD-Cr/MELD评分比较。肝硬化患儿2DE及尸检标本的左心室质量显著高于非肝硬化对照,约25%存在左心室肥厚,OR为6.9[CI 3,16],p<0.0001。在肝硬化队列中,LVMI与LT应激下血管活性药物需求相关(p<0.001),且在等待列表失代偿、复合严重不良事件及非存活者中显著更高。在肝硬化中,校正PELD-Cr/MELD、胆红素和INR后,LVMI≥88 g/m2.7、≥91 g/m2.7和≥95 g/m2.7分别与等待列表失代偿、复合严重不良事件和死亡独立相关(p<0.01)。LVMI+PELD-Cr/MELD联合模型在判别等待列表失代偿和复合严重不良事件方面显著优于PELD-Cr/MELD,而LVMI单独在复合严重不良事件方面显著优于PELD-Cr/MELD,在等待列表失代偿方面与PELD-Cr/MELD相当。三种模型判别死亡的表现相当。LVMI是患病和死亡的强预测指标,可作为肝硬化患儿的预后标志物。将LVMI纳入PELD-Cr/MELD可能改善风险分层和器官分配。

22胸部肿瘤 (1篇)

临床研究 (1篇)

Progress in cardiovascular diseases IF 10.6 2026-10-12 PMID: 42863621
Radiation therapy (RT) is highly efficacious in treating thoracic malignancies. However, RT has been linked to potential cardiotoxicity. Yet, the long-term incidence, severity, and implications of HTN-development post-RT are unknown. Leveraging a large US-based Comprehensive-Cancer-Center-cohort of patients treated with thoracic-RT from 2007 to 2019, we included patients ≥18 years old with histologically confirmed esophageal or lung cancers. The primary outcome was incidence of incident/new or worsened HTN [systolic-blood-pressure-(SBP) ≥130 mmHg] after RT-initiation. The secondary outcomes were major-adverse-cardiac-events (MACE- heart-failure, myocardial-infarction, arrhythmia, stroke, and sudden-death), disease-progression, and overall-survival, by HTN-status. Differences in outcomes by HTN-status were also evaluated via landmark-analysis, excluding those with undiagnosed HTN. Observed new HTN rates were compared to Framingham-predicted-rates, and absolute-excess-risks were estimated. Multivariate regression was used to define the relation between clinical and RT measures and both new or worsened HTN-development and survival-outcomes. Overall, 439 RT-treated patients (238 esophageal; 201 lung; 66.7% male; mean age 63.6 years; 65% baseline HTN) were identified. Over a median follow-up of 23 months, 255 (58.1%) developed new or worsened HTN; median SBP increase of 7 mmHg. In landmark-analysis, the cumulative incidence of new or worsened HTN by 1-year was 48.0% and 63.4%, respectively. Using the JNC-8 cutoff of ≥140/90 mmHg, the new HTN rate was 21.6% at 1-year, translating to a 3.4-fold higher rate than the Framingham-predicted-rate (RR 3.37, P < 0.001). In multivariate regression, RT-dose was consistently associated with new or worsened HTN-development (P < 0.05); those with RT-induced-HTN saw improved progression-free-survival and overall-survival (HR 0.67 and 0.54, P < 0.01, respectively). Beyond traditional factors, only RT-dose is consistently associated with MACE (P < 0.05). No specific antihypertensive class prevented RT-related HTN. These data suggest that thoracic-RT increases early HTN risk.
中文摘要:放射治疗对胸部恶性肿瘤疗效显著,但可能与心脏毒性相关。放疗后发生高血压的长期发生率、严重程度及影响仍不清楚。我们利用美国一家大型综合癌症中心2007至2019年接受胸部放疗的患者队列,纳入年龄≥18岁、经组织学确诊的食管癌或肺癌患者。主要结局为放疗开始后新发或加重高血压(收缩压≥130 mmHg)的发生率。次要结局按高血压状态评估主要不良心脏事件(心力衰竭、心肌梗死、心律失常、脑卒中及猝死)、疾病进展和总生存。还通过里程碑分析评估不同高血压状态下的结局差异,分析中排除未确诊高血压者。将观察到的新发高血压率与Framingham预测率比较,并估算绝对超额风险。采用多因素回归分析临床与放疗指标与新发或加重高血压及生存结局的关系。共识别439例接受放疗的患者(食管癌238例,肺癌201例;男性66.7%;平均年龄63.6岁;基线高血压65%)。中位随访23个月期间,255例(58.1%)出现新发或加重高血压;收缩压中位升高7 mmHg。里程碑分析中,1年时新发或加重高血压的累积发生率分别为48.0%和63.4%。按JNC-8标准≥140/90 mmHg,1年新发高血压率为21.6%,为Framingham预测率的3.4倍(RR 3.37,P < 0.001)。多因素回归中,放疗剂量与新发或加重高血压持续相关(P < 0.05);出现放疗相关高血压者无进展生存和总生存改善(HR分别为0.67和0.54,P < 0.01)。除传统因素外,仅放疗剂量与主要不良心脏事件持续相关(P < 0.05)。未发现特定类别降压药可预防放疗相关高血压。这些数据提示胸部放疗增加早期高血压风险。

23睡眠呼吸暂停 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-12 PMID: 42860838
Obstructive sleep apnoea's prognostic value is limited by reliance on the apnoea-hypopnoea index (AHI), which fails to capture physiological heterogeneity of respiratory events. We developed a composite metric, event-weighted desaturation burden (EWDB), integrating weighted respiratory event load, regularity of consecutive inter-event intervals, and cumulative desaturation area. We evaluated its association with cardiovascular mortality and its incremental prognostic value compared with AHI and established hypoxic metrics. We analysed 4,904 adults from the Sleep Heart Health Study with baseline polysomnography and adjudicated follow-up. EWDB was derived by combining a respiratory weighted index, a distribution factor based on inter-event interval regularity, and event-linked hypoxic burden (HB). The primary outcome was cardiovascular mortality. Over a median follow-up of approximately 11 years, 341 cardiovascular deaths occurred. In fully adjusted multivariable Cox models, higher EWDB was independently associated with cardiovascular mortality. However, AHI and HB associations were attenuated and lost statistical significance after full adjustment. EWDB (per 1-SD increase) remained robustly associated with cardiovascular mortality, whereas AHI did not. Incorporating EWDB into a comprehensive clinical model provided incremental risk stratification. Similar robust associations were observed for fatal coronary heart disease and incident heart failure. EWDB was independently associated with cardiovascular mortality and provided incremental prognostic information beyond established clinical and sleep-related factors in this cohort. By integrating respiratory event intensity, cumulative burden, and inter-event interval regularity, EWDB may better characterize cardiovascular stress related to sleep-disordered breathing.
中文摘要:阻塞性睡眠呼吸暂停的预后价值受限于依赖呼吸暂停低通气指数(AHI),该指标不能反映呼吸事件的生理异质性。我们构建了一个复合指标——事件加权血氧饱和度下降负荷(EWDB),整合了加权呼吸事件负荷、连续事件间期规律性和累积血氧下降面积。评估其与心血管死亡的相关性,以及与AHI和既有低氧指标相比的增量预后价值。分析睡眠心脏健康研究中4,904名成人,具有基线多导睡眠图和裁定随访。EWDB由呼吸加权指数、基于事件间期规律性的分布因子和事件相关低氧负荷(HB)组合得出。主要结局为心血管死亡。中位随访约11年,发生341例心血管死亡。在充分校正的多变量Cox模型中,较高EWDB与心血管死亡独立相关。AHI和HB的关联在充分校正后减弱并失去统计学显著性。EWDB每增加1个标准差仍与心血管死亡稳健相关,而AHI无此关联。将EWDB纳入综合临床模型可提供增量风险分层。对致死性冠心病和新发心力衰竭也观察到类似稳健关联。EWDB与心血管死亡独立相关,并在该队列中提供超出既有临床和睡眠相关因素的增量预后信息。通过整合呼吸事件强度、累积负荷和事件间期规律性,EWDB可能更好地刻画与睡眠呼吸障碍相关的心血管应激。

24脑血管畸形 (1篇)

基础研究 (1篇)

Molecular biomedicine IF 13.0 2026-10-10 PMID: 42859354
Cerebral cavernous malformations (CCMs) are cerebrovascular diseases characterized by vascular lesions of the central nervous system (CNS) that can result in epileptic seizures, headaches, focal neurologic deficits (FNDs), and hemorrhagic stroke. Germline and somatic loss-of-function (LOF) mutations in one of the three established CCM-associated genes, namely CCM1 (or krev interaction trapped protein 1, KRIT1), CCM2, and CCM3 (or programmed cell death 10, PDCD10), which have been validated as core drivers of CCM pathogenesis and progression. Over the past few decades, a substantially improved understanding of the hallmarks and molecular basis of CCMs has been achieved. Key pathological hallmarks include but are not limited to excessive angiogenesis, vascular leakage, endothelial-mesenchymal transition (EndMT), defective autophagy, inflammation and immune response, oxidative stress, influenced gut microbiome and altered brain vascular microenvironment. These hallmarks are orchestrated by dysregulated signaling cascades, notably MEKK3-KLF2/4, PI3K-mTOR, and RhoA-ROCK, which integrate genetic, inflammatory, and hemodynamic cues. Concurrently, sophisticated neuroimaging (MRI with SWI/QSM) and genetic testing now enable precise diagnosis and risk stratification. Although surgical resection remains the mainstay for accessible symptomatic lesions, a wave of mechanism‑based pharmacological candidates has shown promising efficacy in preclinical models, and several have advanced to early‑phase clinical trials. This review summarizes the current understanding of CCM epidemiology, molecular pathogenesis, diagnosis and therapy, highlighting how the evolving multi‑hit concept and the dissection of downstream signaling are paving the way towards personalized management of this complicated vascular disease.
中文摘要:脑海绵状血管畸形(CCMs)是一类脑血管疾病,以中枢神经系统(CNS)血管性病变为特征,可导致癫痫发作、头痛、局灶性神经功能缺损(FNDs)和出血性卒中。三个已确立的CCM相关基因之一发生胚系和体细胞功能缺失(LOF)突变,即CCM1(或称Krev相互作用截获蛋白1,KRIT1)、CCM2和CCM3(或称程序性细胞死亡10,PDCD10),这些突变已被验证为CCM发病和进展的核心驱动因素。过去几十年里,对CCM标志性特征和分子基础的理解已有显著提升。关键病理标志包括但不限于过度血管生成、血管渗漏、内皮-间质转化(EndMT)、自噬缺陷、炎症与免疫反应、氧化应激、肠道微生物组改变以及脑血管微环境改变。这些标志由失调的信号级联所编排,尤其是MEKK3-KLF2/4、PI3K-mTOR和RhoA-ROCK,它们整合遗传、炎症和血流动力学线索。与此同时,先进的神经影像学(MRI联合SWI/QSM)和基因检测已能实现精确诊断和风险分层。手术切除仍是可及症状性病变的主要治疗手段,一批基于机制的药物候选物在临床前模型中显示出有希望的疗效,其中若干已进入早期临床试验。本综述总结当前对CCM流行病学、分子发病机制、诊断和治疗的理解,强调不断演变的多重打击概念以及对下游信号通路的解析如何为这种复杂血管疾病的个体化管理铺平道路。

25心肾综合征 (1篇)

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-10-10 PMID: 42855910
Cardiorenal syndrome type-1 (CRS1), defined as acute kidney injury occurring in the setting of acute cardiac illness, is associated with substantial morbidity and mortality. Our objective was to determine whether extracellular vesicles (EVs) derived from the injured heart localize to the kidneys and contribute to renal injury in CRS1, and to elucidate mechanisms by which cardiac-derived EVs mediate kidney damage. Using cardiomyocyte-specific EV reporter mice, we characterized the release of cardiac-derived EVs and their biodistribution to the kidneys. Acute myocardial infarction increased circulating levels of these EVs and enhanced their uptake by proximal tubular epithelial cells. To directly assess their impact on the kidney, EVs derived from cardiomyocytes cultured under normoxic (N-EV) or hypoxic (H-EV) conditions were injected into the renal arteries of wild-type mice. H-EV, but not N-EV, induced proximal tubular epithelial cell injury and worsening of kidney function. To identify EV biomarkers, we performed proteomic profiling of cargo from N-EV and H-EV, and validated the muscle-specific protein TRIM72 as a biomarker of EVs originating from injured cardiomyocytes. In a porcine CRS1 model, plasma levels of TRIM72 positive-EVs were increased, and we demonstrate their delivery to the kidney. Similarly, in CRS1 patients, higher plasma levels of TRIM72-positive EVs correlated with the development of acute kidney injury. Mechanistically, uptake of H-EVs by proximal tubular epithelial cells induced transcription of lipogenic genes and caused lipid accumulation, whereas lipogenesis blockade protected these cells from H-EV-induced injury. We subsequently found that reduced expression of the transcription factor FOXO3 drove H-EV-induced transcriptomic reprogramming. H-EV cargo was enriched with specific Foxo3-targeting miRNAs, whose delivery promoted proximal tubular epithelial cell cytotoxicity, oxidative stress, and suppressed FOXO3 levels. Overall, this work demonstrates that a Foxo3-targeting miRNA heart-to-kidney signal mediated by injured cardiac-derived EVs contributes to kidney injury in CRS1.
中文摘要:1型心肾综合征(CRS1)指急性心脏疾病背景下发生的急性肾损伤,与显著发病率和死亡率相关。研究目标是确定受损心脏来源的细胞外囊泡(EVs)是否定位至肾脏并参与CRS1肾损伤,并阐明心脏来源EVs介导肾损伤的机制。利用心肌细胞特异性EV报告小鼠,研究描述了心脏来源EVs的释放及其向肾脏的生物分布。急性心肌梗死提高这些EVs的循环水平并增强近端小管上皮细胞对其摄取。为直接评估其对肾脏的影响,将常氧(N-EV)或缺氧(H-EV)条件下培养的心肌细胞来源EVs注入野生型小鼠肾动脉。H-EV而非N-EV诱导近端小管上皮细胞损伤并加重肾功能恶化。为识别EV生物标志物,对N-EV与H-EV货物进行蛋白质组学分析,并验证肌肉特异性蛋白TRIM72作为来源于受损心肌细胞EVs的生物标志物。在猪CRS1模型中,血浆TRIM72阳性EVs水平升高,并显示其被递送至肾脏。同样,在CRS1患者中,血浆TRIM72阳性EVs水平较高与急性肾损伤发生相关。机制上,近端小管上皮细胞摄取H-EVs后诱导脂肪生成基因转录并造成脂质蓄积,阻断脂肪生成可保护这些细胞免受H-EV诱导的损伤。随后发现转录因子FOXO3表达降低驱动H-EV诱导的转录组重编程。H-EV货物富含特异性靶向Foxo3的miRNA,其递送促进近端小管上皮细胞细胞毒性、氧化应激并抑制FOXO3水平。这些结果说明,受损心脏来源EVs介导的靶向Foxo3的miRNA心到肾信号参与CRS1肾损伤。

26心肌衰老 (1篇)

基础研究 (1篇)

Cardiovascular research IF 12.5 2026-10-10 PMID: 42535507
Ageing is the strongest risk factor for heart failure, yet the molecular mechanisms underlying cardiomyocyte (CM) ageing remain unclear. We aimed to map the transcriptomic and epigenomic landscape of CM ageing and to test whether DNA hypermethylation is a causal driver of diastolic dysfunction. We performed single-nucleus multi-omics (concurrent snRNA-seq and snATAC-seq) on 4- and 28-month-old ventricular myocardium of C57BL/6J mice. Aged CMs showed widespread chromatin remodelling, with 28 324 regions having greater accessibility compared to only two with reduced accessibility. 1963 genes were differentially expressed in aged ventricular CMs, with 78.5% neighbouring differentially accessible regions. Promoter accessibility positively associated with expression. Reduced-representation bisulphite sequencing of ventricular CM nuclei identified 1422 regions associated with genes that were hypermethylated in aged CMs, compared to only 167 that were hypomethylated. CpG hypermethylation inversely correlated with differential gene expression. Multi-omic integration revealed ageing signatures shared across cell types and identified the long non-coding RNA Gm12381 as a CM-selective ageing marker. To test whether DNA hypermethylation is associated with ageing phenotypes, we used an engineered cardiotropic AAV (MyoAAV) to overexpress Dnmt3a in adult hearts. Dnmt3a overexpression induced CM hypermethylation, causing cardiac hypertrophy and diastolic dysfunction, key ageing phenotypes, and altering the transcriptome profile towards that of aged CMs. Gain of chromatin accessibility and CpG hypermethylation associated with transcriptomic reprogramming characterize CM ageing. Experimental elevation of DNA methylation is sufficient to induce diastolic dysfunction and hypertrophy, supporting DNMT3A-mediated hypermethylation as a mechanistic driver. Further work should test whether attenuating methylation prevents or reverses age-related cardiac dysfunction.
中文摘要:衰老是心力衰竭最强的危险因素,但心肌细胞衰老的分子机制仍不清楚。本研究旨在绘制心肌细胞衰老的转录组与表观基因组图谱,并检验DNA高甲基化是否为舒张功能障碍的因果驱动因素。我们对4月龄和28月龄C57BL/6J小鼠心室心肌进行单核多组学分析,同步开展snRNA-seq与snATAC-seq。衰老心肌细胞出现广泛染色质重塑,28 324个区域可及性升高,仅2个区域可及性降低。衰老心室心肌细胞中有1963个基因差异表达,其中78.5%邻近差异可及区域。启动子可及性与表达呈正相关。对心室心肌细胞核进行简化代表性亚硫酸氢盐测序,发现1422个区域相关基因在衰老心肌细胞中高甲基化,仅167个低甲基化。CpG高甲基化与差异基因表达呈负相关。多组学整合揭示不同细胞类型共享的衰老特征,并确定长链非编码RNA Gm12381为心肌细胞选择性衰老标志物。为检验DNA高甲基化是否与衰老表型相关,我们用工程化心脏趋向性AAV(MyoAAV)在成年心脏过表达Dnmt3a。Dnmt3a过表达诱导心肌细胞高甲基化,引起心脏肥厚和舒张功能障碍这两个关键衰老表型,并使转录组谱向衰老心肌细胞转变。染色质可及性增加与CpG高甲基化伴随转录组重编程,构成心肌细胞衰老的特征。实验性提高DNA甲基化足以诱导舒张功能障碍和肥厚,支持DNMT3A介导的高甲基化作为机制驱动因素。后续工作应检验减弱甲基化能否预防或逆转年龄相关心脏功能障碍。

27其他 (1篇)

临床研究 (1篇)

European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 40680099
While obesity is a well-established risk factor for cardiovascular disease, the relationship between visceral obesity, as assessed by imaging modalities of visceral adipose tissue (VAT), and the risk of atherosclerotic cardiovascular disease (ASCVD) has been insufficiently explored in large-scale studies, particularly across different body mass index (BMI) categories. We aimed at investigating the association between VAT and aortic distensibility as well as risk of ASCVD and comparing the magnitude of VAT-aortic distensibility and VAT-ASCVD association across BMI groups. Leveraging data from the UK Biobank, we examined the association between body weight-normalized VAT (VAT-index, VATi), assessed via abdominal MRI (VATi-MRI) or dual-energy X-ray absorptiometry (DXA; VATi-DXA), and aortic distensibility (a direct local measure of aortic stiffness) as well as the risk of ASCVD over a median follow-up period of 4.7 years. The abdominal MRI sub-cohort of the UK Biobank included 36 829 individuals, among whom 28 888 individuals were additionally evaluated using DXA. VATi was associated with a decrease in ascending aortic distensibility [VATi-MRI adjusted beta = -0.05 (95% CI: -0.07 to -0.04, P < 0.001)]; [VATi-DXA adjusted beta = -0.04 (95% CI: -0.06 to -0.03, P < 0.001)] and increased risk of ASCVD [VATi-MRI: HR 1.16 (95% CI: 1.09-1.23, P < 0.001)]; [VATi-DXA: 1.21 (95% CI: 1.13-1.3), P < 0.001], adjusted for age, sex, socioeconomic status, lifestyle factors, and cardiometabolic comorbidities. Across BMI categories, these associations were more pronounced in non-obese individuals. The cumulative incidence of ASCVD was higher in individuals with high VATi compared with those with low VATi, consistently observed across BMI categories. With a total of 1461 ASCVD events, incidence rates were higher in individuals with high VATi-MRI (VATi-DXA) compared with low VATi across all BMI categories: 5.3% (5.5%) vs. 2.2% (2.2%) in the normal BMI group, 5.5% (5.7%) vs. 2.5% (2.4%) in the overweight group, and 5.7% (5.9%) vs. 2.1% (2.1%) in the obese group (P log-rank <0.001). Overall, in the multivariable-adjusted Cox proportional hazard model, VATi was associated with increased ASCVD risk, but this association was attenuated when adjusted for the clinical marker of central obesity, the waist-to-hip ratio (WHR). In contrast, the association remained significant in the normal BMI group even after adjusting for WHR [HR for VATi-MRI 1.22 (95% CI: 1.06-1.42, P < 0.01); VATi-DXA 1.35 (95% CI: 1.11-1.65, P < 0.01)]. Visceral obesity, measured by advanced imaging modalities, is linked to greater aortic stiffness and elevated risk of ASCVD, independent of BMI, in individuals without known ASCVD. Notably, these associations were observed mostly in non-obese subjects, with the strongest associations found in the normal BMI group. These findings highlight the additional predictive value of visceral obesity over general measures like BMI or WHR, particularly among non-obese individuals.
中文摘要:肥胖是明确的心血管疾病危险因素,但通过影像学评估的内脏脂肪(VAT)与动脉粥样硬化性心血管疾病(ASCVD)风险之间的关系,在大规模研究中探讨不足,尤其在不同体质量指数(BMI)分层中。本研究旨在分析VAT与主动脉可扩张性及ASCVD风险的关联,并比较不同BMI组间上述关联的强度。基于英国生物银行数据,分析经腹部MRI(VATi-MRI)或双能X射线吸收法(DXA;VATi-DXA)测定的体重标化VAT(VAT指数,VATi)与主动脉可扩张性(主动脉僵硬的局部直接测量指标)及中位随访4.7年内ASCVD风险的关联。英国生物银行腹部MRI亚队列纳入36 829人,其中28 888人同时接受DXA评估。在校正年龄、性别、社会经济状况、生活方式因素及心血管代谢合并症后,VATi与升主动脉可扩张性下降相关(VATi-MRI校正β=-0.05,95%CI:-0.07至-0.04,P<0.001;VATi-DXA校正β=-0.04,95%CI:-0.06至-0.03,P<0.001),并与ASCVD风险升高相关(VATi-MRI:HR 1.16,95%CI:1.09-1.23,P<0.001;VATi-DXA:HR 1.21,95%CI:1.13-1.30,P<0.001)。在各BMI类别中,这些关联在非肥胖人群中更为明显。高VATi者ASCVD累积发生率高于低VATi者,且在各BMI类别中一致。共1461例ASCVD事件,各BMI类别中高VATi-MRI(VATi-DXA)者的发生率均高于低VATi者:正常BMI组5.3%(5.5%)对2.2%(2.2%),超重组5.5%(5.7%)对2.5%(2.4%),肥胖组5.7%(5.9%)对2.1%(2.1%)(log-rank P<0.001)。在多变量校正Cox比例风险模型中,VATi与ASCVD风险升高相关,但校正中心性肥胖的临床指标腰臀比(WHR)后关联减弱。正常BMI组在校正WHR后关联依然显著(VATi-MRI:HR 1.22,95%CI:1.06-1.42,P<0.01;VATi-DXA:HR 1.35,95%CI:1.11-1.65,P<0.01)。在无已知ASCVD的人群中,以先进影像手段测量的内脏肥胖与更高的主动脉僵硬度和ASCVD风险升高相关,且不依赖BMI。相关关联主要见于非肥胖受试者,以正常BMI组最强。这些结果提示内脏肥胖较BMI或WHR等总体指标具有额外预测价值,在非肥胖人群中尤为突出。